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Abstract 
 
Introduction 
Despite increasing evidence regarding the safety and efficacy of endovascular (EVAR) and 
open abdominal aortic aneurysm repair, it is often unclear which technique is most 
appropriate for an individual patient.  We have designed a decision analysis model that will 
predict survival, reintervention rates and other parameters for individual patients. 
 
Methods 
A Markov decision analysis model was developed in Microsoft Excel to simulate five 
management options; EVAR, open repair, best medical therapy or delayed EVAR or open 
repair at a threshold aneurysm diameter.  Probabilities for the model were determined from 
systematic literature review.  The user can assess the impact of adjusting patient-specific risk-
factors including aneurysm size, threshold diameter for intervention, operative mortality, 
hazard ratios for general mortality, reintervention rate and aneurysm rupture rate.   
 
Results 
Patient and aneurysm specific variables are entered through a user-friendly data-input sheet 
and the model generates graphical and descriptive results regarding estimated survival and 
reintervention rates for the different management options. Individualised survival curves, 
both aneurysm-related and general mortality curves, cumulative reintervention rates and other 
key parameters are generated for each management option.  The model has been validated 
against average data published from recent RCTs and examples have been generated based 
on real and hypothetical patient characteristics. 
 
Conclusions 
An easy-to-use computer model has been developed that will provide meaningful information 
relating to risks and benefits that could assist in shared decision making and obtaining 
informed consent from patients with aneurysms, and could help to guide policy decisions in 
respect to patient selection for EVAR. 
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OBJECTIVE 
 
Conventional management of abdominal aortic aneurysm is by open repair, and is associated 
with a mortality rate of 2-6%.  Endovascular aneurysm repair (EVAR) is an alternative 
technique first introduced in 1991.  There is a growing body of evidence regarding the safety 
and efficacy of both techniques, particularly since the publication of several randomised 
controlled trials (RCT).  Despite this however, it is often unclear which technique is most 
appropriate for an individual patient.  In addition it can be very difficult to decide when, if at 
all, it is most appropriate time to intervene.  Consequently a decision analysis model has been 
developed that will provide survival and reintervention outcome data for an individual patient 
managed by five different options; open repair, EVAR, best medical therapy and best medical 
therapy combined with delayed intervention (EVAR or open repair) at a certain level of 
aneurysm diameter.  In addition, a systematic review was performed to determine the 
required probabilities for the model.  
 
 11 
INTRODUCTION 
 
Definition and epidemiology 
 
An abdominal aortic aneurysm (AAA) is defined as an abnormal dilatation of the artery that 
is 1.5 times the diameter of the normal segment.  A diameter of greater than 3 cm is generally 
regarded as aneurysmal in the abdominal aorta. Most aneurysms are caused by degenerative 
disease affecting the vessel and this process is most common in the infrarenal segment of the 
abdominal aorta, accounting for 90-95% of AAAs. Approximately 75% of aneurysms are 
asymptomatic and are found incidentally during clinical examination or radiographic 
investigations. Therefore the exact prevalence is unknown but various screening studies have 
estimated it to be between 1.7%-6% in the older male population.1-3 The incidence of AAAs 
is known to increase with age: the incidence rate for males over 50 years is approximately 
25/100,000 increasing to 78/100,000 in those over 70 years.4 AAAs are more common in 
men than women with a male: female ratio of 3.5-6: 1.4 Furthermore a number of studies 
have suggested that the incidence of AAA is actually increasing.5   
 
Pathology 
 
Aneurysmal disease is associated with degeneration of the vessel wall with loss of intima and 
a reduction in the elastin and collagen content of the media.  The exact cause of these changes 
is largely unknown; however the risk factors for atherosclerotic disease (smoking, 
hypertension, hyperlipidaemia and diabetes mellitus) are thought to be largely responsible.  
 
The natural history of AAA is one of progressive structural deterioration, gradual expansion 
and eventual rupture. An ectatic abdominal aorta is defined as one that is diffusely and 
irregularly dilated with a diameter less than 3 cm. One study demonstrated that the median 
growth rate was 0.65 mm/year with 19% becoming aneurysmal within a 2-year follow-up 
period.6 Another study demonstrated expansion rates of 0.09 cm/year for aneurysms 2.6-2.9 
cm, 0.16 cm/year for aneurysms 3.0-3.4 cm, and 0.32 cm/year for aneurysms 3.5-3.9cm.7  
Other studies have shown expansion rates of 0.2-0.4 cm/year for aneurysms <4 am diameter, 
02-0.5 cm/year for aneurysms 4-5 cm and 0.3-0.7 cm/year for those larger than 5 cm.8 The 
UK Small Aneurysm Trial demonstrated that ultrasound surveillance is a safe management 
option for patients with small abdominal aortic aneurysms (4.0 – 5.5 cm diameter) with an 
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annual rupture rate of 1%.9  After 3 years of surveillance, it has been shown that the annual 
rate of aneurysm rupture is 2.2%.10,11  The rate of rupture may be up to 25 % annually for 
aneurysms with diameters larger than 6 cm, while a number of studies indicate that without 
surgery the 5-year survival rate for patients with aneurysms larger than 5 cm is about 20 %.136 
 
Current management strategy 
 
Intervention for AAA is designed to prevent rupture, which is associated with an overall 
mortality rate of approximately 80%, with only half of those undergoing emergency 
operation surviving.  The UK Small Aneurysm Trial demonstrated that there was no long-
term survival advantage from elective surgery on small aneurysms (<5.5 cm diameter).9 This 
finding was also supported by the ADAM trial.137  Therefore current guidelines recommend 
that a size of 5.5 cm diameter and larger, or >4.5 cm with an increase in size of >0.5 cm in 
the preceding 6 months before elective treatment is undertaken.  Conventional management 
of AAA is by open repair and when performed electively is associated with a mortality rate of 
2-6%.  More recently an alternative, less invasive technique for repair of AAA has been 
developed.  This is endovascular repair (EVAR). 
 
The use of EVAR in the treatment of infrarenal abdominal aortic aneurysms was established 
in 1991 by Parodi et al.1  Since then, both the technique and devices have been developed so 
that this procedure may be used in elective, symptomatic and ruptured cases. The technique 
was initially developed in Europe and subsequently the AneuRx, Ancure and Guidant stent-
graft devices were approved by the Food and Drug Administration (FDA) in September 1999. 
 
Early trials have demonstrated lower mortality and early morbidity rates and consequently 
EVAR has been used with increasing frequency.3-5  This is particularly true in the case of 
elderly and high-risk patients for whom traditional open repair carries significant risks.  In 
order to repair an aneurysm by endovascular methods, certain anatomical and morphological 
criteria must be met.  However there are no fixed criteria and they differ between different 
centres and for different stent-grafts. Typical criteria include: proximal neck length >10mm 
length, <26mm diameter and <60 degrees angulation; iliac artery diameter <16mm and 
>7mm.  Significant iliac artery tortuosity or calcification, or circumferential thrombus at the 
proximal neck are usually considered to be contraindications.  
 
 13 
Intervention techniques 
 
Open repair of AAA is performed in an operating theatre under general anaesthesia.  Access 
to the abdominal aorta is via a transperitoneal approach through a midline incision.  
Following retroperitoneal dissection of the aorta, a cross-clamp is placed across the proximal 
aneurysm neck and across each iliac arteries.  An arteriotomy is then made and an 
interposition Dacron graft (either tube or bifurcated configuration) is sutured into place.   The 
wound is then closed according to standard surgical techniques.    
 
Endovascular aneurysm repair involves positioning of an endograft within the abdominal 
aorta by a transfemoral or transiliac route with the aim of exclusion of the aneurysm from 
within the circulation.  The procedure is carried out in an operating room or endovascular 
suite under general or regional anaesthesia.  Access to the femoral arteries is achieved by 
surgical cut-down and the prosthesis is inserted via a preloaded delivery catheter system.  
One lumen of the catheter is used for guide wire access and flushing, whilst the other lumen 
contains the deployment line.  The delivery system usually has a tapered balloon creating an 
atraumatic tip during insertion.  Radio-opaque markers on the catheter and stent graft allow 
the endoprosthesis to be manoeuvred into position under fluoroscopic guidance.  The stent-
graft of appropriate size and configuration is selected on the basis of diagnostic imaging.  The 
stent graft is usually oversized by 10-20% to decrease the incidence of type I endoleak.  
Following successful insertion of the stent-graft a completion angiogram is performed to 
document exclusion of the aneurysm from the circulation. The femoral arteriotomies are 
closed according to standard surgical techniques.  Following open repair or EVAR patient is 
transferred to an appropriate after-care setting for observation. 
 
Prior to undertaking endovascular aneurysm repair, the patient must undergo preoperative 
contrast-enhanced computed tomographic (CT) scanning to accurately determine aneurysm 
morphology.  A full clinical assessment must also be carried out to identify any risk factors 
for open and endovascular repair.  These two processes are required to ensure that the patient 
fulfils the clinical and anatomical inclusion criteria for endovascular aneurysm repair. 
 
The lower physiological stress of the minimally invasive endovascular approach is associated 
with lower morbidity and mortality rates, and consequently is a therapeutic option for high 
risk patients for whom conventional open repair would not be appropriate.  Endovascular 
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aneurysm repair has been performed not only as an elective procedure, but also on 
symptomatic and ruptured aneurysms.  However, only the technique of elective aneurysm 
repair has been considered in this review. 
 
 
Current practice in the UK 
 
There are currently around 40 centres in the UK undertaking EVAR for abdominal aortic 
aneurysms (AAA). The majority of these centres have been involved in the EVAR 1 trial 
(randomised controlled trial comparing EVAR to open repair). Before being considered for 
participation in the trial, a new centre had to submit outcome data on 20 cases. 
 
Commercially-available endovascular stent-grafts are of one of three designs: aortic tube 
graft, aortic uniiliac graft or aortic biiliac (bifurcated) graft.  The stent-graft typically 
comprises a self-expanding nickel-titanium (nitinol) stent attached to a woven polyester 
fabric graft.  The tube graft is composed of a single structure, whilst the bifurcated grafts are 
modular and comprise multiple segments. Tube grafts are no longer used in this country.  The 
bifurcated graft consists of a proximal tube, a flow divider, a full-length ipsilateral iliac limb 
and a short contralateral stump for attachment of the second iliac limb.  The stent-grafts are 
attached to the native aortic wall by a number of metallic wires, hooks and anchors.  
Additional modular components include aortic and iliac extender cuffs and are used for the 
treatment of type I endoleaks.  The main stent-grafts used in this country are made by Cook 
(Zenith bifurcated graft, a custom made graft and an aortouniliac device), Medtronic (Talent 
endograft) and Gore (Excluder). 
 
Potential complications of aneurysm repair 
 
Traditional open surgical repair of abdominal aortic aneurysms is associated with significant 
morbidity and mortality risks, particularly as there are significant levels of co-morbidity in 
the relevant population.  Common complications of open aneurysm repair include 
haemorrhage, local wound infections, chest infections, the need for post-operative ventilation 
and clinical cardiac events.  Other less common complications include renal impairment 
(transient and permanent), lower limb ischaemia and trash foot, colonic ischaemia, graft 
infection and delayed rupture.  In assessing the efficacy and safety of alternative therapeutic 
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options, i.e. EVAR, it is important to consider all the above outcome measures.  However, 
endovascular repair is also associated with certain other complications such as endoleak, stent 
migration and stent wire fracture from metal fatigue. 
 
Endoleaks are a well recognised complication following aneurysm repair that is specific to 
endovascular repair. The classification of endoleaks used in this thesis is that developed by 
White et al, 1998.12 
 Type Ia  -  Perigraft leak from poor proximal attachment or seal 
 Type 1b  -  Perigraft leak from poor distal attachment or seal 
 Type II  -   Collateral backflow / retrograde endoleak 
 Type III -   Mid-graft fabric tear / modular disconnection or poor seal 
 Type IV -   Porosity – graft-wall fabric porosity or suture holes 
 
 
Decision analysis modelling and randomised controlled trials 
 
Level one evidence, (randomised controlled trial (RCT) data) is widely quoted as the gold 
standard for research in medicine and there have been a number of such trials that have 
reported medium-term results on the use of EVAR in the management of abdominal aortic 
aneurysms.  The EVAR 1, DREAM and OVER trials compared the endovascular approach 
against open repair in aneurysm patients considered medically ‘fit’ for an open procedure.  
The EVAR 2 trial compared EVAR to best medical therapy in a group of aneurysm patients 
deemed ‘unfit’ for surgical repair.  In addition, there are other RCTs that are currently being 
carried out to assess the role of EVAR in the management of abdominal aortic aneurysms.  
These trials include the ACE trial in France. 
 
However there are a number of issues regarding the role of RCTs in evaluating the safety and 
efficacy of new developments such as EVAR.  EVAR is a new technique that was only 
developed in 1991.  Consequently such a technique is not stable, but is continually evolving.  
This has a number of inevitable consequences; firstly operators will have a limited amount of 
experience, and there is obviously a learning curve associated with any new technique.  
Secondly the stent-graft device itself has undergone substantial development and the first 
generation stents which were of a tube-configuration have all been withdrawn from current 
usage.  In addition a significant number of second and third-generation commercially 
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developed devices have been withdrawn and the devices in use today are undergoing 
continual modification in response to clinical demand.  Therefore a number of participants in 
the RCTs will have had their aneurysm repaired by devices which are now withdrawn, or 
modified; a fact that requires consideration when interpreting the results. 
 
Another issue with RCTs is the underlying heterogeneity of the study population.  The 
inclusion and exclusion criteria must be sufficiently relaxed to allow for sufficient 
recruitment to the trial, whilst at the same time be sufficiently rigorous to minimise 
heterogeneity.  Creation of a homogenous study population generates more robust results 
which enables their application to more specific cases and sub-groups.  Further disadvantage 
of RCTs are the time and cost factors associated with such a research technique.   
 
Modelling techniques have a number of advantages and disadvantages over RCTs.  It is 
possible assess the outcome of adjusting various parameters within the model, something that 
is not possible from randomised trials without conducting a new one, with its associated time 
and expense.  Modelling is therefore particularly beneficial for evolving techniques such as 
EVAR, as the impact of ongoing developments can be assessed more easily.  However 
models are limited by the availability of high quality data that is necessary to generate the 
required transition probabilities. 
 
The management of a patient with an AAA is a time dependent process, and requires 
modelling using Markov techniques.  A Markov model contains a finite number of states in 
which a person may be found at any time.  Markov processes occur within a discrete length 
of time.  Progression through time occurs in cycles, the length of which is fixed and defined 
by the creator of the model.  During each cycle, a patient makes transitions from one state to 
another, until either the preset number of cycles has been completed or they reach the state 
death.  Death is an absorbing state which means that once a patient enters this state, they 
cannot leave.143 
 
Despite recent publications of large RCT concerning the use of EVAR, it can be difficult to 
translate these results to accurately reflect risks and benefits on an individual basis.   Decision 
analysis is a technique used to aid decision-making under conditions of uncertainty by 
systematically representing and examining all of the relevant information for a decision and 
the uncertainty around that information.  Evidence based medicine is more than just the 
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application of trial evidence to an individual; it is influenced the fact not every individual will 
have the same absolute treatment response as a clinical trial and also by the fact that 
individuals differ in their choices.  Each individual will trade off different outcomes against 
potential adverse consequences (utilities) in making a particular decision.144    
 
Therefore the Markov model created has predefined health states in which a patient with an 
aneurysm can exist and the transition probabilities used do determine movement between the 
health states are determined from a systematic review of the literature.  In addition the user of 
the model can input patient specific variables so that the model will provide meaningful, 
individualised information relating to risks and benefits that could assist in shared decision-
making and obtaining informed consent from patients with aneurysms, and could help to 
guide policy decisions in respect to patient selection for EVAR. 
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METHODS 
 
Creation of the model involved several key areas.  These included development of a 
conceptual model to reflect the clinical management of a patient with an aneurysm, 
identification of input parameters and transition probabilities, and validation of the model by 
recent RCT outcome data.    
 
Development of the model 
 
The clinical states, transition probabilities, management options and outcome measures were 
established from a combination of a systematic literature review and expert opinion from 
clinicians involved in the care of patients with abdominal aortic aneurysms.  The Markov 
model was developed as a spreadsheet in Microsoft Excel.  The model was developed in 
Microsoft Excel rather than other modelling specific software such as Datapro by TreeAge 
for several reasons.  Firstly once developed it was envisaged that the model would be readily 
accessible in clinical practice and Microsoft Excel software is available in most NHS Trusts, 
unlike the TreeAge software.  Secondly it was considered that significantly more people 
would be familiar with Excel than TreeAge and consequently the model would be easier to 
use in Microsoft Excel. 
 
A user-friendly data input sheet was created to allow the vascular surgeon to enter patient-
specific variables so that the results created from the model would be applicable to that 
particular patient. 
The following variables were listed on the data input sheet: 
• Patient age  
• Operative mortality rate – It was clear from the systematic literature review that there was 
wide variation in 30-day mortality rate for both open repair and EVAR.  In addition there 
are a variety of scoring methods available to assess the 30-day mortality rate from open 
aneurysm repair.  Consequently the data input sheet contained a pick-list from which the 
expected 30-day mortality for open repair could be chosen.  The pick list contained six 
different expected mortality rates; these were from a meta-analysis of EVAR 1 trial type 
patient studies, EVAR 2 trial, an expected value based upon a calculation from a 
Bayesian risk model145, an expected value based upon a calculation from the P-POSSUM 
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risk model146, the Glasgow aneurysm score147 and an option to enter the operative 
mortality rate from the user’s own clinical practice.  The P-POSSUM risk model was 
chosen as this had been demonstrated to be as accurate in risk prediction as the V-
POSSUM model and the author assumed a greater familiarity amongst model users with 
the P-POSSUM equation.148  The data input sheet is therefore divided into three sections.  
At the top of the data input sheet there are tables containing pick-lists for all the variables 
required to calculate the expected mortality rate from the three risk models, (Bayesian, 
Glasgow aneurysm score and P POSSUM).  The user of the model can enter data into any 
or all of the risk prediction tables at the top of the data input sheet.  The table in the 
middle of the data input sheet then displays the mortality rates for the six options so that 
the model user can compare the expected mortality rates.  The table at the bottom of the 
data input sheet then contains a pick-list of the six thirty-day open surgical mortality rates 
and it is this value that is then used in the model to calculate the patient’s results.  The 
results from the literature review provided a hazard ratio for 30-day mortality rate for 
EVAR compared to open repair.  The 30-day mortality rate for EVAR was then 
calculated based upon the hazard ratio of the operative mortality rate selected by the 
model user.  For the delayed EVAR and delayed open repair pathways, the patient would 
have increased in age by the time the procedure was carried out.  Consequently the 
operative mortality rate at the point at which the delayed intervention is carried out is 
adjusted by an interpolated hazard ratio obtained from the UK Small Aneurysm Trial. 
• Hazard ratio for general mortality – The model was programmed to cross-reference the 
patient’s age during that particular cycle against the expected general mortality rate for a 
person of that age.  The general mortality rates referred to in the model are adjusted to 
reflect the individual patient’s co-morbidities.  The hazard ratio is generated by the model 
and is determined by the expected 30-day mortality rate for any particular patient. 
• Aneurysm size – The patient’s aneurysm size is inputted into the data entry sheet, and this 
value is then entered into the model.  The aneurysm size increases during each cycle 
according to a table of expansion rates obtained from the literature review.  The aneurysm 
rupture rate is calculated during each cycle by cross-referencing the size at that stage 
against the probability of rupture for that given size. 
• Threshold for aneurysm repair – Two of the five management pathways envisaged during 
development of the conceptual model involved delaying treatment of the aneurysm until a 
larger diameter had been reached, at which the probability of death from the procedure 
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would approach the probability of rupture in a patient with multiple co-morbidities.  
Therefore the threshold diameter at which the vascular surgeon considered treatment to be 
of benefit could be entered so that the impact of delaying intervention in that particular 
patient could be assessed.  
• Hazard ratio for rupture rates - The option of manipulating the rupture rate for a given 
diameter of aneurysm was also included on the data-entry sheet.  Although the 
probabilities of rupture were acquired from a systematic literature review, there was a 
wide variety of rupture rates that were reported.  The model user could therefore alter the 
likelihood of rupture and assess its impact on the model. 
• Discount rate for quality adjusted survival – One of the outcomes from the model is 
quality adjusted survival.  A variable discount rate could be applied to this so that the 
model user could assess the impact of adjusting the discount rate. 
• Anatomical suitability for EVAR – From the systematic review it was noted that there 
was a wide variety in anatomical requirements in order to undertake an endovascular 
procedure.  It was considered that the anatomical suitability for EVAR would affect the 
operative mortality rate for EVAR, the primary conversion rate and probability of 
undergoing a secondary procedure subsequently.  Therefore a pick-list of four options for 
anatomical suitability was created on the data-entry sheet.  These options were; very 
unsuitable, unsuitable, suitable and highly suitable.  If very unsuitable was selected then 
the value corresponding to two standard deviations above the mean for operative 
mortality rate for EVAR, primary conversion rate and reintervention rate would be 
returned into the model.  Likewise unsuitable would return values one standard deviation 
above the mean, suitable would return the mean values and highly suitable would return 
values one standard deviation below the mean.  Therefore by adjusting the anatomical 
suitability for EVAR, the model user would be able to assess the likely success of an 
endovascular procedure in that patient. 
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Systematic review 
 
Having devised the conceptual model, a systematic review of the literature was performed to 
obtain the required transition probabilities. 
 
Search strategy 
The search aimed to identify all references relating to the safety and efficacy of using 
endovascular stents for the treatment of abdominal aortic aneurysms.   
 
Sources searched 
Thirteen electronic bibliographic databases were searched, covering biomedical, health-
related, science, and social science literature:  
• BIOSIS 
• Cinahl 
• Central Database 
• Cochrane Database of Systematic Reviews (CDSR) 
• Centre for Reviews and Dissemination (CRD) Databases  
• Database of Abstracts of Reviews of Effects (DARE) 
• Embase 
• Health Technology Assessment (HTA) Database 
• Medline 
• Medline In Process 
• NHS Economic Evaluations Database (NHS EED) 
• Science Citation Index 
• Social Sciences Citation Index 
 
Search terms 
A combination of free-text and thesaurus terms were used.  'Population' terms (for example, 
abdominal aortic aneurysm, AAA) were combined with 'intervention' terms (for example, 
EVAR, endovascular aneurysm repair, endovascular stent). 
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Search restrictions 
The searches were restricted to English language articles and restricted to papers published 
from the year 2000 to November 2009.   
Inclusion and exclusion criteria 
Types of studies 
Randomised controlled trials, controlled clinical trials, comparative observational studies, 
case series studies, and population-based registries assessing the efficacy and/or safety of 
EVAR were included.  Systematic reviews and single case reports were excluded from the 
review.  Case series comprising less than two hundred patients or contained no primary 
outcome data of interest were excluded.  For studies with multiple publications, those with 
the greatest number of participants, the longest follow-up, or the latest publications with the 
most amount of outcome data were included. 
Types of participants 
Studies including adults with asymptomatic infrarenal abdominal aortic aneurysms 
undergoing elective intervention were eligible for inclusion.  Patients with symptomatic or 
ruptured aneurysms were excluded from this review. 
Types of interventions 
Endovascular aneurysm repair of abdominal aortic aneurysms.  Thoracic and thoraco-
abdominal aortic aneurysms were excluded. 
 
Types of outcome 
Efficacy 
Main clinical outcomes: 
• Successful endograft deployment 
• Primary technical success – defined as complete exclusion of the aneurysm from the 
circulation immediately following completion of the procedure 
• Thirty day technical success – defined as complete aneurysm exclusion at thirty days 
• Secondary technical success – defined as complete aneurysm exclusion following a 
secondary intervention 
• Aneurysm rupture following successful EVAR 
• Changes in size of aneurysm during follow-up 
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• Primary conversion rate (conversion to open procedure) 
• Delayed conversion rate (conversion to open procedure) 
• Secondary intervention rate 
Other clinical outcomes 
• Proportion of population for whom EVAR technically feasible 
• Procedural blood loss 
• Length of ITU stay 
• Total length inpatient stay 
 
Safety 
The frequency and type of adverse events were tabulated to assess the safety of EVAR.  
Safety endpoints were considered in the following categories:  
• Technical problems 
o Stent migrations 
o Stent fracture 
o Stent wire fracture 
o Graft limb thrombosis 
o Graft stenosis 
o Graft kinking 
o Endoleak – type I, II and III 
o Access artery injury 
o Contrast reaction 
• Major morbidity 
o Thirty day mortality rate 
o Subsequent death from aneurysm and non-aneurysm related causes 
o Cardiac event 
o Renal impairment 
o Graft infection 
o Colonic ischaemia 
o Lower limb ischaemia 
o Minor morbidity 
o Wound infection 
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Quality assessment strategy 
The methodological quality of all full-text reports was assessed by one reviewer using three 
separate quality assessment forms.  The 17-question checklist used to assess the quality of the 
case series studies (Appendix 2) was adapted from the NHS Centre for Reviews and 
Dissemination’s guidance for those carrying out or commissioning reviews (2001) and from 
Downs and Black.  The 18-question checklist used to assess the quality of the non-
randomised controlled trials and comparative observational trials (appendix 3) is also adapted 
from the NHS Centre for Reviews and Dissemination’s guidance for those carrying out or 
commissioning reviews (2001) and from Downs and Black.  The 11-question checklist used 
to assess randomised controlled trials is a modified version of the Delphi List, a criteria list 
developed using Delphi consensus methods by Verhagen and colleagues to assess the quality 
of randomised controlled trials (Appendix 4). 
 
Data extraction strategy 
A data extraction form was specifically developed in an Access database to record details of 
the design of included studies, characteristics of participants, technical aspects of EVAR, and 
outcome measures of interest.  Data extraction was carried out by one reviewer and checked 
for accuracy by a second. Reviewers were not blinded to the names of study authors, 
institutions, or publications. 
Data synthesis 
For binary outcomes the pooled odds ratio and its 95% confidence interval were calculated 
using a fixed effects model in Review Manager Version 4.2.7.  Where significant 
heterogeneity was indicated the results were recalculated using a random effects model.  For 
continuous outcomes, a weighted mean difference and its 95% confidence interval were 
calculated, also in Review Manager Version 4.2.7.  Where standard deviations were not 
reported by the authors they were estimated from the interquartile range (if available) using 
methods described in the Cochrane Reviewers Handbook (based on the width of the 
interquartile range being equivalent to approximately 1.35 times the standard deviation), in 
order to calculate a weighted mean difference (WMD).  Such calculations make the 
assumption that the data follows a normal distribution.  If this data was also not available, 
studies were not combined in the meta-analysis.  For studies that did not include a 
comparison group, an overall mean and its 95% confidence interval was calculated. 
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Validation of the model 
 
The first stage of validation of the model involved building various internal checking systems 
into it.  These systems ensured that for all cycles within the model, no negative figures were 
generated and that the sum of all the states in which a person could exist totalled one.  This 
was important to check that all patients were accounted for as they progressed through the 
model and that no patients were being lost or created.  Face validity was used to test the 
results generated by the model against a variety of scenarios.  Firstly the 5Y survival outcome 
results from the model were compared against expected survival for different patient cohorts.  
Secondly the data from the recent randomised control trials that have published short and 
medium-term results was used to validate the model.  Average patient data from each of the 
RCTs was used to generate a hypothetical patient that was inputted into the model.  The 
outcomes generated by the model for an average hypothetical patient from each trial were 
then compared against the published results from that trial.  The model was designed to 
generate results for all the major outcome parameters reported by the trials and therefore the 
model was validated against all of these. 
 
Thirdly the model contains an anatomical suitability for EVAR parameter, which in turn 
affects the operative mortality rate and primary conversion rate for EVAR.  Consequently a 
highly anatomically unsuitable aneurysm for EVAR would be expected to generate results for 
the EVAR pathway that approximated those generated by the open repair pathway.  
Therefore scenarios in which the anatomical suitability for EVAR was adjusted were also 
used to validate the model.   The methods of sensitivity analysis describe above are known as 
point-estimate or expected value analysis and are a form of deterministic sensitivity analysis.  
Other more complex methods of sensitivity analysis such as Monte Carlo simulation, also 
known as probabilistic sensitivity analysis were considered but not used for several reasons.  
During Monte Carlo simulation the model will run many times over assigning values that are 
randomly drawn from probability distributions to the different parameters and consequently 
the results produced quantify the total impact on uncertainty in the model.  However the 
methods actually used to assess parameter uncertainty within the model did not generate 
significantly different results and as Monte Carlo simulation required specific programmes 
such as TreeAge, it was not considered necessary to use such analytical techniques. 
 
 26 
The final stage in the validation of the model would involve the application of the model in 
clinical practice.  The model could be used by a variety of vascular surgeons and patients to 
assess whether the graphical and tabulated results generated were of any benefit in the 
management process of an individual patient with regards to decision-making and informed 
consent. 
 
 
Outcome results generated by the model 
 
From the systematic literature review, five elective management strategies were identified for 
a patient with an abdominal aortic aneurysm.  These were EVAR, open repair, best medical 
therapy (BMT), delayed open repair at a threshold aneurysm diameter and delayed EVAR at 
a threshold aneurysm diameter.  For each of these management strategies, the model 
produces graphical and results regarding estimated survival and reintervention rates.  
Individualised survival curves, quality adjusted survival curves and discounted quality 
adjusted survival curves are generated for each management option.  Health related quality of 
life data published from the EVAR 1 trial demonstrated no significant reduction in quality of 
life in the long-term for either open repair or EVAR.   Therefore utility estimates were based 
upon published figures derived from the EuroQol tariff values for male’s age 65-74 years in 
the Health Survey for England 1996.  Expected survival at specific time points and estimated 
median survival are also generated as tabulated results for each option.  In addition both 
aneurysm-related and general mortality curves, cumulative reintervention rate curves and 
cumulative rupture rate curves are generated for each therapeutic option. 
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Potential applications for the model 
 
The model is designed to produce individualised results that can be used by a vascular 
surgeon and patient to make an evidence-based management decision for that particular 
patient.  In particular, for high-risk patients there is likely to be an increase in median survival 
associated with delayed intervention.  By adjusting the threshold aneurysm diameter at which 
intervention is carried out, the optimal time delay that is associated with either greatest 
overall survival or greatest median survival can be determined.  For example the model could 
be used at a Multi-Disciplinary Team Meeting in which one could use the model to look at 
the predicted outcomes based upon patient’s clinical and demographic characteristics to 
decide upon the most appropriate management strategy for an individual patient.    
 
The model could be used to help put the patient in a position where they can weigh up their 
preferences for the different outcomes and risk distributions; however for this a number of 
factors need to be considered.  There are different potential distributions of risk and 
individual patients may have differing strength of preference for early vs delayed risks.  For 
example there is an early higher risk of open surgery, but there is a need for more instensive 
follow-up following endovascular repair with a potentially higher re-intervention rate.  A 
patient may have a particular preference for early or late risk, but the model could be used to 
show the different risk profiles to help an individual patient make a balanced, informed 
decision.    
 
In addition, the model may be used as a research tool to assess the likely outcome changes 
that may occur with a continually evolving relatively new technique such as EVAR. 
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RESULTS 
 
Systematic review 
Type and quantity of evidence available 
From the literature search, one hundred and fifty-one papers were identified as being 
potentially relevant and full papers were obtained and assessed in detail for inclusion.  From 
these, a total of 116 studies were identified for inclusion. There were 6 randomised controlled 
trials (8 reports), 36 non-randomised controlled trials, 17 comparative observational studies, 
44 case series and 11 registry publications.  
 
A summary of the included studies is shown in Table 1 
 
The number of participants in the included studies ranged from 40 to 65506 (total n=146,883) 
and the mean age (where reported) ranged from 65 to 85 years.  The number of patients 
receiving EVAR ranged from 20 to 65506 (total n=128,374). 
Mean follow-up ranged from 1 to 62 months.  Seventy two studies had a mean follow-up of 
12 months or more, and 21 had a mean follow-up of at least 36 months.  The mean follow-up 
period was not recorded in 33 of the papers. 
Forty-one of the primary studies were set in North-America, two were set in Australia, and 
the rest were set in Europe (6 UK papers and 8 EUROSTAR database publications).  In 
addition, 22 of the studies were multi-centre studies.  The device manufacturer funded eight 
of the studies and one was funded by the US government. The remaining studies did not 
declare a source of funding.  
There appeared to be overlap in the patient populations in the included studies.  Some studies, 
for example, were single-centre reports of patients, some of whom had been included in 
larger, multi-centre studies.  However, the numbers of patients included in the trials was not 
always clearly reported in these articles.  Where possible these studies have been grouped 
together.  It is therefore not possible to give an exact representation of the number of patients 
who have received EVAR in the included studies. 
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Table 1 Summary of included studies  
Author, Year RCT/NRCT/
Case series/ 
Comparative 
study 
Mean 
age 
 
Enrolled (all 
interventions) 
No receiving 
EVAR 
Months of 
follow-up  
(range) 
Aarts 200513 NRCT NR 215 99 23 (0-73) 
Abbruzzese 200814  Case Series 76 565 565 30 (±21) 
Anderson 200415 NRCT NR 4769 1706 NR 
Arko 200716 Comp Study NR 65506 65506 NR 
Aune 200717 NRCT 74 504 118 44 (0-117) 
Becquemin 200418 Case Series 71 250 250 28 
    Becquemin 200019 NRCT 70 180a 73 7 (0-40) 
Bertrand 200120 NRCT 71 386 193 NR 
Blankensteijn 200521 RCT 70 351 173 21 (0-42) 
     Prinssen 200422 RCT 70 351 173 1 
Blum 200123 Comp study 70 298 298 (2-50) 
Bolke 200124 NRCT 72 40 20 NR 
Boult 200625 Case Series 
(R) 
75 961 961 NR (5-60) 
    Boult 200426 Case Series 
(R) 
75 950 950 NR 
Borchard 200527 NRCT 74 166 65 21 (1-74) 
Bos 200828 Case Series 72 234 234 27 (1-104) 
     Verhoeven 200429 Case Series 70 308 308 36 (±22) 
Brewster 200630 Case Series 73 873 873 27  
Bush 200731 NRCT 72 2368 788 NR 
Cao 200432 NRCT 72 1119 534 33 (13-50)c 
     Cao 200933 Case Series 74 349 349 25 (12-60) 
     Cao 200634 Case Series 72 649 649 38  
     Parlani 200235 Comp study 70 336 336 14 (1-46) 
     Zannetti 200136 Comp study 70 266a 266 11 (1-32) 
Carpenter 2004a37 Case Series NR 227 227 11 (0-41) 
Chahwan 200638 NRCT 73 677 260 36 
Chisci 200939 NRCT 73 187 74 25 (0-39) 
Conrad 200940 Case Series 76 832 832 35 (0-113) 
Corriere 200441 Case Series 72 220 220 NR 
Cuypers 200142 RCT 69 76 57 NR 
Dias 200943 Case Series 74 304 304 54 
El Sayed 200944 Case Series NR 444 444 57 (±9) 
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Author, Year RCT/NRCT/
Case series/ 
Comparative 
study 
Mean 
age 
 
Enrolled (all 
interventions) 
No receiving 
EVAR 
Months of 
follow-up  
(range) 
Espinosa 200945 Case Series 73 337 337 59 (12-120) 
    Espinosa 200546 Case Series 71 193 193 36 
Garcia-Madrid 
200447 
NRCT NR 83 53 26 
Greenhalgh 2005d48 RCT 74 1047 531 35 (23-48)c 
   Greenhalgh 2004d49 RCT 74 1047 531 1 
Greenhalgh 2005be 50 RCT 76 238 166 29 (19-43)c 
Go 200851 Case Series 74 376 376 NR 
Hansman 200352 NRCT 72 100 50 NR 
Hinchliffe 200453 Case Series 74 269 269 12 
Hiramoto 200654 Case Series 76 325 325 30 (1-85) 
Hynes 200755 NRCT 75 162 66 23 (±16) 
Iannelli 200556 NRCT 75 62 34 14 (12-36) 
Jiminez 200757 Case Series 78 574 574 42 (±32) 
Jones 200758 Case Series 76 873 873 33 
Jordan 200459 NRCT 73 404 259 28 
Lederle 200960 RCT 70 881 444 21.6 
Lee 200461 NRCT 72 7172 2565 NR 
Maldonado 200762 Case Series 73 430 430 36 (2-94) 
   Maldonado 200463 Case Series 72 311 311 22 (2-72) 
May 200064 Case Series 72 266 266 >6 
Mistry 200765 NRCT 66 278 122 33 (0-88) 
Moore 200366 NRCT 73 684 573 NR (1-60) 
Nevala 200967 Case Series 73 206 206 29 (±20) 
Ohki 200168 Case Series 76b 239 239 15 (<75) 
Ouriel 200369 Comp study 75b 704 704 NR 
     Ouriel 200370 Comp study 75 700a 700 12 
Park 200671 NRCT 75 410 342 NR 
Paolini 200872 NRCT 83 150 81 25 (1-80) 
Pitoulias 200973 Case Series 69 617 617 47 (1-94) 
Qu 200974 Case Series 72 612 612 62  
     Qu 200775 Case Series 69 378 378 27 (1-84) 
Ricco 200376 Case Series 72 1012 1012 11 
Sahal 200877 NRCT 72 895 452 21.2 (0-136) 
  Teufelsbauer 200378 NRCT 72 756 275 NR 
Sampaio 200979 Case Series 75 241 241 10 (1-65) 
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Author, Year RCT/NRCT/
Case series/ 
Comparative 
study 
Mean 
age 
 
Enrolled (all 
interventions) 
No receiving 
EVAR 
Months of 
follow-up  
(range) 
     Sampaio 200480 Case Series 75 241 241 10 (1-71) 
     Elkouri 200381 Case Series 76 100 100 7 (1-60) 
     Elkouri 200482 Case Series 74 355 94 NR 
Schermehorn 200883 NRCT 76 22830 22830 NR 
Siccard 200684 NRCT 75 565 61 32 (0-123) 
Soulez 200585 RCT 70 40 20 27 (12-48) 
Szmidt 200786 Case Series NR 445 445 30 
Thomas 200587 Case Series 
(R) 
73 1000 1000 37 
Traul 200888 Case series 73 245 245 30 (±18) 
Waasdorp  200889 Case Series 71 291 291 4 
   Herwaarden 200790 Case series 71 212 212 52 (1-109) 
Wald 200691 NRCT 72 6516 2651 NR 
Wales 200892 Case Series 73 286 286 16 (0-70) 
Vasquez 200493 Comp study 75 212 212 NR 
Zeebregts 200494 NRCT 72 286 93 19 
      
EUROSTAR database (n=7043) 
Hobo 200895 Case Series 
(R) 
72 7043 7043 18.6 (0-108) 
     Koning 200796 Case Series 
(R) 
74 5612 5612 NR 
     Marrewijk 200597 Case series 
(R) 
71 6787 6787 21 (0-108) 
     Lange 200598 Case series 
(R) 
71 4888 4888 19 
    Hobo 200699 Case Series 
(R) 
72 2846 5846 23 
    Fransen 2003100 Case Series 
(R) 
71 4613 4613 21 (1-72) 
    Laheij 2002101 Case Series 
(R) 
NR 2863a 2863 NR 
  Vallabhaneni 
2001102 
Case Series 
(R) 
71 2862 a 2862 12 (0-72) 
Excluder Clinical Trial(n=334)a 
Peterson 2007103 NRCT 7 334 235 60 
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Author, Year RCT/NRCT/
Case series/ 
Comparative 
study 
Mean 
age 
 
Enrolled (all 
interventions) 
No receiving 
EVAR 
Months of 
follow-up  
(range) 
Lifeline Registry (n=2998) 
Zarins 2005104 NRCT 73 2998 2664 34 
Powerlink Clinical Trial (n=349) 
Carpenter 2004105 NRCT 73 258 192 NR 
Carpenter 2006106 NRCT 73 258 192 36 
Parmer 2006107 NRCT 73 283 283 NR 
Wang 2008108 NRCT 73 258 192 49 (±20) 
Talent Clinical Trial (n=471) 
Criado 2001109 Comp study NR 471 471 NR 
    Criado 2003110 NRCT 76 366a 240 13 
   Fairman 2004111 Comp study NR 237 237 21 
AneuRx Clinical Trial (n=1193)a 
Arko 2002112 NRCT 73 497 200 12 (1-60) 
    Arko 2003113 Comp study 73 206a 206 32 (3-55) 
Ayerdi 2003114 Comp study 73 96 96 12 
Howell 2001115 Case Series 72 215 215 14 
    Howell 2000116 Comp study 72 89a 89 (1-18) 
Lee 2002117  Comp study 74 150 150 NR 
    Lee 2000118 Case Series 74 67a 67 18 
Ramaiah 2002119 Comp study 74 260 260 NR 
Shames 2003120 Comp study 73 245 245 11 (1-26) 
Tonnessen 2005121 Comp study 73 130 130 39 (12-72) 
Wolf 2002122 Comp study 75 189 189 13 
Zarins 2000123 Case Series NR 149 149 12 (1-39) 
Zarins 2004124 Case Series NR 1193 1193 <48 
    Zarins 2003125 Case Series 73 383a 383 36 
Zenith Clinical Trial (n=432) 
Greenberg 2004126 NRCT NR 432 352 NR 
     Hugl 2007127 Case Series  74 366 366 NR 
     Lalka 2005128 Case Series NR 136 369 36 (1-61) 
Total  73 146883 128374  
aExcluded from count of enrolled population (all interventions and EVAR) as duplicate series 
b Some participants may overlap with the Talent and AneuRx clinical trial populations 
cIQR given for follow-up 
d EVAR 1 Trial                                   e EVAR 2 Trial  
NR – Not reported                              (R) Registry publication 
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Number and type of excluded studies 
Out of the 151 papers initially assessed as potentially relevant for the review, 35 papers were 
judged as being unsuitable for inclusion in the current review.  A summary of the reasons for 
exclusion is shown in Table 2. 
 
Table 2 Reasons for study exclusion 
Reason for exclusion Number of articles 
Not a primary study 4 
Small case series (n<200) 1 
Insufficient outcome data of interest 6 
More recent/relevant publication available 23 
Other 1 
Total 35 
 
Quality of the available evidence 
Randomised controlled trials 
The results of the quality assessment of the six RCTs (eight papers) is summarised in Table 3.  
How patients were assigned to treatment groups was reported and random in all of the 
included RCTs with the exception of the study by Cuypers et al.45  Patients were randomised 
to EVAR with a 3:1 ratio, but no information is provided as to the method of randomisation.  
In the two EVAR trials,52,53 patients were randomised using a 1:1 ratio in randomly sized 
permuted blocks.  Abdominal aortic aneurysm repair cannot be blinded to the care provider 
or the patient as it is an invasive procedure, so these checklist items were not applicable.  
Primary outcome measures were presented as point estimates and measures of variability in 
all RCTs.  In the study by Cuypers et al.45 there was no record of losses to follow-up and it 
was unclear whether the procedure was undertaken by an experienced person.  The study by 
Soulez et al also failed to document the level of operator experience.  In the remaining 
studies, the losses to follow-up and level of operator experience were well documented. 
 
Table 3 Summary of the quality assessment of the randomised controlled trials  
Criteria Yes No Unclear 
Was the assignment to the treatment groups really random? 5 0 1 
Was the treatment allocation concealed? 0 N/A 0 
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Were the groups similar at baseline in terms of prognostic factors? 6 0 0 
Were the eligibility criteria specified? 6 0 0 
Were the groups treated in the same way apart from the intervention 
received? 
6 0 0 
Was the outcome assessor blinded to the treatment allocation? 5 0 1 
Was the care provider blinded? 0 N/A 0 
Were the patients blinded? 0 N/A 0 
Were the point estimates and measures of variability presented for the 
primary outcome measures? 
6 0 0 
Was the withdrawal/drop-out rate likely to cause bias? 0 5 1 
Did the analyses include an intention-to-treat analysis? 5 0 1 
Was the operation undertaken by somebody experienced in performing 
the procedure 
4 0 2 
 
Non-randomised controlled trials 
These studies compared a group of patients undergoing EVAR against a group of patients 
undergoing open repair.  A summary of the quality assessment of the 36 non-randomised 
controlled trials is presented in Table 4.  
The participants were generally a representative sample, although the inclusion and exclusion 
criteria for the studies were only moderately-well documented overall and were only clear in 
seventeen studies.22;55;107   Enrolment of patients was reported to be consecutive in twelve 
studies.20;22;87;107 and data was collected prospectively in twenty-three studies.18;87  The level 
of operator experience was not clearly documented in any of the studies. 
Valid outcome measures were used in all studies, although only fifteen considered all 
outcomes considered important.71;107  Only five studies provided information on non-
respondents or dropouts and in the majority of the remaining studies it was unclear as 
whether participants lost to follow-up were likely to introduce bias.  Analyses were adjusted 
for confounding factors in only three of the studies. 
 
Table 4 Summary of the quality assessment of the non-randomised controlled 
trials  
Criteria Yes No Unclear 
Were participants a representative sample selected from a relevant patient 
population? 
30 0 6 
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Were the inclusion/exclusion criteria of participants clearly described? 24 4 8 
Were participants entering the study at a similar point in their disease 
progression? 
13 9 14 
Was selection of patients consecutive? 12 3 21 
Was data collection undertaken prospectively? 23 6 7 
Were the groups comparable on demographic characteristics and clinical 
features? 
10 23 3 
Was the intervention (and comparison) clearly defined? 34 2 0 
Was the intervention undertaken by someone experienced at performing the 
procedure? 
0 0 36 
Were the staff, place, and facilities where the patients were treated 
appropriate for performing the procedure? (E.g. access to back-up facilities? 
26 0 10 
Were all the important outcomes considered? 15 21 0 
Were objective (valid and reliable) outcome measure/s used? 36 0 0 
Was the assessment of main outcomes blind? 1 4 31 
Was follow-up long enough to detect important effects on outcomes of 
interest? 
24 0 12 
Was information provided on non-respondents, dropouts? 5 29 2 
Were participants lost to follow-up likely to introduce bias? (e.g. high drop-
out rate; differential drop-out; no description of those lost) 
1 5 30 
Was length of follow-up similar between comparable groups 18 5 13 
Were all the important prognostic factors identified? 27 6 3 
Were the analyses adjusted for confounding factors? 3 26 7 
 
Comparative observational studies 
These studies compared two or more subgroups of patients undergoing endovascular repair.  
A summary of the quality assessment of the 24 comparative observational studies is 
presented in Table 5. 
The participants were a representative sample from a relevant population in twenty of the 
twenty-four studies.  The inclusion and exclusion criteria were only clearly described in half 
of the studies.  The groups were only comparable on demographic features in seven of the 
studies; in three studies, this was not applicable as the groups were set by different 
demographic or clinical features.  Objective outcome measures were used in all studies, 
although none reported on all important outcome measures of interest.  The description of 
participants lost to follow-up was poorly reported and consequently it was unclear whether 
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this was likely to introduce bias.  Important prognostic factors were reported in eleven 
studies, and in only four studies were the analyses adjusted for confounding factors. 
 
Table 5 Summary of the quality assessment of the comparative observational 
studies  
Criteria Yes No Unclear 
Were participants a representative sample selected from a relevant patient 
population? 
15 0 2 
Were the inclusion/exclusion criteria of participants clearly described? 10 4 3 
Were participants entering the study at a similar point in their disease 
progression? 
10 3 4 
Was selection of patients consecutive? 9 1 7 
Was data collection undertaken prospectively? 10 6 1 
Were the groups comparable on demographic characteristics and clinical 
features? 
6 7 4 
Was the intervention (and comparison) clearly defined? 17 0 0 
Was the intervention undertaken by someone experienced at performing the 
procedure? 
1 0 16 
Were the staff, place, and facilities where the patients were treated 
appropriate for performing the procedure? (E.g. access to back-up facilities? 
10 0 7 
Were all the important outcomes considered? 0 6 11 
Were objective (valid and reliable) outcome measure/s used? 17 0 0 
Was the assessment of main outcomes blind? 1 16 0 
Was follow-up long enough to detect important effects on outcomes of 
interest? 
15 0 2 
Was information provided on non-respondents, dropouts? 1 16 0 
Were participants lost to follow-up likely to introduce bias? (e.g. high drop-
out rate; differential drop-out; no description of those lost) 
0 1 16 
Was length of follow-up similar between comparable groups 12 1 4 
Were all the important prognostic factors identified? 8 9 0 
Were the analyses adjusted for confounding factors? 2 15 0 
 
Case Series 
A summary of the quality assessment of the 55 case series studies is presented in Table 6. 
The patients were a representative sample selected from a relevant population in two-thirds of 
the studies.  The exclusion and inclusion criteria were only clearly described in a third of 
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cases.  Data collection was prospective in just over half of the studies, but selection of 
patients was consecutive in a minority of studies. An attempt to blind the outcomes assessors 
was only made in one study.  
The level of experience of the person performing the procedure was only documented in one 
of the studies reviewed.  Although objective outcomes were used by all of the studies, only 
five studies reported on all outcomes considered important.  Information on losses to follow-
up was generally reported poorly and therefore it was unclear whether this was likely to 
introduce any bias. 
 
Table 6 Summary of the quality assessment of the case series 
Criteria Yes No Unclear 
Were participants a representative sample selected from a relevant patient 
population?  
39 1 15 
Are the inclusion/exclusion criteria of patients in the study clearly 
described?) 
24 23 8 
Were participants entering the study at a similar point in their disease 
progression? 
11 23 18 
Was selection of patients consecutive?   13 1 41 
Were all important prognostic factors identified? 27 11 17 
Was data collection undertaken prospectively? 29 10 14 
Was the recruitment period clearly stated? 52 3 0 
Was the intervention that which is being considered in the review? (or was 
it a significant modification?) 
54 0 1 
Was an attempt made to blind outcomes assessors? 1 54 0 
Was the operation undertaken by someone experienced in performing the 
procedure? 
1 0 54 
Did the staff, place, and facilities where the patients were treated provide an 
appropriate environment for performing the procedure? (e.g. was the 
intervention undertaken in a centre with the necessary back-up facilities?) 
10 0 15 
Were objective (valid and reliable) outcome measures used? 54 0 0 
Were all the important outcomes considered? 17 38 0 
Was follow-up long enough to detect important effects on outcomes of 
interest? 
49 0 6 
Was information provided on non-respondents, dropouts? 20 35 0 
Were participants lost to follow-up likely to introduce bias? (e.g. high drop-
out rate; no description of those lost) 
1 17 37 
Were the main findings clearly described? (to allow replication)  53 0 2 
 38 
EVAR VERSUS OPEN REPAIR 
Major outcomes 
30 day outcomes 
• Mortality 
Thirty-day mortality rates are displayed in Tables 8 and 9, and Figure 1.  Data from the 
RCTs25;45;52 showed a significant reduction in 30-day mortality for EVAR compared to open 
repair, (OR 0.27; 95% CI 0.15 to 0.51).  The results from the NRCTs are concordant with the 
above findings, showing a significant reduction following EVAR compared to open repair 
(OR 0.28; 95% CI 0.25 to 0.31). 
 
Table 7 30 day mortality rate for EVAR versus open repair (RCTs) 
Study ID EVAR Open repair 
n/N % n/N % 
Cuypers 200142 1/57 1.8% 1/19 5.3% 
Greenhalgh 200448 9/531 1.7% 24/516 4.7% 
Lederle 200960 1/444 0.2% 10/437 2.3% 
Prinssen 200422 2/171 1.1% 8/174 4.6% 
Soulez 200585 0/20 0% 0/20 0% 
 
Table 8 30 day mortality rate for EVAR versus open repair (NRCTs) 
Study ID EVAR Open repair 
n/N % n/N % 
Aarts 200513 1/99 1.0% 5/116 4.3% 
Anderson 200315 19/1706 1.1% 121/3063 4.0% 
Arko 200216 1/200 0.5% 10/297 3.4% 
Aune 200717 2/117 1.7% 16/386 4.1% 
Becquemin 200019 2/73 2.7% 12/107 1.9% 
Bertrand 200120 6/193 3.1% 12/193 6.2% 
Bolke 200124 0/20 0.0% 1/20 5.0% 
Borchard 200527 3/99 3.0% 0/65 0.0% 
Cao 200432 5/534 0.9% 24/585 4.1% 
Carpenter 200437 2/192 1.0% 4/66 6.1% 
Chahwan 200638 7/260 2.7% 14/417 3.5% 
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Chisci 200939 1/74 1.4% 2/61 3.3% 
Criado 2003110 1/240 0.4% 0/126 0.0% 
Elkouri 200482 0/94 0% 3/261 1.1% 
Garcia-Madrid 200447 2/53 3.8% 2/30 6.7% 
Greenberg 2004126 1/200 0.5% 2/80 2.5% 
Hansman 200352 1/50 2.0% 0/50 0.0% 
Hynes 200755 2/66 3.0% 3/52 5.8% 
Iannelli 200556 0/34 0% 1/28 3.6% 
Jordan 200459 6/259 2.3% 12/145 8.3% 
Lee 200461 33/2565 1.3% 176/4607 3.8% 
Mistry 200765 4/122 3.3% 7/156 4.5% 
Moore 200366 10/573 1.7% 3/101 3.0% 
Park 200671 7/342 2.0% 4/68 5.3% 
Paolini 200872 4/81 4.9% 6/69 8.7% 
Sahal 200877 10/452 2.2% 18/443 4.1% 
   Teufelsbauer 200378 7/275 2.5% 23/481 4.8% 
Schermehorn 200883 274/22830 1.2% 1096/22830 4.8% 
Sicard 200684 16/565 2.9% 3/61 5.1% 
Wald 200591 39/3865 1.0% 103/2651 3.9% 
Zarins CK 2005104 45/2664 1.7% 5/334 1.4% 
Zeebregts 200494 1/93 1.1% 15/194 7.7% 
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Figure 1 30 day mortality rate for EVAR versus open repair: Forest plot 
 
 
• Aneurysm rupture 
The primary objective of EVAR is to prevent subsequent rupture and its associated high 
morbidity and mortality rates.  Only four NRCTs reported on early rupture rates occurring in 
the first 30 days post procedure (see Table 9). The early rupture rate from these studies was 
0.1%.  Data from the included case series indicated an overall early rupture rate of 0.2% 
(95% CI 0.1% to 0.3%). 
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Table 9 Early (<30 days) aneurysm rupture rates following EVAR 
Author Number of patients Rupture 
Rate (%) EVAR With rupture 
Carpenter 2006106 192 0 0.0 
Cao 200432 534 1 0.2 
Sicard 200684 565 1 0.2 
Zarins 2005104 2664 3 0.04 
 
 
• Primary conversion to open repair 
This is defined as the number of patients undergoing conversion to open surgery immediately 
following a failed attempt at endovascular repair.  
From the four RCTs25;52 that reported this outcome, the primary conversion rate averaged 
1.2%, (see Table 10).  Seventeen NRCTs (see Table 11) reported the primary conversion rate 
and the results are displayed in Table 10.  The overall mean conversion rate was 1.8% (95% 
CI 1.6% to 1.9%).  Data from the 42 case series that reported on this outcome indicated a 
mean conversion rate of 1.3% (95% CI 1.1% to 1.4%). 
 
Table 10 Primary conversion rates following EVAR (RCTs) 
Author 
 
Total number of 
EVAR 
Primary conversion 
Number of patients Rate (%) 
Greenhalgh 200548 531 4 0.8 
Lederle 200960 444 7 1.6 
Prinssen 200422 171 3 1.8 
Soulez 200585 20 0 0 
 1166 11 0.94 
 
Table 11 Primary conversion rates following EVAR (NRCTs) 
Author 
 
Total number of 
EVAR 
Primary conversion 
Number of patients Rate, % (95% CI) 
Arko 200213 200 2 1 
Bertrand 200120 193 6 3.1 
Borchard 200527 99 0 0 
Cao 200432 534 7 1.3 
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Carpenter 2004105 192 3 1.6 
Criado 2003110 240 1 0.4 
Elkouri 200482 94 1 1.1 
Garcia-Madrid 200447 53  0 0 
Greenberg 2004126 200 0 0 
Hansman 200352 50 0 0 
Ianelli 200556 34 0 0 
Jordan 200459 259 1 0.4 
Mistry 200765 122 1 0.8 
Moore 200366 573 42 7.3 
Schermerhorn 200883 22830 365 1.6 
Zarins 2005104 2664 68 2.6 
Zeebregts 200494 93 1 1.1 
 28430 498 1.8 (1.6% - 1.9%) 
 
Longer term outcomes 
• Aneurysm-related mortality 
There were 10 studies that had documented deaths that were directly attributable to the 
aneurysm.  From the DREAM25 EVAR 152 and OVER trials, there was a significant reduction 
in AAA related deaths in the EVAR group from 30-days post-procedure which was 
maintained throughout the follow-up period.  This difference in aneurysm-related mortality 
was based entirely on the difference in in-hospital (perioperative) mortality.  The OVER trial 
demonstrated no long term difference in AAA-related death at follow-up to 2 years.  The 
NRCTs demonstrated a non-significant difference between AAA related mortality, 0.9% for 
EVAR and 1.4% for open repair. 
 
Table 12 Aneurysm-related mortality for EVAR versus open repair 
Study ID EVAR Open repair 
n/N % n/N % 
Blankensteijn 200521 2/173 1.2% 8/178 4.5% 
Greenhalgh 200548 19/543 3.5% 34/539 6.3% 
Lederle 200960 6/444 1.4% 13/437 3.0% 
Carpenter 2004105 1/192 0.5% 0/66 0% 
Chisci 200939 3/71 4.1% 2/61 3.3% 
Greenberg 2004126 1/200 0.5% 3/80 3.8% 
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Hynes 200755 2/66 3.3% 3/52 6.1% 
Mistry 200765 0/122 0% 0/156 0% 
Peterson 2007103 2/235 0.9% 0/99 0% 
Sicard 200684 5/565 0.9% 0/61 0% 
 
• Non-aneurysm related mortality 
There were three NRCT (see Table 13) that reported a mortality rate that was not AAA 
related.  Overall, there was a significantly increased rate of death in the EVAR group 
compared to the open repair group (OR 1.42; 95% CI 1.07 to 1.89). 
 
Table 13 Non-aneurysm related mortality for EVAR versus open repair 
Study ID EVAR Open repair 
n/N % n/N % 
Cao 200432 101/534 18.9% 78/585 13.3% 
Carpenter 2004105 19/192 9.9% 9/66 13.6% 
Criado 2003110 20/240 8.3% 6/126 4.8% 
 
• All-cause mortality 
Three NRCT (see Table 14) reported total mortality rates at one year, showing no significant 
difference in mortality in the EVAR group compared to the open repair group (OR 0.81, 95% 
CI 0.43 to 1.52;  p=0.53). 
 
Table 14 All-cause mortality at 1 year for EVAR versus open repair 
Study ID EVAR Open repair 
n/N % n/N % 
Becquemin 200019 5/73 6.8% 3/107 2.8% 
Greenberg 2004126 7/200 3.5% 3/80 3.8% 
Zeebregts 200494 7/93 7.5% 26194 13.4% 
 
During more prolonged follow up the EVAR 1 trial and OVER trial it was reported that there 
was no significant difference in mortality rates between the EVAR and open repair groups.  
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In the EVAR 1 trial at four years, approximately 28% of the study population had died in the 
EVAR and open repair groups (hazard ratio 0.9, 95% CI 0.69 to 1.19; p=0.46). 
At two years, the DREAM trial47 reported cumulative survival rates of 89.6% following open 
repair and 89.7% following EVAR, a difference of -0.1 percentage points (95% CI -6.8 to 6.7 
percentage points; p=0.86). 
In all of the RCTs,25;52 the initial significant reduction in 30-day mortality rate was lost by 
one to two years follow up.  The EVAR 1 trial52 reported a hazard ratio for EVAR compared 
to open repair during the first 6 months of 0.55 (95% CI 0.33 to 0.93) and 1.10 (95% CI 0.80 
to 1.52) after 6 months. These findings were similar from the NRCTs with slight difference in 
favour of EVAR, hazard ratio 1.16 (95% CI 1.02 – 1.33) that just reached significance. 
 
Table 15 All-cause mortality at >1 year for EVAR versus open repair 
Study ID EVAR Open repair 
n/N % n/N % 
Greenhalgh 200549 100/543 18.4% 109/539 20.2% 
Lederle 200960 31/444 7.0% 43/437 9.8% 
Aune 200717 33/118 28% 85/386 22% 
Wang 2008108 42/192 21.9% 13/66 19.7% 
     Carpenter 2004105 20/192 10.4% 9/66 13.6% 
Chahwan 200638 41/260 16% 65/417 15% 
Garcia-Madrid 200447 5/53 9.4% 6/30 20% 
Hynes 200755 14/66 21.2% 8/52 15.1% 
Ianelli 200556 3/34 8.8% 3/28 10.7% 
Mistry 200765 17/122 13.9% 10/156 6.4% 
Paolini 200872 41/81 51% 40/69 58% 
Peterson 2007103 66/235 28% 19/99 19% 
Sahal 200877 214/452 47.3% 192/443 43.3% 
Sicard 200684 249/565 44% 21/61 34% 
Zarins 2005104 819/2664 26% 97/334 29% 
Zeebregts 200494 11/93 11.8% 27/194 13.9% 
 
• Aneurysm rupture rates  
The primary objective of EVAR is to prevent subsequent rupture and its associated high 
morbidity and mortality rates.  Two RCTs and fourteen NRCTs (see Tables 16 and 17, 
respectively) reported data on delayed rupture rates following EVAR. 
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Data from the RCTs gave a combined odds-ratio of 5.00 (95% CI 0.58 to 42.94; p=0.14).  Of 
the ten NRCTs, six studies reported delayed rupture rates of 0%. The study by Aune et al, 
reported the highest rate of 2.5%.  Overall the mean rupture rate reported was 1.6% during 
the studies follow up period.  The 30 case series (involving over fifteen thousand patients) 
that assessed this outcome gave a mean rupture rate of 0.8% over 22 months). 
 
Table 16 Delayed aneurysm rupture rates for EVAR versus open repair (RCT) 
Study ID EVAR Open repair Follow-up, months 
median (IQR) n/N % n/N % 
Blankensteijn 200521 0/178 0.0 0/173 0.0 21 (0-42)a 
Greenhalgh 200548 5/543 0.9 1/539 0.2 35 (23-48) 
aMean and range 
 
Table 17 Delayed aneurysm rupture rates for EVAR versus open repair (NRCT) 
Study ID EVAR Open repair Follow-up, months 
median (IQR) n/N % n/N % 
Aune 200717 3/118 2.5 NS NS 44 (0-117) 
Becquemin 200019 0/73 0.0 0/107 0.0 7 (0-40) 
Cao 200432 6/529 1.1 0/585 0.0 Not Reported 
Chisci 200939 2/74 2.7 0/61 0.0 25 (0-39) 
Criado 2003110 0/190 0.0 0/240 0.0 Not Reported 
Jordan 200459 0/259 0.0 NS - Not Reported 
Mistry 200765 1/122 0.8 0/156 0.0 32 
Moore 200366 0/684 0.0 NS - NR (1-60) 
Paolini 200872 1/77 1.3 0 0.0 25 (1-80) 
Peterson 2007103 0/235 0 0/99 0.0 60 
Schermerhorn 200883 411/22830 1.8 114/22830 0.5 Not Reported 
Sicard 200684 6/565 1.1 0/61 0.0 26(0-123) 
Wang 2008108 0/192 0.0 0/66 0.0 49 (±20) 
     Carpenter 2004105 0/192 0.0 0/66 0.0 Not Reported 
Zarins 2005104 15/2664 0.6 0/334 0.0 34 
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• Changes in aneurysm size 
Changes in aneurysm size following endovascular repair were reported in nine NRCTs (see 
Table 18). Arko 200716 defined decrease in size as >10 mm decrease from pre-op size and an 
increase as >5mm increase from pre-op size, whereas a change in size of 5mm either way 
was considered a significant increase or decrease in eight studies.  Overall, an increase in 
aneurysm size occurred in 7.9% of patients (95% CI 6.0% to 8.2%).  Data from 25 case series 
indicated that overall 6.5% (95% CI 6.1% to 7.0%) of the EVAR population experienced an 
increase in size of their aneurysm. 
 
Table 18 Change in aneurysm size following EVAR 
Author Number of 
cases 
Changes in aneurysm size n (%) Follow-up 
(mean) Increase No change Decrease 
Aarts 200513 99 5 (5.1) 79 (79.8) 15 (15.2) 23 
Cao 200432 506 39 (7.7) NR 282 (55.7) NR 
Chisci 200939 74  9 (12) NR NR 25 
Criado 2003110 240 2 (0.8) NR NR 13 
Elkouri 200482 94 2 (2.1) 28 (29.8) 63 (67) NR 
Greenberg 2004126 200 3 (1.5) NR NR NR 
Peterson 2007103 235 30 (38) 32 (41) 16 (21) 60 
Sicard 200684 565 62 (11) NR NR 26 
Wang 2008108 192 20 (10.3) 13 (7) 159 (83) 49 (±20) 
     Carpenter 2004105 133d 4(2.0) NR NR  22 
Total 2205 172 (7.9) 152  535   
d n= number of patients who were available for evaluation at 24 months 
 
• Delayed conversion to open repair 
Any conversion to an open procedure following an initially successful endovascular repair is 
considered in this section and the results of the studies that reported this outcome are 
displayed in Tables 19 and 20.  From the RCTs48 the delayed conversion rates were 1.9% 
10% respectively and from twelve NRCTs the overall mean delayed conversion rate was 
0.6% (95% CI 0.5% to 0.7%). 
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Table 19 Delayed conversion rates (RCT) 
Author N Secondary conversions Follow-up 
Median (IQR) n % 
Greenhalgh 200548 531 10 1.9 35(23-48) 
Soulez 200585 20 2 10 27 
 
Table 20 Delayed conversion rates (NRCTs) 
Author N Secondary conversions Follow-up 
Mean (range) n % 
Aarts 200513 99 2 2.0 23 (0-73) 
Becquemin 200019 73 3 4.1 7 (0-40) 
Cao 200432 534 19 3.6 33 (13-50) 
Chisci 200939 74 2 2.7 25 (0-39) 
Criado 2003110 240 5 2.1 13 (NS) 
Greenberg 2004126 200 4 2 NS 
Hansman 200352 50 1 2 NS 
Ianelli 200556 34 0 34 14 (12-36) 
Peterson 2007103 235 10 4.3 60 
Schermerhorn 200883 22830 91 0.4 NR 
Wang 2008108 192 3 1.6 49 (±20) 
   Carpenter 2004105 192 3 1.6 NS 
Zarins 2005104 2664 28 1.1 34 
 
4321 75 0.6%  
(95% CI 0.5% - 0.7%)  
 
 
• Secondary intervention rate 
Any procedure (surgical or radiological) that had been carried out to maintain exclusion of 
the aneurysm sac from the circulation or to maintain graft patency was counted as a 
secondary procedure and was included in this outcome analysis.  The results of the included 
studies are shown in Tables 21 and 22, and Figure 2.  
From the EVAR 1 trial52 the secondary intervention rate following EVAR was 16.1% 
compared to 6.9% following open repair (OR 2.57, 95% CI 1.70 to 3.87; p<0.00001). From 
the DREAM trial22 the rate of intervention was almost three times the rate after open repair, 
(hazard ratio 2.9, 95% CI 1.1 to 6.2; p=0.03).  From 20 NRCTs the overall secondary 
 48 
intervention rate following EVAR was 11.7% compared to 2.1%.  Overall the odds ratio was 
in favour of higher reintervention following EVAR (OR 2.87, 95% CI 1.80 to 4.57; 
p<0.00001). 
 
Table 21 Secondary intervention rates for EVAR versus open repair (RCT) 
Study ID EVAR Open repair Follow-up, months 
median (IQR) n/N % n/N % 
Greenhalgh 200548 85/529 16.1 36/519 6.9 35 (23-48) 
Lederle 200960 46/444 10.4 40/437 9.2 21.6 
 
Table 22 Secondary intervention rates for EVAR versus open repair (NRCT) 
Study ID EVAR Open repair Follow-up, months 
median (IQR) n/N % n/N % 
Arko 2002112 30/200 15.0 32/297 10.8 12 (1-60) 
Aune 200717 27/118 22.9 NS NS 44 (0-117) 
Becquemin 200019 16/73 21.9 8/107 7.5 7 (0-40) 
Cao 200432 95/534 18.7 17/585 2.9 NS 
Chisci 200939 15/74 20.3 6/61 9.8 25 (0-39) 
Criado 2003110 9/240 3.8 NS NS 13 (NS) 
Elkouri 200482 20/95 21.1 22/261 3.0 NS 
Garcia-Madrid 200447 9/53 17 1/30 3.3 26 (NS) 
Greenberg 2004126 22/200 11 2/80 2.5 NS 
Hansman 200352 6/50 12.0 NS NS NS 
Hynes 200755 3/66 4.5 1/52 1.9 23 (±16) 
Mistry 200765 14/122 11.5 16/156 10 33  
Moore 200366 212/573 37.0 NS NS NS (1-60) 
Paolini 200872 13/77 16.9 NS NS 25 (1-80) 
Park 200677 66/342 19 NS NS NS 
Peterson 2007103 57/235 24.3 NS NS 60 
Schermerhorn 200883 2215/22830 9.7 388/22830 1.7 NS 
Wang 2008108 37/192 19.3 NS NS 49 (±20) 
    Carpenter 2004105 29/192 15.1 2/66 15.1 22 (NS) 
Zarins 2005104 487/2664 18.2 NS NS 34 
Zeebregts 200494 17/93 18.3 19/194 9.8 19 (NS) 
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Figure 2 Secondary intervention rates for EVAR versus open repair: Forest plot 
 
 
Complications 
Safety findings are reported according to whether they were endovascular device-related 
(technical complications) or not (non-technical complications).  As outcomes of interest were 
not reported a priori in the majority of studies, in some cases it was not clear whether there 
were no cases of a complication, or whether the authors had chosen not to report this 
outcome. 
Common technical complications 
The incidence of the common technical complications is shown in Table 23 and the results 
are described below by complication. 
• Stent migration 
A total of 9 studies, reported cases of stent-graft migration following EVAR at <1 year and 
>1 year.   A non-standardised definition of stent-graft migration of either 5mm or 10mm 
caudal displacement was quoted by most studies which could partly account for the 
heterogeneity of the results. At < 1 year the incidence was 1.4%, rising to a mean of 2.6% 
during follow up beyond 1 year. 
• Stent fracture 
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There was no report of this adverse event in the included studies. 
• Stent wire fracture 
Only 2 studies reported on the outcome of stent wire fracture.  This adverse event was 
reported from follow-up plain X-rays or CT scans and occurred with an overall incidence of 
3.4% during follow-up periods up to 1 year.  
• Graft-limb thrombosis 
During the first 30-days, this was reported to occur in 6.4% of patients by the DREAM trial.22 
During follow up, incidence rates varied from 0.5% to 11.0% amongst the included studies, 
but the EVAR trial reported a rate of 2.6%.48 
• Graft stenosis 
Four studies reported this outcome.  Within the first year, one NRCT reported the rate as 
5.5%, but one of the EVAR 1 trial52 reported a rate of 0.8% during their follow-up period. 
• Graft kinking 
Four studies reported this outcome, with the RCT reporting a rate of 1.7% during the follow-
up period.   
• Type I endoleak  
< 30 days: This adverse event is defined as the occurrence of a type Ia or Ib endoleak in the 
first 30 days post-EVAR.  In seven NRCTs, the incidence of this adverse event ranged from 
0.8% to 11.0% with an overall rate of 4.7%.  
1 year: Four NRCTs reported 8 (2.3%) cases of type I endoleak during the first year with a 
range of 0% to 4.4%.  
Beyond 1 year: Ten NRCTs reported 69 (3.7%) cases of type I endoleak during follow-up 
>1Y with a range of 0% to 4.4%.  The two RCTs reported rates of 5.5% and 10% during 
follow-up. 
• Type II endoleak  
<30 days: This adverse event is defined as the occurrence of a type II endoleak in the first 30 
days post-EVAR.  In 6 NRCTs, the incidences reported ranged from 1.1%107 to 31.2%,71 with 
an overall mean of 17.4%.  
1 year: Three NRCTs reported incidences with a range of 5.0%107 to 21.8%71 with a mean of 
15.3% for this adverse event.  
Beyond 1 year: There were 9 NRCT that reported the incidence of type II endoleak beyond 
1Y with a mean rate of 14.6%. Two RCTs reported rates of 18.9% and 10% during follow-
up.  
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• Type III endoleak 
Six NRCTs reported this outcome, with reported incidences between 0% and 11.3%, with an 
overall mean of 1.8%.  The rate reported by one RCT was 1.9% during follow-up. 
• Access artery injury: 
Only two NRCT reported this with rates of 4.1 and 12.9% for arterial injury but did not offer 
any further definitions for the type of injury sustained.  In the case series studies, types of 
arterial injury were listed as femoral artery damage, iliac artery dissection / injury, external 
iliac artery rupture, femoral or iliac artery dissection, false femoral aneurysm, femoral artery 
pseudoaneurysm / iliac dissection.   The overall rate of access artery injury was 4.9% from 
the case series. 
• Contrast reaction 
There was no report of this adverse event in the included studies. 
• ‘Overall complication’ rate 
This was only reported by the EVAR 1 trial.52  This trial was the only study to consider 
majority of the technical complications listed above.  By 4 years, the proportion of patients 
with at least one complication following AAA repair was 41% in the EVAR group and 9% in 
the open repair group.  Overall complication rates were 17.6 per 100 person years in the 
EVAR group and 3.3 per 100 person years in the open repair group, hazard ratio 4.9 (95% CI 
3.5, 6.8), p<0.001. 
 
Table 23 Incidence of common technical complications following EVAR (RCT and 
NRCT) 
Complication Author EVAR  n/N % (95% CI) 
Stent migration    
< 1 year Criado 2003110 3/240 1.3% 
 Hansman 200352 1/50 2.0% 
 Total 4/290 1.4% 
    
> 1 year Greenhalgh 200548 14/529 2.6% 
 Aarts 200513 1/99 1.0% 
 Borchard 200527 5/99 5.1% 
 Greenberg 2004126 4/200 2% 
 Paolini 200872 1/77 1.3% 
 Peterson 2007103 0/75 0% 
 Wang 2008108 8/192 4.3% 
 52 
      Carpenter 2006106 5/192 2.6% 
 Total 33/1271 2.6% 
    
    
Stent wire fracture Criado 2003110 11/240 4.6% 
up to 1 year Greenberg 2004126 4/200 2% 
 Total 15/440 3.4% 
    
Graft limb thrombosis    
<30 Days Prinssen 200422 11/171 6.4% 
 Borchard 200527 6/99 6.1% 
 Moore 200366 17/573 3.0% 
 Total 34/843 4.0% 
    
<1 year Arko 200717 1/200 0.5% 
 Becquemin 200019 8/73 11.0% 
 Hansman 200352 2/50 4.0% 
 Ianelli 200556 1/34 2.9% 
 Total 12/357 3.4% 
    
>1 year Greenhalgh 200548 14/529 2.6% 
 Aarts 200513 1/99 1.0% 
 Aune 200717 7/118 5.9% 
 Borchard 200527 3/99 3.1% 
 Chisci 200939 3/74 4.1% 
 Hynes 200755 1/66 1.5% 
 Moore 200366 31/573 5.4% 
 Paolini 200872 2/77 2.6% 
 Wang 2008108 6/192 3.1% 
      Carpenter 2006106 4/188 2.1% 
 Total 68/1827 3.7% 
    
Graft stenosis Becquemin 200019 4/73 5.5% 
<1 year    
    
>1 year Greenhalgh 200548 4/529 0.8% 
 Carpenter 2004105 3/188 1.6% 
 Peterson 2007103 0/77 0% 
 Total 7/794 0.9% 
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Graft Kinking Greenhalgh 200548 9/529 1.7% 
>1 year Borchard 200527 2/99 2.1% 
 Carpenter 2006106 0/192 0.0% 
 Hynes 200755 1/66 1.5% 
 Total 12/886 1.4% 
    
Type I endoleak Becquemin 200019 8/73 11.0% 
< 30 days Borchard 200527 6/99 6.1% 
 Carpenter 2004105 1/121 0.8% 
 Chisci 200939 3/74 4.1% 
 Criado 2003110 11/190 5.8% 
 Garcia-Madrid 200447 2/53 3.8% 
 Moore 200366 12/308 3.9% 
 Total 43/918 4.7% 
    
up to 1 year  Carpenter 2004105 0/140 0% 
 Criado 2003110 7/159 4.4% 
 Hansman 200352 1/50 2.0% 
 Ianelli 200556 1/34 2.9% 
 Total 9/383 2.3% 
    
>1 year Greenhalgh 200548 29/529 5.5% 
 Soulez 200585 2/20 10% 
 Aarts 200513 4/99 4.0% 
 Borchard 200527 2/99 2.1% 
 Carpenter 2004105 0/90 0% 
 Chisci 200939 4/74 5.4% 
 Criado 2003110 8/179 4.5% 
 Garcia-Madrid 200447 1/53 1.9% 
 Moore 200366 4/225 1.8% 
 Paolini 200872 4/77 5.2% 
 Park 200671 11/342 3.2% 
 Peterson 2007103 0/68 0% 
 Total 69/1855 3.7% 
    
Type II endoleak Becquemin 200019 9/73 12.3% 
<30 days Borchard 200527 1/99 1.1% 
 Carpenter 2004105 22/121 18.2% 
 Garcia-Madrid 200447 3/53 5.7% 
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 Criado 2003110 16/190 8.4% 
 Moore 200366 96/308 31.2% 
 Total 147/844 17.4% 
    
up to 1 year Criado 2003110 8/159 5.0% 
 Hansman 200352 7/50 14.0% 
 Moore 200366 57/262 21.8% 
 Total 72/471 15.3% 
    
>1 year Greenhalgh 200548 100/529 18.9% 
 Soulez 200585 2/20 10% 
 Aarts 200513 16/99 16.2% 
 Borchard 200527 11/99 11.1% 
 Chisci 200939 19/74 25.7% 
 Carpenter 2004105 3/90 3.3% 
 Garcia-Madrid 200447 2/53 3.8% 
 Moore 200366 38/225 16.9% 
 Paolini 200872 4/77 5.2% 
 Parks 200671 47/342 13.7% 
 Peterson 2007103 2/68 2.9% 
 Total 244/1676 14.6% 
    
Type III endoleak Greenhalgh 200548 10/529 1.9% 
>1 year Aarts 200513 3/99 3.0% 
 Borchard 200527 1/99 1.1% 
 Carpenter 2004103 0/144 0% 
 Chisci 200939 1/74 1.4% 
 Garcia-Madrid 200447 6/53 11.3% 
 Parks 200671 3/342 0.9% 
 Total 24/1340 1.8% 
    
Access artery injury Borchard 200527 4/99 4.1% 
 Moore 200366 74/573 12.9% 
 Total 78/672 11.6% 
*Results from the RCT trial are stated in bold 
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Figure 3 Incidence of new or persisting endoleak following EVAR 
 
Results are taken from from the mean of NRCT and RCT data available. 
 
Figure 4 Incidence of technical complications - other 
 
Common non-technical complications 
The incidences of the non-technical adverse events are displayed in Table 24.  Forest 
plots are available for selected outcomes in Appendix 2. 
• Cardiac event rate (<30 days) 
From the two RCTs22;42 that reported this outcome, there was a slight reduction in 
cardiac events following EVAR, but this difference was not significant, (OR 0.80, 95% 
CI 0.35 to 1.84; p=0.60).  From the 22 NRCTs, there was a significant reduction in 
cardiac event rate following EVAR, (OR 0.44, 95% CI 0.34 to 0.57; p<0.00001). 
• Renal impairment 
Data from the RCTs indicated that there was no significant difference in renal 
impairment between the two groups at 30-days, (OR 1.02, 95% CI 0.14 – 7.31).  
However data from the NRCTs demonstrated a significant reduction in renal 
impairment in favour of EVAR, (OR 0.52, 95% CI 0.34 – 0.79; p=0.003). 
In addition, two NRCTs reported renal impairment rates during follow up of > 1 year 
and found no significant difference between EVAR and open repair (OR 1.22, 95% CI 
0.38 to 3.95; p=0.21). 
• Graft infection 
From the 2 RCT that reported this outcome, there was no significant difference in graft 
infection rates between the two groups at either 30-days, or during follow-up. 
• Colonic ischaemia 
From both the RCT and NRCT data, there was no significant difference in the rates of 
graft infection post either procedure. Overall odds ratio for EVAR compared to open 
repair 0.90 (95% CI 0.76 – 1.08; p=0.26). 
• Lower limb ischaemia:   
This outcome included cases of lower limb ischaemia in the perioperative (<30 day) 
period only.  The incidence of this outcome was reported to vary between 0% and 
15.4% following EVAR and 0.9% and 4.0% following open repair.  There was no 
significant difference between EVAR and open repair (OR 0.88, 95% CI 0.47 to 1.64; 
p=0.69). 
• Pulmonary complications 
From the DREAM trial there was a significant reduction in pulmonary complications 
following EVAR compared to open repair, (OR 0.25, 95% CI 0.09 to 0.67; p=0.006). 
Analysis of the NRCT results also demonstrated a significant reduction in pulmonary 
complications following EVAR, (OR 0.43, 95% CI 0.40 to 0.46), p<0.00001). 
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• Haemorrhage 
From the DREAM trial, there was a non significant reduction in the incidence of 
haemorrhage following EVAR, (OR 0.5, 95% CI 0.12 to 2.03; p=0.33). 
However, a meta-analysis of the NRCT studies demonstrated a significant reduction in 
haemorrhage following EVAR, (OR 0.23, 95% CI 0.15 to 0.36; p<0.00001). 
• Local wound complications:   
All local wound complications were considered in this section and included haematoma 
formation, wound infection, lymph leak / lymphocoele, femoral nerve damage.  A meta-
analysis of the eleven NRCTs that reported this event demonstrated a significantly 
higher rate of complications after EVAR, (OR 1.37, 95% CI 1.01 to 1.86; p=0.04). 
 
Table 24 Common non-technical complications for EVAR versus open repair 
Study ID EVAR Open repair P 
n/N % n/N %  
Cardiac event rate (<30 days) 
Cuypers 200142 3/57 5.3% 2/19 10.5%  
Prinssen 200422 9/171 5.3% 10/174 5.7%  
Anderson 200315 52/1706 3.0% 230/3063 7.5%  
Arko 2002112 10/200 5.0% 15/297 5.1%  
Aune 200717 3/118 2.5% 18/386 4.7%  
Becquemin 200019 2/73 2.7% 7/107 6.5%  
Bertrand 200120 26/193 13.5% 41/193 21.2%  
Bolke 200124 1/20 5.0% 5/20 25.0%  
Borchard 200527 5/99 5.1% 35/65 54%  
Cao 200432 9/534 1.7% 25/585 4.3%  
Chisci 200939 4/74 5.4% 7/61 11.5%  
Criado 2003110 3/240 1.3% 4/126 3.2%  
Elkouri 200482 10/94 10.6% 57/261 21.8%  
Garcia-Madrid 200447 2/53 3.8% 1/30 3.3%  
Greenberg 2004126 6/200 3.0% 9/80 11.3%  
Hansman 200352 1/50 2.0% 1/50 2.0%  
Ianelli 200556 0/34 0% 2/28 7.1%  
Jordan 200459 8/259 3.1% 9/145 6.2%  
Lee 200461 77/2565 3.0% 320/4607 6.9%  
Moore 200366 56/573 9.8% 23/111 20.7% <0.01 
Park 200671 3/342 0.9% 3/68 4.5%  
Schermerhorn 200883 1598/22830 7% 2146/22830 9.4%  
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Wang 2008108 16/192 8.3% 12/66 18.1%  
    Carpenter 2004104 2/192 1.0% 5/66 7.6%  
Zeebregts 200494 4/93 4.3% 12/194 6.2%  
 
Renal impairment (<30 days) 
Prinssen 200422 2/171 1.2% 2/174 1.1%  
Arko 2002112 1/200 0.5% 1/297 0.3%  
Becquemin 200019 3/73 4.1% 3/107 2.8%  
Bertrand 200120 10/193 5.2% 21/193 10.9% <0.02 
Bolke 200124 3/20 15.0% 4/20 20.0%  
Cao 200432 6/534 1.1% 4/585 0.7%  
Chisci 200939 2/74 2.8% 2/61 3.3%  
Criado 2003110 3/240 1.3% 4/126 3.2%  
Elkouri 200482 4/94 4.3% 11/261 4.2%  
Greenberg 2004126 5/200 2.5% 9/80 11.3%  
Ianelli 200556 2/34 5.9% 3/28 10.7%  
Moore 200366 31/573 5.4% 2/111 1.8%  
Park 200671 14/342 4.1% 15/68 22.2%  
Schermerhorn 200883 1256/22830 5.5% 2488/22830 10.9%  
Wald 200591 439/2651 6.7% NR NR  
Wang 2008108 2/192 1.0% 6/66 9.1%  
 
Renal impairment (>1 year) 
Carpenter 2006106 4/190 2.1% 1/62 1.6%  
Greenberg 2004126 5/200 2.5% 3/80 3.8%  
 
Graft infection (< 30 days) 
Prinssen 200422 1/171 0.6% 2/174 1.1%  
 
Graft infection (>1 year) 
Greenhalgh 200548 1/529 0.2% 2/519 0.4%  
Chisci 200939 0/74 0% 0/61  0%  
Peterson 2007103 1/235 0.4% 0/99 0%  
Schermerhorn 200883 2/22830 0.01% 20/22830 0.09  
 
Colonic ischaemia (<30 days) 
Prinssen 200422 1/171 0.6% 2/174 1.1%  
Aarts 200513 1/99 1.0% 1/116 0.9%  
Borchard 200527 2/99 2.1% 0/65 0%  
Cao 200432 3/534 0.6% 2/585 0.3%  
Chisci 200939 0/74 0%  0/61 0%  
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Hansman 200352 1/50 2.0% 0/50 0.0%  
Schermerhorn 200883 228/22830 1.0% 256/22830 1.1%  
 
Lower limb ischaemia (<30 days) 
Arko 2002109 2/200 1.0% 5/297 1.7%  
Cao 200432 8/534 1.5% 14/585 2.4%  
Hansman 200352 0/50 0.0% 2/50 4.0%  
Moore 200366 24/573 4.2% 1/111 0.9%  
Park 200671 15/342 15.4% NR NR  
 
Pulmonary complications (<30 days) 
Prinssen 200422 5/171 2.9% 19/174 10.9%  
Aarts 200513 4/99 4.0% 22/116 18.9%  
Anderson 200315 33/1706 1.9% 235/3063 7.7%  
Arko 200216 0/200 0.0% 6/297 2.0%  
Becquemin 200019 3/73 4.1% 14/107 13.1% <0.05 
Bertrand 200120 10/193 5.2% 52/193 26.9% <0.001 
Bolke 200124 2/20 10.0% 4/20 20.0%  
Borchard 200527 5/99 5.1% 19/65 23.2%  
Cao 200432 2/534 0.4% 27/585 4.6%  
Criado 2003110 2/240 0.8% 5/126 4.0%  
Elkouri 200482 3/94 3.2% 42/261 16.1%  
Greenberg 2004126 2/200 1.0% 13/80 16.3%  
Hansman 200352 1/50 2.0% 5/50 10.0%  
Ianelli 200556 0/34 0% 4/28 14.3% <0.05 
Jordan 200459 2/259 0.8% 9/145 6.2%  
Moore 200366 30/573 5.2% 25/111 22.5% <0.01 
Schermerhorn 200883 1256/22830 5.5% 2488/22830 10.9%  
Wang 2008108 5/192 2.6% 11/66 16.7%  
     Carpenter 2004105 4/192 2.1% 5/66 6.1%  
Zeebregts 200494 2/93 2.2% 42/194 21.6%  
 
Haemorrhage (<30 days) 
Prinssen 200422 3/171 1.8% 6/174 3.4%  
Anderson 200315 54/1706 3.2% 321/3063 10.5% <0.001 
Criado 2003110 67/240 27.9% 92/126 73.0% <0.001 
Ianelli 200556 0/34 0% 5/28 17.8% <0.01 
Moore 200366 105/573 18.3% 40/111 36.0% <0.01 
Sicard 200684 66/309 21.4% 11/17 64%  
Zeebregts 200494 0/93 0% 23/194 11.9%  
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Local wound complications (<30 days) 
Aune 200717 16/118 13.6% 23/386 6.0%  
Becquemin 200019 1/73 1.4% 2/107 1.9%  
Bertrand 200120 13/193 6.7% 14/193 7.3%  
Borchard 200527 16/99 16.1% 3/65 4.6%  
Cao 200432 13/534 2.4% 11/585 1.9%  
Criado 2003110 7/240 2.9% 6/126 4.8%  
Elkouri 200482 6/94 6.4% 15/261 5.7%  
Hansman 200352 3/50 6.0% 5/50 10.0%  
Jordan 200459 6/259 2.3% 1/145 0.7%  
Mistry 2007 65 5/122 4.1% 10/156 6.4%  
Moore 200366 69/573 12.0% 4/111 3.6% <0.05 
Zeebregts 200494 10/93 10.8% 14/194 7.2%  
 
Figure 5 Incidence of common non-technical complications: EVAR versus 
Open repair 
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Other peri- and post-operative outcomes 
 Deployment success rate 
The success of endograft deployment was documented in 8 studies (see Tables 25 and 
26). Success is defined as accurate placement of the graft in the correct position 
without the need for surgical intervention / open conversion.  The only RCT to report 
this outcome reported a rate of 97%.48  In seven NRCTs, the deployment success rate 
ranged from 93%110 to 100%,126 and overall averaged 96.5%, (95% CI 95.6% to 
97.4%).   
 
Table 25 Successful endograft deployment rate (RCT) 
Author Number of patients (n) Deployment success 
rate (%) Undergoing EVAR Successful deployment 
Greenhalgh 200548 543 529 97% 
 
Table 26 Successful endograft deployment rate (NRCT) 
Author Number of patients (n) 
Undergoing EVAR Successful deployment   % (95% CI) 
Borchard 200527 99 99 100 
Criado 2003110 240 237  99 
Elkouri 200482 94 93  99 
Greenberg 2004126 200 199  100 
Moore 200366 573 531 93 
Wang 200883 192 188 98 
     Carpenter 2004104 192 188 98 
Zeebregts 200494 93 92 99 
 1491 1439  96.5%  
(95.6% - 97.4%) 
 
Technical success rate 
• Primary technical success rate 
The primary technical success rate was reported in 6 of the NRCTs and by just one of 
the RCTs (see Table 27).  Studies included in this section had reported success based 
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either on completion angiograms or on pre-discharge angiograms.  Primary technical 
success was defined as successful placement of the endoluminal-stent with complete 
exclusion of the aneurysm from the circulation.  Where no definition was stated or 
where an alternative definition was used, there was sufficient data to determine the 
primary technical success rate as defined at the start of this section.  
The success rate averaged 76.7% (95% CI 77.9%, to 84.0%).  This success rate was 
lower than that reported by the case series (83%) because of the variability in 
definition of this outcome. 
 
Table 27 Primary technical success rate  
Author Number of patients (n) Technical success rate 
(%, 95% CI)) Undergoing EVAR Technical success 
Soulez 200585 20 20 100 
Borchard 200527 99 83 84 
Criado 2003110 240 168 70 
Chisci 200939 74 71 96 
Elkouri 200482 94 69 73 
Garcia-Madrid 200447 53 48 91 
Hynes 200755 66 64 97% 
Total 646 523 81.0% (71.9% – 79.5%) 
 
2.2.2   Thirty day technical success 
The thirty day technical success rates are displayed in Table 28.  This was defined as 
successful graft placement resulting in complete aneurysm exclusion, with or without 
prior secondary intervention.  The success rate averaged 87% (95% CI 84.4% to 
88.7%).  This result was similar to that indicated by data from 12 case series, 89% 
(95% CI 88.7% to 90.7%). 
 
Table 28 Thirty day technical success 
Author Number of patients (n) Technical success rate 
(%, 95% CI)) Undergoing EVAR Technical success 
Becquemin 200019 73 56 77 
Cao 200432 534 479 90 
Criado 2003110 190 163 86 
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Greenberg 2004126 200 165 83 
Total 997 863 87% (84.4% – 88.7%) 
 
• Blood loss 
The results of blood loss following EVAR or open repair are displayed in Tables 29 
and 30. Forest plots are available in Appendix 2. 
Blood loss was reported by two RCTs.  From the DREAM trial the median blood loss 
was 250 ml following EVAR and 1500 ml following open repair (WMD -1260 ml, 
95% CI -1420 to -1099; p<0.00001).  Data from six NRCT (see Table 30) also 
indicated that there was a significant reduction in blood loss following EVAR (WMD 
-1130 ml, 95% CI -1519.11 to -741.39; p<0.00001).    
 
Table 29 Procedural blood loss (RCT) 
Author Number of participants Blood loss in ml 
Median (IQR) 
WMD (CI) 
Prinssen 200422    
    EVAR 171 250 (100-500) -1260 (-1420 to -1099)  
    Open 174 1500 (900-2100)  
Lederle 200960    
    EVAR 444 200 (150-400)  
    Open 437 1000 (650 – 2000)  
 
Table 30 Procedural blood loss (NRCT) 
Author Number of participants Blood loss (ml) 
EVAR 
Mean (SD) 
Blood loss (ml)  
Open repair 
Mean (SD) EVAR OPEN  
Aarts 200513 99 116 150 1300 
Becquemin 200019 73 107 96 (300) 985 (2450) 
Bertrand 200120 193 193 650 (1100) 1800 (1600) 
Cao 200432 534 585 200 (100-300)b 1400 (1000-2100) 
Carpenter 2004126 192 66 341b 1583b 
Chahwan 200638 260 417 536 (708) 2532 (1982) 
Chisci 200939 74 61 400 (400-975)b 1550 (1050-1800) 
Criado 200381 240 126 345.5 (337.2) 1541.6 (1218.5) 
Hansman 200352 50 50 451 (363) 783 (514) 
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Moore 200366 573 101 400 800 
Paolini 200872 81 69 325b  2800b 
bValues are median and IQR 
 
• Length of ITU stay 
The results of length of stay on ITU, where reported, are displayed in Tables 31 and 
32. 
From four RCTs (see Table 31), there was a significant reduction in ITU stay post 
EVAR compared to open repair (WMD -1.50 days, 95% CI -1.64 to -1.36; p<00001). 
From thirteen NRCTs (see Table 32) there was also a significant reduction in ITU 
stay post EVAR compared to open repair (WMD -0.92 days, 95% CI -1.29 to -0.55; 
p<0.00001). 
 
Table 31 Length of ITU stay (RCT) 
Author 
Number of participants 
ITU stay, days 
Mean (SD) 
EVAR Open repair EVAR Open repair 
Cuypers 200142 57 19 0.8 (0.84)a 0.9 (3.58)a 
Greenhalgh 200548 543 539 0.7 (3.8) 2.4 (5.9) 
Lederle 200960 444 437 1a 4a 
Prinssen 200422 171 174 1.5 (0.61) 3 (0.80) 
Soulez 200585 20 20 0.1 (0.5) 1.6 (1.4) 
aValue is median 
 
Table 32 Length of ITU stay (NRCT) 
Author 
Number of participants 
ITU stay days 
Mean (SD) 
EVAR Open repair EVAR Open repair 
Bertrand 200120 193 193 0.9 (1.46) 1.1 (1.47) 
Bolke 200124 20 20 1.2b 3.4 
Borchard 200527 99 65 0.71 2.0 
Carpenter 2004105 192 66 0.78 4.1 
Criado 2003110 240 126 0.6b (8.67) 2.3 (4.25) 
Elkouri 200482 94 261 1 (3.75) 2 (22.25) 
Garcia-Madrid 200447 53 30 0.1 (0.06) 1 (0.96) 
Hansman 200352 50 50 0.0 (0.3) 1.2 (0.5) 
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Hynes 200755 66 52 0.5 3.8 
Ianelli 200556 34 28 0.65 (.4) 1.73(.6) 
Moore 200366 573 101 1.0 a 1.1 
Park 200671 342 68 0.6 3.8 
Sicard 200684 565 61 0.9 (2) 2.1 (2.2) 
aMedian 
b Statistically significant difference 
 c Calculation excludes medians 
 
• Length of hospital stay 
The results of length of hospital stay are displayed in Tables 33 and 34.  All five of 
the RCTs reported a significant reduction in length of hospital stay following EVAR 
compared to open repair (WMD -5.50 days, 95% CI -7.58 to -3.41; p<0.00001).  
From a meta-analysis of 20 NRCTs, there was also a significant reduction in total 
hospital stay in the EVAR group compared to the open repair group (WMD -5.12 
days, 95% CI -5.74to -4.55; p<0.00001). 
 
Table 33 Length of hospital stay (RCT) 
Author Number of participants Hospital stay, days 
Mean (SD) 
P 
EVAR Open EVAR Open 
Cuypers 200142 57 19 5 (2-21)a 11 (8-50)a <0.01 
Greenhalgh 200548 531 516 10.3 (17.8) 15.7 (16.9) <0.00001 
Lederle 200960 444 437 3 7 <0.001 
Prinssen 200422 171 174 6 (3-6)b 13 (8-15)b <0.01 
Soulez 200585 20 20 4 (13) 15 (34) <0.001 
a Median and range 
b IQR 
 
Table 34 Length of hospital stay (NRCT) 
Author Number of participants Mean length stay, days 
Mean (SD) 
P 
EVAR Open EVAR Open 
Aarts 200513 99 116 7 11  
Anderson 200415 1706 3063 4 10 p<0.001 
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Arko 2002112 200 297 2.8 (2.8) 8.3 (4.5)  
Aune 200717 118 386 4.4 9.2 p<0.01 
Becquemin 200019 73 107 7 (2) 13 (7) p<0.01 
Bertrand 200120 193 193 10 (6) 14 (11) p<0.01 
Bolke 200124 20 20 10 14 p<0.01 
Borchard 200527 99 65 4 13 p<0.0001 
Cao 200432 534 585 2 (2-3)a 6 (5-7)a  
Carpenter 2004105 192 66 3 10  
Chahwan 200638 260 417 3.4 9 p<0.001 
Garcia-Madrid 200447 53 30 2 (2-2)a 6 (5-7)a  
Hansman 200352 50 50 2.3 (1.9) 5.9 (2.2) p<0.0001 
Hynes 200755 66 52 10.2 20.4 p<0.0001 
Ianelli 200556 34 28 3.7(.9) 7.3(2.6) p<0.01 
Jordan 200459 259 145 4 12  
Lee 200461 4607 2565 3.6 (5.9) 8.8 (7.8)  
Moore 200366 564 108 2 6 p<0.0001 
Paolini 200872 81 69 3 (3.2) 9 (7.6)  
Park 200671 342 68 4.8 11.6  
Schermerhorn 200883 22830 22830 3.4 (4.7) 9.3 (8.1)  
Sicard 200684 565 61 3.5 (4.7) 9.7 (8.8) p<0.0001 
Wald 200591 2651 3865 2 7  
Zeebregts 200494 93 81 9.2 (14) 19.2 (18.2)  
aMedian and IQR 
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EVAR IN HIGH RISK PATIENTS 
Overview of the trial  
The EVAR 2 trial50 was designed to assess whether EVAR would have an impact on 
survival in a group of patients deemed unfit for open repair.  Therefore, 338 patients 
were entered into the trial, with 166 participants randomised to EVAR, and 172 to no 
intervention.  However, in the EVAR arm of the trial, 14 patients died before surgery, 
1 patient refused, 1 patient was unsuitable for EVAR and 4 patients underwent open 
repair, leaving 146 patients undergoing EVAR.  In the no intervention arm of the trial, 
47 of the 172 patients underwent AAA repair (35 by EVAR and 12 by open repair). 
The results provided below are, therefore displayed by intention to treat where 
available, but otherwise are stated as by intervention received (per protocol), 
depending upon what information was provided in the actual paper.  A study by 
Hynes 200755 also compared best medical therapy against EVAR, but this was not a 
randomised trial and patients were selected for each group by the surgeon involved 
and consequently the groups were not fully matched.  The results of this trial have 
been included for comparison against the EVAR 2 trial. 
 
Major outcomes 
Mortality 
• 30-day mortality 
Using an intention to treat analysis, the 30-day mortality rate was 8.7% (13/150), but 
if only elective procedures are taken into account, the operative mortality reduced to 
6.8% (10/147).  Based upon analysis by intervention received, the 30 day mortality 
rate was 7.9% (14/178).  
From the study by Hynes 2007, the 30-day mortality rate was 3.0%. 
 
• Mortality AAA related 
Aneurysm-related death based upon all-cause mortality by randomised group, was 
found to be 12% (20/166) in the EVAR group and 12.8% (22/172) in the no-
intervention group, (adjusted hazard ratio 1.00, 95% CI 0.54 to 1.84).  The authors 
undertook a post hoc analysis, dividing follow-up into the first 6 months after 
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randomisation and the period after 6 months.  The hazard ratios for AAA related 
mortality comparing EVAR and non intervention groups were 1.67 (95% CI 0.72 to 
3.86) for the first 6 months and 0.53 (95% CI 0.20 to 1.39) for the period after 6 
months. 
Hynes 2007 reported a 4Y aneurysm related death rate of 33.2% for the group 
undergoing no intervention and 3.3% in the EVAR group, (p=0.002) 
 
• All-cause mortality 
The total mortality rates were 44.6% (74/166) for the EVAR group and 39.5% 
(68/172) for the no-intervention group during the follow-up period.  The difference 
was not statistically significant.  
Hynes 2007 reported a 4Y total mortality rate of 82.1% for the no intervention group 
and 21.2% in the EVAR group (p<0.001). 
 
Aneurysm rupture 
Based upon an intention to treat analysis, there was a 3.6% rupture rate pre-EVAR, 
the median time from randomisation to aneurysm exclusion was 163 days (IQR 78-
477).  In the perioperative period (<30 days), there was a 2.0% rupture rate and post-
EVAR, there were no documented aneurysm ruptures.  In the no-intervention group 
there were 21 ruptures in 172 participants giving a rupture rate of 12.2%.  Results are 
shown in Table 36. 
 
Table 35      Aneurysm rupture rates for EVAR verses no intervention 
Time period EVAR No intervention 
n/N % n/N % 
Pre-operation 6/166 3.6 21/172 12.2 
<30-days post opa 3/150 2.0 - - 
<30-days post opb 1/178 0.6 0/47 0 
>30-days post op 0/137 0 - - 
a intention to treat analysis 
b analysis by treatment received 
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Conversion to open repair 
Based upon analysis by treatment received, during the primary procedure there was 
just one primary conversion giving a primary conversion rate of 0.6% (1/178).  
During follow-up there were 2 further conversions equating to a delayed conversion 
rate of  1.2% (2/178). 
Secondary re-intervention rate 
According to the paper, the overall intention rate was 11.5 per 100 person years in the 
EVAR group and 1.8 per 100 person years in the no intervention group.  At 4 years 
26% of the EVAR group had required at least one intervention compared to only 4% 
in the no intervention group, (hazard ratio 5.8, 95% CI 2.4 to 14.0; p<0.001). 
However if the significant number of crossovers are considered as secondary 
interventions in the no-intervention group then the secondary intervention rate in this 
group becomes considerably greater, (approximately 30%). 
Hynes 2007 reported a secondary intervention rate of 4.5% for the EVAR group 
during the mean follow-up period of 23 months. 
Technical complications 
The incidence of technical complications associated with EVAR are displayed in 
Table 36. 
 
Table 36 Incidence of common technical complications in EVAR  
Complication Number of 
participants 
Number of 
cases 
%  
Graft infection 178 1 0.6% 
Stent migration 178 2 1.1% 
Type I endoleak 178 11 6.2% 
Type II endoleak 178 23 12.9% 
Type III endoleak 178 6 3.4% 
Graft thrombosis 178 8 4.5% 
Graft stenosis 178 0 0% 
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Analysis by intention to treat revealed that 58/178 patients developed a complication 
following an initially successful EVAR equating to a total complication rate of 32.6% 
in this group during follow-up.  
Other peri- and postoperative outcomes 
Deployment success rate 
From analysis by intention to treat, successful endograft deployment occurred in 89% 
(143/160) of participants. Analysis by treatment received (per protocol) gives a 
success rate of 97% (176/181). 
Length of Hospital stay 
The mean length of hospital stay was 12 days (versus 10 days in fit patients in EVAR 
group of EVAR 1 trial). 
Hynes 2007 reported a mean length of stay of 10.2 days post EVAR. 
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Expansion and rupture rates 
 
A Medline search on aneurysm expansion rates and rupture rates provided results 
listed in Tables 37 and 38.  The expansion and rupture rates selected for the model 
were those that corresponded to a 1cm diameter band, and also appeared consistent 
with the other rates quoted in the literature.  The aneurysm expansion rates were then 
adjusted to monthly rates for use in the Markov model.  The aneurysm expansion 
rates were also adjusted to monthly rates, but were also interpolated to reflect the fact 
that a 6.9 cm diameter aneurysm would have a higher rupture rate than a 6.1 cm 
aneurysm. 
 
Table 37  Aneurysm expansion rates 
 
Source Aneurysm diameter (cm) Growth rate (cm / Y) 
Powel 200411 < 5.0 0.25 - 0.35 
Brown 199910 4.5 – 4.9 0.5 
Santili 2002129 3.0 – 3.9 0.11 
Brady 2004130 4.0 – 4.5 0.26 
Hallin 20018 < 4.0 0.2 - 0.4 
 4.0 – 5.0 0.2 - 0.5 
 > 5.0 0.3 - 0.7 
Stonebridge 1996131 < 4.1 0.26 
 4.1 – 6.0 0.41 
 > 6.0 0.65 
Cook 1996132 2.5 – 3.9 0.22 
 4.0 – 4.9 0.27 
 5.0-5.9 cm 0.5 
 >6 cm 0.65 
 
Actual expansion rates used in model 
Aneurysm diameter (cm) Growth rate (cm / Y) 
3.0-3.9 cm 0.11 
4.0 - 4.9 cm 0.27 
5.0-5.9 cm 0.5 
>6 cm 0.65 
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Table 38  Aneurysm rupture rates 
 
Source AAA Diameter Rupture rate / year 
Brown 19989 4.0-5.5 0.0067 
Brown 199910 3.0-6.0 0.01 
McCarthy 2003133 3.5-3.9 0.007 
Hallin 20018 <4.0 cm 0.005 
 4-5 cm 0.026 
 >5 cm 0.06 
Powell 200111 4.0-5.5 cm 0.0065 
Conway 2001134 5.5-5.9 cm 0.36 
 6.0-7.0 cm 0.50 
 >7.0 cm 0.55 
Scott 1998135 <5.9 cm 0.008 
Aziz 2004136 5.0 - 5.9 cm 0.0223 
Perko 1993137 <6 cm 0.05 
 6 cm 0.10 
 >6 cm 0.15 
Lederle 2002138 4.0-5.0 cm 0.006 
Lederle 2002139 5.5-5.9 cm 0.094 
 6.0-6.9 cm 0.102 
 7.0 - 7.9 cm 0.325 
 >8.0 cm 0.514 
 
Actual rupture rates used in model 
Aneurysm diameter (cm) Rupture rate / year 
4.0 - 4.9  0.006 
5.0 - 5.9  0.0223 
6.0 - 6.9 0.102 
7.0 - 7.9  0.325 
>8.0  0.514 
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Validation of the Model 
 
 
EVAR 1 
A hypothetical patient based upon average data from the EVAR 1 trial was generated, 
and these characteristics were entered into the model.  The data input sheet for this 
patient is displayed in Table 39.  The suitability for endovascular repair was set as 
average, and the hazard ratio for rupture rates was set as 1.  The hazard ratio for 
general mortality is determined by the operative mortality rate and is programmed to 
return a value of 1 for an EVAR 1 type patient.   In addition the discount rate was set 
to 3% and the threshold aneurysm diameter for delayed intervention was arbitrarily 
set at 7.5 cm to demonstrate the results generated from the alternative management 
pathways generated by the model.  The results generated from the model are 
displayed in Figs 6-10 and Table 41. 
 
From Table 42, it can be seen that all-cause mortality, aneurysm-related mortality and 
post procedure aneurysm rupture rates are very similar between the Markov model 
and the EVAR 1 trial.  At 4 years the number of people with at least 1 reintervention 
was 20%.  However at 4 years the cumulative reintervention rate from the Markov 
model was 38.9%.  This result is higher than that of the EVAR 1 trial because the 
reintervention rate used in the model is based upon the total number of reinterventions 
and the rate used assumes that 1 reintervention is performed per person.  The EVAR 1 
trial reports the reintervention rate as number of people with at least 1 reintervention. 
In addition the result of 38.9% is similar to extrapolated results from the EUROSTAR 
registry and NRCT data from the systematic review. 
 
Table 39  Data input sheet with characteristics for hypothetical EVAR 1 patient. 
 
Patient Age 74 
 
   
Glasgow Aneurysm Score 
 
Risk factor 
score 
Pt age 
 
74 
Shock No shock 0 
Myocardial disease No Myocardial disease 0 
Cerebro-vascular disease No cerebro-vascular disease 0 
Renal disease No renal disease (urea <20mmol/L) 0   
 74 
  
74 
 
Mortality risk 0.35 
   Bayesian mortality Calculation 
  Patient age 71 - 75Y 1.001 
Gender Male 0.972 
Lowest Blood Pressure 131-140 1.236 
ECG  Normal 0.783 
Cardiac History Positive History 1.176 
White cell count 6.0 - 6.9 0.551 
Bayesian operative MR 0.045 
 
   
   P-Possum Score 
  Physiological score 
  Age >71 4 
Cardiac signs 
Diuretic, digoxin, antianginal or 
hypertensive therapy 2 
Respiratory history Dyspnoea on exertion, mild COPD 2 
Blood pressure (systolic) (mmHg) 131-170 2 
Pulse (bpm) 50-80 1 
GCS 15 1 
Haemoglobin (g/100ml) 13.0-16.0 1 
WCC 4.1-10.0 1 
Urea <7.6 1 
Sodium (mmol/l) >135 1 
Potassium (mmol/l) 3.5-5.0 1 
ECG AF (rate 60-90) 4 
  
21 
Operative score 
  Operative severity Major+ 8 
Multiple procedures 1 1 
Total blood loss (ml) 501-999 4 
Peritoneal soiling None 1 
Presence of malignancy None 1 
Mode of surgery Elective 1 
P-Possum MR 0.051 16 
   Enter own Institution MR 0.05 
 
   Operative MR table 
  Bayesian 0.045 
 EVAR 1 Type Patient 0.044 
 EVAR 2 0.264 
 Local Institutional MR 0.050 
 P-POSSUM 0.051 
 Glasgow aneurysm score 0.350 
 
   OPEN Operative MR EVAR 1 Type Patient 0.044 
EVAR operative MR 
 
0.012 
Anatomical suitability Average suitability 0.280 
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OPEN Operative MR EVAR 1 Type Patient 0.044 
EVAR operative MR 
 
0.012 
Anatomical suitability Average suitability 0.28 
   
   Hazard ratio for general mortality 1 
 Hazard ratio for rupture rates 1 
 Aneurysm Size (cm) 5.5 
 Repair Threshold (cm) 7.5 
 
   Discount rate for quality adjusted survival 0.03 
 
 
  
   
 
Table 40  Other parameters used in the model with source of data. 
 
Parameter 
(Probabilities) 
Value Source Comments 
Mortality rate for 
open conversion  
4.4% Systematic 
review 
Assumption made that open 
conversion morality rate equals 
mortality rate of primary open 
repair 
Probability late 
AAA related 
death post EVAR 
0.040% Systematic 
review 
Review showed 17/1160 late 
AAA deaths during follow up.  
Proportion of late deaths allocated 
to post intervention 
Probability late 
AAA related 
death post open 
repair 
0.05% Systematic 
review 
Review showed 10/539 late AAA 
deaths over 35 months 
Probability death 
post 
reintervention 
1.31% Systematic 
review 
Mortality rate assumed to be 
equivalent to 30-day mortality 
rate for EVAR 
General 
Mortality 
Age 
related 
mortality 
tables 
 Interim life tables, Government 
Actuary Department, based on 
data years 2001-2003 
Probability of 
secondary 
reintervention 
0.74% Systematic 
review 
Reintervention occurred in 
865/5180 over average of 23 
months 
Probability of 
primary open 
conversion of 
EVAR 
0.94% Systematic 
review - RCT 
Primary conversion occurred in 
11/1166 
Probability of 
delayed open 
conversion of 
0.015% Systematic 
review  
Delayed conversion occurred in 
84/4696 during follow up 
 76 
EVAR 
Utility for living 
patient following 
treatment 
Age 
related 
tariff 
 Based on Health survey for 
England 1996 EQ tariff for 65-74 
year old men12 
Discount rate 3%   
Time horizon 
(months) 
120  Model set to display results over 
10 Year period 
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Table 41  Tabulated results from Markov model 
   
Survival 
   Management 1 month  6 month  1 Year 5 Years 10 Years Median 
Open repair 0.956 0.936 0.913 0.706 0.436 8.750 
EVAR 0.988 0.967 0.943 0.730 0.450 9.000 
Best medical therapy 0.995 0.967 0.928 0.307 0.096 3.750 
Delayed open repair 0.995 0.967 0.928 0.595 0.367 7.000 
Delayed EVAR 0.995 0.967 0.928 0.617 0.381 7.417 
       
       
 
Quality adjusted survival 
   Management 6 month  1 Year 5 Years 10 Years 
  Open repair 0.320 0.692 3.180 5.369 
  EVAR 0.328 0.713 3.283 5.544 
  Best medical therapy 0.330 0.713 2.725 3.353 
  Delayed open repair 0.330 0.713 2.916 4.797 
  Delayed EVAR 0.330 0.713 2.996 4.910 
  
       
       
 
Discounted quality adjusted survival 
  Management 6 month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.318 0.682 1.930 2.963 3.797 4.719 
EVAR 0.326 0.702 1.992 3.058 3.921 4.873 
Best medical therapy 0.327 0.702 1.894 2.561 2.849 3.069 
Delayed open repair 0.327 0.702 1.892 2.762 3.465 4.241 
Delayed EVAR 0.327 0.702 1.897 2.800 3.529 4.335 
       
       
  
AAA related death 
   Management 1 month  6 month  1 Year 5 Years 10 Years 
 Open repair 0.044 0.046 0.049 0.068 0.085 
 EVAR 0.012 0.015 0.017 0.037 0.055 
 Best medical therapy 0.001 0.011 0.029 0.505 0.646 
 Delayed open repair 0.001 0.011 0.029 0.198 0.213 
 Delayed EVAR 0.001 0.011 0.029 0.172 0.187 
 
       
       
 
Cumulative reintervention rate 
   Management 6 month  1 Year 5 Years 10 Years 
  EVAR 0.035 0.077 0.367 0.621 
  Best medical therapy 0.003 0.007 0.126 0.160 
  Delayed open repair 0.003 0.007 0.038 0.038 
  Delayed EVAR 0.003 0.007 0.169 0.377 
  
       
       
 
Cumulative aneurysm rupture rate 
  Management 1 month  6 month  1 Year 5 Years 10 Years 
 EVAR 0.000 0.001 0.003 0.013 0.022 
 Best medical therapy 0.002 0.014 0.036 0.629 0.801 
 Delayed open repair 0.002 0.014 0.036 0.190 0.190 
 Delayed EVAR 0.002 0.014 0.036 0.195 0.202 
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Fig 6  Aneurysm survival curve for hypothetical EVAR 1 patient 
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Fig 7  Quality adjusted survival curve for hypothetical EVAR 1 patient 
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Fig 8  Discounted quality adjusted survival curve for hypothetical EVAR 1 
patient 
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Fig 9  Cumulative aneurysm rupture rate for hypothetical EVAR 1 patient 
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Fig 10  Aneurysm related morality rate for hypothetical EVAR 1 patient 
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Table 42   Comparison of EVAR 1 and Markov model results. 
 
Outcome measure Markov model EVAR 1 
All cause mortality at 4Y, 
EVAR 
22.0% 28% 
All cause mortality at 4Y, 
open repair 
24.0% 28% 
Aneurysm related death at 
4Y, EVAR 
3.3% 4% 
Aneurysm related death at 
4Y, open repair 
6.4% 7% 
Cumulative aneurysm 
rupture rate at 35 months, 
EVAR 
1.09% 0.92% 
Cumulative aneurysm 
rupture rate at 35 months, 
open repair 
0% 0% 
Reintervention rate at 4Y, 
EVAR 
30.1% 20%a 
Approx 38 - 40% from 
NRCT and EURSTAR 
registry 
areintervention rate stated as number of people with at least 1 reintervention by 4Y.  
Reintervention rate in Markov model calculated from total number of reinterventions 
performed over a period of time and rate therefore assumes that 1 reintervention was 
performed per person.  Reintervention rates reported in literature review are very 
variable and results from the model lie within expected range from other NRCTs and 
EUROSTAR reports. 
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EVAR 2 
 
A hypothetical patient based upon average data from the EVAR 2 trial was generated, 
and these characteristics were entered into the model.  The data input sheet for this 
patient is displayed in Table 43.  The suitability for endovascular repair was set as 
average, and the hazard ratio for rupture rates was set as 1.  The hazard ratio for 
general mortality was programmed to return a value of 3 to reflect the increased 
mortality rate of this high-co-morbidity population, compared to ‘normal’ aged 
matched controls.  In addition the discount rate was set to 3% and the threshold 
aneurysm diameter for delayed intervention was set at 7.0 cm to demonstrate the no-
intervention arm of EVAR 2 whereby the patients underwent EVAR if the vascular 
surgeon thought that the balance between aneurysm rupture and operative mortality 
rate had been exceeded, or the aneurysm became symptomatic.  The results generated 
from the model are displayed in Figs 11-16 and Table 45. 
 
From Table 46, it can be seen that the results are similar for all-cause mortality, 
aneurysm related death, cumulative aneurysm rupture rates and reintervention rates 
between the Markov model and the EVAR 2 trial for both the EVAR and delayed 
EVAR management options. 
 
Table 43  Data input sheet with characteristics for hypothetical EVAR 2 patient. 
 
Patient Age 76  
   Glasgow Aneurysm Score 
 
Risk factor score 
Pt age 
 
76 
Shock No shock 0 
Myocardial disease No Myocardial disease 0 
Cerebro-vascular disease No cerebro-vascular disease 0 
Renal disease Renal Disease (urea >20mmol/L) 14 
  
90 
 
Mortality risk 0.62 
   
   
Bayesian mortality Calculation   
Patient age 76 - 80Y 1.169 
Gender Male 0.972 
Lowest Blood Pressure 131-140 1.236 
ECG  Non-normal 1.326 
Cardiac History Positive History 1.176 
White cell count >9.9 1.387 
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Bayesian operative MR 0.145  
   
   
P-Possum Score   
Physiological score   
Age >71 4 
Cardiac signs Diuretic, digoxin, antianginal or hypertensive therapy 2 
Respiratory history Limiting dyspnoea (one flight), moderate COPD 4 
Blood pressure (systolic) (mmHg) 131-170 2 
Pulse (bpm) 50-80 1 
GCS 15 1 
Haemoglobin (g/100ml) 13.0-16.0 1 
WCC 4.1-10.0 1 
Urea <7.6 1 
Sodium (mmol/l) >135 1 
Potassium (mmol/l) 3.5-5.0 1 
ECG AF (rate 60-90) 4 
  23 
Operative score   
Operative severity Major+ 8 
Multiple procedures 1 1 
Total blood loss (ml) 501-999 4 
Peritoneal soiling Free bowel content, pus or blood 8 
Presence of malignancy None 1 
Mode of surgery Elective 1 
  23 
P-Possum MR 0.2503246  
Enter own Institution MR 0.05  
   
Operative MR table   
Bayesian 0.145  
EVAR 1 0.047  
EVAR 2 0.264  
Local Institutional MR 0.05  
P-POSSUM 0.250  
   
OPEN Operative MR EVAR 2 0.264 
EVAR operative MR  0.087 
Anatomical suitability Average suitability 0.28 
   
   
Hazard ratio for general mortality 3  
Hazard ratio for rupture rates 1  
Aneurysm Size (cm) 6.6  
Repair Threshold (cm) 7  
   
Discount rate for quality adjusted 
survival 0.03  
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Table 44  Other parameters used in the model with source of data. 
 
Parameter 
(Probabilities) 
Value Source Comments 
Mortality rate 
for open 
conversion  
26.4% Systematic 
review – 
from recent 
RCTs 
Assumption made that open 
conversion morality rate equals 
mortality rate of primary open 
repair 
Probability late 
AAA related 
death post 
EVAR 
0.040% Systematic 
review 
Review showed 17/1160 late 
AAA deaths during follow up.  
Proportion of late deaths allocated 
to post intervention 
Probability late 
AAA related 
death post open 
repair 
0.05% Systematic 
review 
Review showed 10/539 late AAA 
deaths over 35 months 
Probability 
death post 
reintervention 
1.31% Systematic 
review 
Mortality rate assumed to be 
equivalent to 30-day mortality 
rate for EVAR 
General 
Mortality 
Hazard 
ratio of 3 
applied to 
mortality 
tables 
 Interim life tables, Government 
Actuary Department, based on 
data years 2001-2003 
Probability of 
secondary 
reintervention 
0.74% Systematic 
review 
Reintervention occurred in 
865/5180 over average of 23 
months 
Probability of 
primary open 
conversion of 
EVAR 
1% Systematic 
review - RCT 
Primary conversion occurred in 
7/702 
Probability of 
delayed open 
conversion of 
EVAR 
0.015% Systematic 
review  
Delayed conversion occurred in 
84/4696 during follow up 
Utility for 
living patient 
following 
treatment 
Age related 
tariff 
 Based on Health survey for 
England 1996 EQ tariff for 65-74 
year old men12 
Discount rate 3%   
Time horizon 
(months) 
120  Model set to display results over 
10 Year period 
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Table 45  Tabulated results from Markov model 
   Survival    
Management 1 month  6 month  1 Year 5 Years 10 Years Median 
Open repair 0.7379 0.6870 0.6304 0.2602 0.0474 2.1667 
EVAR 0.9139 0.8478 0.7749 0.3095 0.0542 3.0833 
Best medical therapy 0.9774 0.8624 0.7205 0.0912 0.0130 1.7500 
Delayed open repair 0.9774 0.8624 0.5704 0.2354 0.0429 1.6667 
Delayed EVAR 0.9774 0.8624 0.7097 0.2837 0.0497 2.6667 
       
       
 Quality adjusted survival    
Management 6 month  1 Year 5 Years 10 Years   
Open repair 0.2463 0.5019 1.8441 2.3724   
EVAR 0.2897 0.6048 2.2333 2.8529   
Best medical therapy 0.3024 0.6165 1.6129 1.7737   
Delayed open repair 0.3024 0.5927 1.7915 2.2850   
Delayed EVAR 0.3024 0.6111 2.1031 2.6712   
       
       
 Discounted quality adjusted survival   
Management 6 month  1 Year 5 Years 10 Years   
Open repair 0.2446 0.4947 1.7326 2.1623   
EVAR 0.2876 0.5960 2.0984 2.6025   
Best medical therapy 0.3001 0.6076 1.5372 1.6684   
Delayed open repair 0.3001 0.5844 1.7044 2.0932   
Delayed EVAR 0.3001 0.6024 1.9788 2.4411   
       
       
  AAA related death    
Management 1 month  6 month  1 Year 5 Years 10 Years  
Open repair 0.2621 0.2638 0.2658 0.2760 0.2800  
EVAR 0.0861 0.0913 0.0970 0.1263 0.1373  
Best medical therapy 0.0089 0.0599 0.1357 0.5138 0.5294  
Delayed open repair 0.0089 0.0599 0.3042 0.3134 0.3170  
Delayed EVAR 0.0089 0.0599 0.1589 0.1854 0.1953  
       
       
 Cumulative reintervention rate    
Management 6 month  1 Year 5 Years 10 Years   
EVAR 0.0383 0.0807 0.2978 0.3790   
Best medical therapy 0.0150 0.0339 0.1280 0.1317   
Delayed open repair 0.0150 0.0210 0.0210 0.0210   
Delayed EVAR 0.0150 0.0413 0.2543 0.3339   
       
       
 Cumulative aneurysm rupture rate   
Management 1 month  6 month  1 Year 5 Years 10 Years  
EVAR 0.0002 0.0013 0.0026 0.0089 0.0113  
Best medical therapy 0.0111 0.0749 0.1696 0.6401 0.6583  
Delayed open repair 0.0111 0.0749 0.1049 0.1049 0.1049  
Delayed EVAR 0.0111 0.0749 0.1057 0.1113 0.1134  
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Fig 11  Aneurysm survival curve for hypothetical EVAR 2 patient 
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Fig 12  Quality adjusted survival curve for hypothetical EVAR 2 patient 
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Fig 13  Discounted Quality adjusted survival curve for hypothetical EVAR 2 
patient 
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Fig 14  Cumulative reintervention rates for hypothetical EVAR 2 patient 
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Fig 15  Cumulative aneurysm rupture rate for hypothetical EVAR 2 patient 
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Fig 16  Aneurysm related morality rate for hypothetical EVAR 2 patient 
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Table 46   Comparison of EVAR 2 and Markov model results. 
 
Outcome measure Markov model EVAR 2 
All cause mortality at 4Y, 
EVAR 
58.7% ≈64% 
All cause mortality at 4Y, 
delayed EVAR 
64.1% ≈64% 
Aneurysm related death at 
4Y, EVAR 
10.1% 14% 
Aneurysm related death at 
4Y, delayed EVAR 
17.7% 19% 
Cumulative delayed 
aneurysm rupture rate at 
29 months, EVAR 
0.6% 0.92%  
Cumulative aneurysm 
rupture rate at 29 months, 
delayed EVAR 
13.1% 13.4% 
Reintervention rate at 4Y, 
EVAR 
20.6% 20%a 
 
Reintervention rate at 4Y, 
delayed EVAR 
15.4% ≈30%b 
areintervention rate stated as number of people with at least 1 reintervention by 4Y.  
Reintervention rate in Markov model calculated from total number of reinterventions 
performed over a period of time and rate therefore assumes that 1 reintervention was 
performed per person.   
bRate stated in EVAR 2 paper is 4%.  However rate listed in table above considers 
crossovers to EVAR arm of trial to have had a reintervention and therefore 
comparative rate is actually ≈30%. 
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Adjustment of anatomical suitability 
 
The tabulated survival results and AAA-related mortality results for an aneurysm 
considered anatomically average for an EVAR are displayed in Table 47a whilst the 
results for a highly unsuitable aneurysm are displayed in Table 47b.  As can be seen 
from the tables, the results for the EVAR pathway do approximate towards those 
generated for the open repair pathway for a highly unsuitable aneurysm.  
 
Table 47a  Average suitability 
   
Survival 
   Management 1 month  6 month  1 Year 5 Years 10 Years Median 
Open repair 0.948 0.928 0.905 0.700 0.432 8.667 
EVAR 0.985 0.965 0.941 0.727 0.448 9.000 
Best medical therapy 0.995 0.967 0.928 0.307 0.096 3.750 
Delayed open repair 0.995 0.967 0.928 0.589 0.363 6.917 
Delayed EVAR 0.995 0.967 0.928 0.616 0.379 7.333 
 
      
 
  
AAA related death 
  Management 1 month  6 month  1 Year 5 Years 10 Years 
Open repair 0.052 0.054 0.057 0.076 0.093 
EVAR 0.015 0.017 0.020 0.041 0.059 
Best medical therapy 0.001 0.011 0.029 0.505 0.646 
Delayed open repair 0.001 0.011 0.029 0.205 0.219 
Delayed EVAR 0.001 0.011 0.029 0.174 0.190 
      
Table 47b  Highly unsuitable 
   
Survival 
   Management 1 month  6 month  1 Year 5 Years 10 Years Median 
Open repair 0.948 0.928 0.905 0.700 0.432 8.667 
EVAR 0.974 0.953 0.928 0.715 0.438 8.833 
Best medical therapy 0.995 0.967 0.928 0.307 0.096 3.750 
Delayed open repair 0.995 0.967 0.928 0.589 0.363 6.917 
Delayed EVAR 0.995 0.967 0.928 0.605 0.371 7.167 
 
  
AAA related death 
  Management 1 month  6 month  1 Year 5 Years 10 Years 
Open repair 0.052 0.054 0.057 0.076 0.093 
EVAR 0.026 0.029 0.033 0.057 0.078 
Best medical therapy 0.001 0.011 0.029 0.505 0.646 
Delayed open repair 0.001 0.011 0.029 0.205 0.219 
Delayed EVAR 0.001 0.011 0.029 0.186 0.204 
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Assessment of parameter uncertainty within the model 
 
To assess the parameter uncertainty within the model, a series of alternative scenarios 
was developed in which certain key variables were adjusted.  The mean, upper limit 
for the 95% confidence interval and lower limit for the 95% confidence interval for 
each key variable were entered into the model, and the results generated were 
compared.  A fit and healthy patient using average patient characteristics from the 
EVAR 1 trial was used in each case.  The discount rate was set at 3%.  The baseline 
aneurysm size was set to 6.2 cm and the threshold for intervention was set to 7.0 cm. 
 
Operative mortality rate: 
The operative mortality rate for open repair was adjusted between the upper and lower 
95% confidence intervals obtained from the systematic literature review.  The EVAR 
mortality rate was calculated using the hazard ratio of 0.28 compared to open repair.  
From Table 48, it can be seen that an operative mortality rate set at the lower 95% 
confidence interval was only associated with a discounted quality adjusted survival 
benefit of 0.9 months following open repair and 0.4 months following EVAR at 10 
years. 
 
Table 48 
Lower 95% confidence limit 
 Discounted quality adjusted survival   
Management 6 month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3210 0.6902 1.9552 3.0018 3.8477 4.7816 
EVAR 0.3265 0.7036 1.9972 3.0687 3.9359 4.8948 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8187 2.7424 3.4890 4.3133 
Delayed EVAR 0.3247 0.6878 1.8387 2.7848 3.5505 4.3971 
 
Mean 
 Discounted quality adjusted survival   
Management 6 month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9854 3.0489 3.9085 4.8576 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3705 
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Upper 95% confidence limit 
 Discounted quality adjusted survival   
Management 6 month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3130 0.6703 1.8952 2.9085 3.7275 4.6317 
EVAR 0.3238 0.6968 1.9745 3.0303 3.8829 4.8228 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.7894 2.6819 3.4033 4.1998 
Delayed EVAR 0.3247 0.6878 1.8283 2.7614 3.5149 4.3457 
 
 
Reintervention rate: 
The results of using the mean and upper and lower 95% confidence limits for 
reintervention rate are shown in Table 49.  It can be clearly be seen that adjustment of 
the reintervention rate between the upper and lower 95% confidence limits made no 
difference to the discounted quality adjusted survival results generated by the model. 
 
Table 49 
Lower 95% confidence limit 
 Discounted quality adjusted survival   
Management 6 month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9854 3.0488 3.9084 4.8575 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3705 
 
Mean value 
 Discounted quality adjusted survival   
Management 6 month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9854 3.0489 3.9085 4.8576 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3705 
 
Upper 95% confidence limit 
 Discounted quality adjusted survival   
Management 6 month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9855 3.0489 3.9085 4.8576 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3706 
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Primary conversion rate: 
The results of using the mean and upper and lower 95% confidence limits for primary 
conversion rate are shown in Table 50.  Adjusting the rate of primary conversion for 
EVAR obviously only affected the EVAR and delayed EVAR results.  However there 
was virtually no difference in 10 year discounted quality adjusted survival for either 
EVAR or delayed EVAR. 
 
Table 50 
Lower 95% confidence limit 
 Discounted quality adjusted survival   
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9852 3.0485 3.9081 4.8570 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3705 
 
Mean 
 Discounted quality adjusted survival   
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9854 3.0489 3.9085 4.8576 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3705 
 
Upper 95% confidence limit 
 Discounted quality adjusted survival   
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7002 1.9857 3.0492 3.9089 4.8581 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3705 
 
 
Anatomical suitability: 
In the data entry sheet there is the option to set how anatomically suitable the 
particular aneurysm is for endovascular repair.  This parameter is in turn set to adjust 
the 30-day mortality rate for EVAR, the primary conversion rate for EVAR and the 
reintervention rate following EVAR as these results are likely to be poorer for an 
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unsuitable aneurysm.  The results from a highly anatomically suitable aneurysm and a 
very unsuitable aneurysm are shown in Table 51.  From the model, a fit and healthy 
patient with a highly anatomically suitable aneurysm would gain 1.6 months 
discounted quality adjusted survival following an EVAR (1.1 months following a 
delayed EVAR) compared to a similar patient with a very unsuitable aneurysm for an 
EVAR. 
 
Table 51 
 
Very unsuitable 
 Discounted quality adjusted survival   
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3213 0.6906 1.9532 2.9940 3.8322 4.7535 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8184 2.7390 3.4804 4.2955 
 
Highly suitable 
 Discounted quality adjusted survival   
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3261 0.7026 1.9936 3.0627 3.9275 4.8833 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8371 2.7812 3.5450 4.3891 
 
 
Mortality rate of ruptured AAA: 
An 80% mortality rate following rupture of an AAA is widely quoted in the literature.  
Tables 52 and 53 demonstrate the impact on discounted QAS and AAA-related death 
of a 70% mortality rate compared to 80% following AAA rupture.  These scenarios 
are based upon an average patient from the EVAR 1 trial.  A decrease in the mortality 
rate by 10% lowers the cumulative AAA-related mortality rate at 10 years by 12.0% 
for those patients undergoing best medical therapy.  The discounted QAS is increased 
by 3.6 months at 10 years for the best medical therapy group.  The AAA-related 
mortality and discounted QAS rates are also altered for the delayed intervention 
groups, but the magnitude is less and also dependent upon the threshold size for 
repair. 
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Table 52 Mortality rate of AAA rupture 80% 
 
 Discounted quality adjusted survival   
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9854 3.0489 3.9085 4.8576 
Best medical therapy 0.3247 0.6878 1.6916 2.1385 2.3607 2.5656 
Delayed open repair 0.3247 0.6878 1.8036 2.7112 3.4448 4.2547 
Delayed EVAR 0.3247 0.6878 1.8333 2.7727 3.5321 4.3705 
 
  AAA related death   
Management 1 month 6 month 1 Year 5 Years 10 Years 
Open repair 0.0467 0.0491 0.0518 0.0712 0.0882 
EVAR 0.0154 0.0178 0.0206 0.0405 0.0579 
Best medical therapy 0.0054 0.0349 0.0834 0.6329 0.6931 
Delayed open repair 0.0054 0.0349 0.0834 0.1749 0.1898 
Delayed EVAR 0.0054 0.0349 0.0834 0.1478 0.1632 
 
Table 53 Mortality rate of AAA rupture 70% 
 Discounted quality adjusted survival   
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.3169 0.6799 1.9242 2.9536 3.7857 4.7042 
EVAR 0.3251 0.7001 1.9854 3.0489 3.9085 4.8576 
Best medical therapy 0.3252 0.6904 1.7328 2.2603 2.5653 2.8667 
Delayed open repair 0.3252 0.6904 1.8253 2.7494 3.4964 4.3211 
Delayed EVAR 0.3252 0.6904 1.8550 2.8110 3.5837 4.4369 
 
  AAA related death   
Management 1 month 6 month 1 Year 5 Years 10 Years 
Open repair 0.0467 0.0491 0.0518 0.0712 0.0882 
EVAR 0.0154 0.0178 0.0206 0.0405 0.0579 
Best medical therapy 0.0047 0.0306 0.0730 0.5552 0.6100 
Delayed open repair 0.0047 0.0306 0.0730 0.1604 0.1756 
Delayed EVAR 0.0047 0.0306 0.0730 0.1333 0.1490 
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Aneurysm rupture rate: 
On the data entry sheet, there is the option of adjusting the aneurysm rupture rates.  
This is because there are a variety of rupture rates quoted in the literature and because 
the EVAR 2 trial reported a rupture rate of 9 per 100 person years in the no-
intervention arm, a rate much lower than used in the Markov model.  However as 
already stated the no-intervention arm of the trial contained a significant number of 
crossovers to the EVAR arm.  The high crossover rate coupled with the relatively 
small number of patients in the trial means that the natural history of the untreated 
aneurysm cannot be reliably determined from the EVAR 2 trial.  Despite this, the 
model user has the option of using a lower rupture rate to reflect that seen in the 
EVAR 2 trial. 
The results using aneurysm rupture rates established from the literature review and 
using these rupture rates multiplied by a hazard ratio of 0.75 are displayed in Fig 17 
and 18.  The scenarios are again based on an average EVAR 1 trial patient.  Lowering 
the aneurysm rupture rate by 25% was associated with an improved discounted QAS 
in the best medical group of 2.7 months and a reduction in cumulative aneurysm 
rupture rate of 3.7% at 10 years.  Smaller improvements occur for the delayed open 
repair and delayed EVAR groups.  If patient characteristics for the average EVAR 2 
patient are entered into the model then the 10 year discounted QAS is only improved 
by 1.8 months by a 25% reduction in rupture rates. 
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Fig 17  Discounted QAS using evidence based rupture rates (EVAR 1type patient) 
 
 
 
 
 Cumulative aneurysm rupture rate  
Management 1 month 6 month 1 Year 5 Years 10 Years 
EVAR 0.0003 0.0015 0.0030 0.0132 0.0221 
Best medical therapy 0.0068 0.0436 0.1042 0.7884 0.8593 
Delayed open repair 0.0068 0.0436 0.1042 0.1478 0.1478 
Delayed EVAR 0.0068 0.0436 0.1042 0.1559 0.1636 
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Fig 18 Discounted QAS with evidence based rupture rates reduced by 25% (EVAR 1 
type patient) 
 
 
 
 Cumulative aneurysm rupture rate  
Management 1 month 6 month 1 Year 5 Years 10 Years 
EVAR 0.0003 0.0015 0.0030 0.0132 0.0221 
Best medical therapy 0.0051 0.0329 0.0791 0.7094 0.8271 
Delayed open repair 0.0051 0.0329 0.0791 0.1129 0.1129 
Delayed EVAR 0.0051 0.0329 0.0791 0.1214 0.1294 
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Repair threshold:  
Alternative scenarios to assess the impact of adjusting the threshold at which 
intervention is carried out were also considered.  This time average patient 
characteristics of an EVAR 2 patient were inputted into the model, with a baseline 
aneurysm diameter of 6.5cm.  The discounted quality adjusted survival curves and 
tables of discounted QAS rates associated with delayed intervention at 7 cm and 8 cm 
are displayed in Figs 19 and 20.  From the tables and figures it can be seen that 
adjusting the intervention threshold at which the aneurysm is treated does 
significantly alter discounted quality adjusted survival for delayed intervention, either 
EVAR or open repair.   
In addition the tables and figures can be used to calculate the discounted quality 
adjusted survival for each management strategy at any given time point.   This then 
has important management implications.  For example, in these scenarios, best 
medical therapy is associated with a superior discounted QAS compared to EVAR for 
the first 7 months, and a superior discounted QAS up to 22 months compared to open 
repair.  Therefore the patient will need to live for at least 7 months to gain any benefit 
from an endovascular procedure and at least 22 months to gain any benefit from an 
open repair.  The survival curves and tabulated results generated from the model give 
the median survival for an individual patient managed by each of the five options.  If 
endovascular repair is delayed until a threshold size of 7 cm is reached then the 
patient will need to live for 14 months to gain any benefit from the procedure 
compared to best medical therapy, but will improve the median survival by 15 
months.  If an open repair were undertaken at a threshold of 7cm, the patient would 
not gain any survival advantage until 2Y, and with equal median expected survivals 
for both strategies of 23 months, the majority of patients would not live long enough 
to gain any benefit. 
If EVAR is delayed until an aneurysm diameter of 8 cm is reached then the patient 
requires a life expectancy of 3Y and 1 month before any benefit of the procedure is 
derived.  In addition, at an intervention threshold of 8cm immediate open repair is 
associated with a superior discounted QAS compared to delayed EVAR after survival 
to 43 months.  However from the survival table and curves generated for such a 
scenarios, (Fig 20), the probability that a patient is alive at 4Y following an open 
repair is approximately 40%, and therefore only a minority of patients would benefit 
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from the increased discounted QAS with an open repair over a delayed EVAR in the 
long term. 
Fig 19  Threshold of 7 cm 
 
 
 Discounted quality adjusted survival  
Management 6 month 1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.2446 0.4947 1.2632 1.7326 1.9943 2.1623 
EVAR 0.2876 0.5960 1.5345 2.0984 2.4078 2.6025 
Best medical therapy 0.3012 0.6129 1.3441 1.5757 1.6608 1.7082 
Delayed open repair 0.3012 0.6129 1.2971 1.7150 1.9480 2.0975 
Delayed EVAR 0.3012 0.6129 1.4619 1.9723 2.2525 2.4289 
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Fig 20  Threshold of 8 cm 
 
 
 
 
Discounted quality adjusted survival 
  
Management 
6 
month  1 Year 3 Years 5 Years 7 Years 10 Years 
Open repair 0.258 0.526 1.341 1.877 2.204 2.442 
EVAR 0.307 0.642 1.657 2.317 2.716 3.001 
Best medical therapy 0.319 0.653 1.428 1.692 1.799 1.866 
Delayed open repair 0.319 0.653 1.407 1.731 1.928 2.072 
Delayed EVAR 0.319 0.653 1.433 1.835 2.079 2.253 
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Fig 21  Survival results for intervention threshold 7 cm 
 
 
  
   
Survival 
   Management 1 month  6 month  1 Year 5 Years 10 Years Median 
Open repair 0.738 0.696 0.649 0.314 0.078 2.583 
EVAR 0.927 0.872 0.811 0.384 0.092 3.667 
Best medical therapy 0.982 0.886 0.760 0.113 0.021 1.917 
Delayed open repair 0.982 0.886 0.577 0.280 0.069 1.917 
Delayed EVAR 0.982 0.886 0.732 0.347 0.083 3.167 
 108 
Fig 22  Survival results for intervention threshold of 8 cm 
 
 
 
   Survival    
Management 1 month 6 month 1 Year 5 Years 10 Years Median 
Open repair 0.7379 0.6870 0.6304 0.2602 0.0474 2.1667 
EVAR 0.9139 0.8478 0.7749 0.3095 0.0542 3.0833 
Best medical therapy 0.9792 0.8721 0.7364 0.0930 0.0130 1.8333 
Delayed open repair 0.9792 0.8721 0.7364 0.1570 0.0286 1.8333 
Delayed EVAR 0.9792 0.8721 0.7364 0.1902 0.0335 1.8333 
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Discussion 
 
Until the publication of the DREAM and EVAR and OVER trials, there had been a 
lack of level one evidence comparing the efficacy and safety of EVAR to open repair.  
Early publications from population registries (RETA and EUROSTAR) and case 
series had suggested a lower operative mortality, lower perioperative complications 
and reduced requirement for hospital beds and critical care for EVAR compared to 
open repair.  These early findings have been supported by the results from the three 
RCTs listed above and medium term outcome data from the EVAR and DREAM 
trials has recently been published in addition.  The results of the randomised 
controlled trials represent a broad spectrum of patients with abdominal aortic 
aneurysms and despite post hoc analyses of sub-groups of patients, it can be difficult 
to apply this evidence base to an individual patient.  The EVAR 1, DREAM and 
OVER trials compared open repair to EVAR in a group of ‘healthy’ patients and 
EVAR 2 compared EVAR to best medical therapy in ‘unhealthy’ patients.  However, 
the majority of patients presenting to a vascular surgeon do not fall neatly into one 
category or the other and it is in this group of patients that it is most difficult to apply 
the RCT evidence. 
 
For the Markov decision analysis model, three different modalities of treatment were 
considered; EVAR, open repair and best medical therapy.  The option of delaying 
either EVAR or open repair until a threshold size for aneurysm diameter was also 
considered thereby creating five different management pathways.  The model 
contained a data input sheet allowing patient and aneurysm specific variables to be 
entered so that the results generated were relevant to that particular patient.  The 
model generates both tabulated and graphical results of survival, quality adjusted 
survival, discounted QAS, aneurysm and non-aneurysm mortality rates cumulative 
reintervention and cumulative rupture rates for each management option.   
 
One implication for the model is that the tabulated and graphical results can be used 
to aid the management of a patient with an abdominal aortic aneurysm in a clinical 
setting.  The vascular surgeon can input the patient and aneurysm specific parameters 
into the model and see the likely outcome for that particular patient in terms of 
operative mortality, likely survival and discounted quality adjusted survival, 
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aneurysm and non-aneurysm related mortality, and cumulative rupture and 
reintervention rates associated with each management option.  The surgeon will then 
be able to explain the different management options to that particular patient and 
show that patient graphically what is likely to happen to them over the following 10 
year period.  Where the management options produce similar discounted QAS results, 
the aneurysm rupture rate and cumulative reintervention rates are likely to play a 
significant part in the consent process as certain management options are associated 
with higher rates of subsequent rupture and reintervention. 
 
In addition, by using the model, it is possible for the surgeon and patient to quickly 
assess the impact of making adjustments to the management process.  However the 
transition probabilities used in the model that are not patient specific are all evidence-
based and the model has been validated against the EVAR 1 and 2 trial results.  The 
parameter uncertainty has been studied above by using values from the upper and 
lower 95% confidence intervals and adjustments to reintervention rate, primary 
conversion rate and anatomical suitability have little impact on the discounted QAS.  
Changes to the reintervention rate and anatomical suitability however will obviously 
alter the likely cumulative reintervention rate generated by the model.  In addition 
adjustment of the operative mortality rate around that expected for that particular 
patient again has been shown to have little impact on discounted QAS over a 10 Y 
period.   
 
The results generated by the model are mainly sensitive to patient specific variables.  
These include age (which affects operative mortality rate and age-related mortality 
rate), patient specific operative mortality rate (a high operative mortality rate is 
associated with reduced discounted QAS but the high rate is linked to a high general 
mortality rate which will also decrease discounted QAS.  The results generated for the 
delayed intervention pathways are also sensitive to the threshold size at which the 
intervention is performed.  This has important clinical consequences; the results 
generated for a high-risk patient with a reduced life expectancy can be assessed using 
a variety of threshold sizes to calculate the time-point at which intervention that is 
expected to be associated with the greatest discounted QAS for that patient.   
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The model is also moderately sensitive to changes in mortality rate following 
aneurysm rupture (a reduction in the mortality rate from 80% to 70% is associated 
with a reduction in cumulative aneurysm rupture rate of 8.3% over 10 years and an 
increase in discounted QAS of 3.6 months over the same period.  This finding implies 
that even modest improvements in the management of a patient with a ruptured AAA 
could result in enhanced discounted QAS.  However in clinical practice there has been 
little change in ruptured AAA survival over the last 20 years. 
 
For the base-case scenario for the EVAR1 type patient, the model generated similar 
results to the randomised controlled trial data.  A review of large (>200 patients) case 
series was conducted to compare the results of the model to results achieved in 
everyday practice.  The case series reported a 30-day mortality rate of 2.5% compared 
to 1.2% from the model.  This difference could be explained by the significant 
heterogeneity of the case series data as most centres were reporting results on a case-
mix of EVAR type 1 and 2 patients and consequently the results would be expected to 
be inferior to those from RCTs treating only fit and healthy patients. The overall 
survival results from the model are also similar to those reported in routine practice 
with the EUROSTAR registry reporting a 5Y overall survival rate of 71.7% compared 
to 73% from the Markov model.  From the model the difference in survival rates 
between open repair and EVAR converge over time, an observation also reported 
from the EVAR 1 trial,48 DREAM trial,21 Schermerhorn et al83 and the recent HTA 
report.142 
 
In addition if one compares the rates of AAA related death (~5% over 10 years from 
the model) against the case series data (~4% over 10 years), then once again the 
model appears to generate acceptable results compared to routine practice.  These 
results are similar to those reported by the recent HTA report, who reported rates of 
0.3% per year.142  Cumulative intervention rates generated by the model suggested a 
ten year rate of 62% compared to an extrapolated rate of 74% from the case series.  
Once again the difference in case mix and difference in management practices 
between different centres could account for this small difference. 
 
There are a number of limitations associated with the use of this model.  The model is 
limited by the availability of high quality data that is necessary to generate the 
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required transition probabilities.  These probabilities were established from a 
systematic literature review, but there were a number of limitations noted from the 
review that generated a few assumptions and uncertainties during model development. 
 
A major limitation of the systematic review relates to the heterogeneity of the study 
population and unknown criteria for patient selection for EVAR, amongst the NRCT 
and case series studies. There are two major issues in this respect, the size of 
aneurysm treated, which determines the risk of rupture in the untreated condition and 
the case mix of patients regarding age and co-morbidity, which affects the risks 
associated with open surgical treatment.  
 
Current evidence from the UK Small Aneurysm Trial suggests that surgical 
intervention is worthwhile if the aneurysm is at least 5.5 cm diameter or greater than 
4.5 cm and has increased by 0.5 cm in the 6 months prior to intervention.  In many of 
the reported studies, the inclusion criteria included aneurysms of less than 5.5 cm in 
diameter.  Furthermore, in studies where inclusion criteria are not defined, there is 
either no documentation of baseline aneurysm size, or the range of aneurysm size 
extends below 5.5 cm.  The expected rupture rate of aneurysms of less than 5.5 cm is 
in the order of 0.5% per year so that the risks and success rate that would be 
acceptable are very different from those for patients with larger aneurysms.  The data 
presented do not allow adequate subgroup analysis to determine whether safety and 
efficacy are related to aneurysm size. 
 
There are also other differences between study populations, with some studies 
including a significant proportion of patients in whom surgical treatment would be 
expected to carry high mortality.  In those patients with a large aneurysm, co-
morbidity or previous abdominal surgery that would add significantly to the risks of 
conventional treatment, the acceptable risks for EVAR may be considerably higher. 
The EVAR 1, DREAM and OVER studies are randomised controlled trials that have 
addressed a number of these issues.  The problem of heterogeneity of the study 
population was minimised by randomly allocating patients to EVAR or open repair.  
This resulted in two groups that were well matched, therefore allowing more accurate 
comparisons between the two groups, as they only differ in terms of treatment 
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received.  All patients in these trials were deemed sufficiently medically fit and 
anatomically suitable to undergo either procedure.  Furthermore, patients were only 
included in the study if the baseline aneurysm size was 5.0 cm or greater (DREAM) 
or 5.5 cm or greater (EVAR 1). 
 
Another important consideration in interpreting these results is the issue of operator 
experience and advances in device technology.  Studies included in this review were 
restricted to papers published from the year 2000 onwards, but the recruitment period 
in some papers precedes this date by five or more years.  Consequently the 
participants included in this review are undergoing a procedure that may have been 
carried out by an operator with limited experience in a relatively new technique 
(EVAR was first introduced in 1991).  Furthermore, the level of operator experienced 
was poorly documented in virtually all of the included studies and the effect of a 
learning curve for EVAR has been well reported.  The level of operator experience 
was again addressed in the RCTs, as only experienced surgeons and interventional 
radiologists were included.  For the EVAR trials, before being considered for 
participation in the trial, a new centre must submit outcome data on 20 cases to an 
independent register (RETA). 
There have been substantial improvements in endovascular device technology in 
recent years.  The ‘first-generation’ stents were home-made tube devices constructed 
using ePTFE graft material and standard endovascular stents.  These are no longer 
used due to the high level of complications associated with these devices.  Further 
improvements of endovascular prostheses have led to the development of modular 
bifurcated and aorto-uniiliac devices.  These developments coupled with advances in 
device-delivery systems, have led to a lower incidence of procedural and post-
procedural complications.  As a consequence, some of the long-term safety and 
efficacy data relates to devices that are no longer used, whilst there is little medium to 
long-term data on devices in current usage. 
 
From the RCTs there is a clear reduction in 30-day mortality rate with a mean 
mortality rate of 3.7% after open repair and 1.1% after EVAR, (OR 0.27, 95% CI 0.15 
to 0.51).  This result is supported from the findings of the NRCT studies and the low 
mortality rate from EVAR is in agreement with that reported from published case 
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series.  However, both the EVAR 1 and DREAM studies have demonstrated that 
during medium-term follow-up, there is no difference in total mortality between 
EVAR and open repair, and the reduction in aneurysm-related mortality that persists 
following EVAR is accounted for by the initial lower perioperative mortality rate.  
These findings are in agreement with results generated by the model, as there is 
convergence of the survival curves for open repair and EVAR, but the AAA-related 
mortality curves remain parallel after the first month.   
 
The above would suggest that although initially superior at 30-days, long term there is 
no survival advantage of EVAR over open repair and in fact the longevity of the 
EVAR technique remains to be proven.  There are several possible explanations to 
account for the overall higher mortality rate during the first year following EVAR. 
Open repair may have precipitated the death of frail patients who would have died 
during the coming year.  However it is possible that EVAR is associated with a higher 
rate of late mortality by failing to prevent late ruptures or by causing complications 
related to the significantly higher secondary intervention rate.  These last two 
hypotheses are supported by the results from the model as there is both an ongoing 
risk of late rupture and a significant rate of reintervention following the EVAR or 
delayed EVAR pathways. 
 
A certain degree of caution needs to be used when interpreting the long-term results 
generated by the model, particularly for late AAA rupture and reintervention results.  
There are results from randomised and non-randomised controlled trials that suggest 
there is an ongoing reintervention requirement and ongoing late rupture rate post 
EVAR, but the follow-up from such studies is only for approximately 3-4 years at 
present.  The long-term results from the model assumes that the reintervention rate 
and late rupture rate continue at similar levels beyond the three to four year mark as 
there is no data at present to support or refute this assumption.  It may be that the rate 
of reintervention declines after a few years, in which case the results from the model 
would tend to underestimate the benefits of EVAR.  However it may be that the rate 
of reintervention and late aneurysm rupture rate both increase in the long-term, in 
which case the results from the model would overestimate the benefits of EVAR. 
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A further limitation of the model is that it uses average rates of expansion and rupture.  
In practice the expansion and rupture rates are probability distributions and there will 
be some patients who expand rapidly and rupture prior to their next scan and others 
who have no change in size or rupture for many years.  In addition the decision to 
delay treatment is not a”once and for all” decision but in reality is reviewed after each 
scan.  Consequently the results of the delayed intervention are limited by the points 
discussed above. 
 
Nonetheless the medium and long-term results from the model demonstrate that there 
is a clear need for complete and accurate follow-up for the life of the patient 
following EVAR. 
 
The technique of EVAR was initially established to treat high-risk surgical candidates 
for whom open repair would be associated with very significant mortality and 
morbidity.  The EVAR 2 trial addressed this issue by comparing EVAR to best 
medical therapy in a group of unfit patients.  The 30-day mortality result of EVAR in 
unfit patients was 7.9%, (compared to 1.7% in fit patients).  However the rate of 
aneurysm-related mortality in the no intervention group was found to be significantly 
lower than that anticipated at the start of the study.  
 
This significantly lower aneurysm-related mortality in the no-intervention group 
coupled with a higher 30-day mortality post EVAR and high rates of complications, 
(43% by 4 years) and secondary intervention, (11.5 per 100 person years) negated any 
potential benefit of EVAR over no intervention in unfit patients.  Analysis by 
intention to treat demonstrated no significant difference in either aneurysm related 
mortality or total mortality during the follow-up period, leading the trial committee to 
conclude that there was no survival benefit following EVAR compared to no 
intervention in unfit patients.   
 
However there are a number of considerations to be made when interpreting these 
results.  It is possible that there may be an element of confounding due to the high rate 
of crossover of patients on best medical therapy to exclusion by EVAR or surgery.  
Over twice as many patients underwent late aneurysm repair as died of aneurysm 
related causes and many of these patients had symptomatic or enlarging aneurysms 
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that would have increased the aneurysm related mortality had such crossovers not 
occurred.  Therefore the model was designed to include a delayed EVAR 
management option that would reflect the no intervention arm of EVAR 2, in addition 
to a best medical therapy option (truly no intervention except for treatment of a 
ruptured aneurysm).   
 
The model that has been developed is designed as a clinical decision aid and does not 
consider the issue of cost.  In the future the model could be adapted to include cost 
data to develop a cost-effectiveness model.  Such an economic model could help 
guide policy development and highlight key areas for further research.  
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Conclusions 
An easy-to-use computer model has been developed that will provide meaningful 
information relating to risks and benefits that could assist in shared decision making 
and obtaining informed consent from patients with aneurysms, and could help to 
guide policy decisions in respect to patient selection for EVAR. 
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APPENDIX 1  Decision analysis trees 
Fig 23    Decision tree for Open repair 
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Fig 24    Decision tree for best medical therapy 
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Fig 25    Decision tree for EVAR 
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Fig 26    Decision tree for delayed intervention 
 
 
 
 
 
 
Best 
medical 
therapy 
General Death 
Rupture 
No Rupture 
Survive open 
repair 
 
AAA related 
death 
 
Survive 
Above threshold 
size for repair 
Below threshold 
size for repair 
EVAR model 
Open repair model 
OR 
 122 
Appendix 2   Risk models for 30-day mortality rate for open repair 
Fig  27     Bayesian risk model for 30-day mortality rate for open repair 
 
Risk Factor 
 
Criteria Likelihood ratio 
Age < 71 Years 
71-75 Years 
76-80 Years 
>80 Years 
0.469 
1.001 
1.169 
2.552 
Gender Male 
Female 
0.972 
1.214 
Lowest Blood Pressure <81 
81-100 
101-110 
111-130 
131-140 
141-150 
151-160 
>160 
1.294 
1.455 
0.475 
0.882 
1.236 
0.437 
1.573 
1.001 
ECG Non-normal result 
Normal 
1.326 
0.783 
Cardiac History No history 
Positive history 
0.846 
1.176 
White cell count <6.0 
6.0-6.9 
7.0-8.9 
9.0-9.9 
>9.9 
1.067 
0.551 
0.974 
0.903 
1.387 
 
 
Posterior odds = Prior odds (0.07) * likelihood 
Damped Posterior odds = 0.07 * Likelihood ratio0.8 
Posterior percentage risk of death = (Damped posterior odds / (1+ Damped posterior odds) 
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Fig 28    P-POSSUM risk model for 30-day mortality rate for open repair 
 
Physiological score (At time of surgery) 
 Score 
Risk Factor 1 2 4 8 
Age (Years) ≤60 61-70 ≥71  
Cardiac signs 
 
 
 
Chest X-ray 
No failure Diuretic, 
digoxin, 
antianginal or 
hypertensive 
therapy 
Peripheral 
oedema; 
warfarin therapy 
 
 
Borderline 
cardiomegaly 
Raised JVP 
 
 
 
 
Cardiomegaly 
Respiratory 
history 
 
Chest X-ray 
No dyspnoea Dyspnoea on 
exertion 
 
Mild COPD 
Limiting 
dyspnoea (one 
flight) 
Moderate COPD 
Dyspnoea at rest 
(rate ≥30/min) 
 
Fibrosis or 
consolidation 
Blood pressure 
(systolic) 
(mmHg) 
110-130 131-170 
100-109 
≥171 
90-99 
 
≤89 
Pulse 
(beats/min) 
50-80 81-100 
40-49 
101-120 ≥121 
 
Glasgow coma 
score 
15 12-14 9-11 ≤8 
Haemoglobin 
(g/100ml) 
13-16 11.5-12.9 
16.1-17.0 
 
10.0-11.4 
17.1-18.0 
≤9.9 
≥18.1 
White cell 
count (x 1012/l) 
4-10 10.1-20.0 
3.1-4.0 
≥20.1 
≤3.0 
 
Urea (mmol/l) ≤7.5 7.6-10.0 10.1-15.0 ≥15.1 
Sodium 
(mmol/l) 
≥136 131-135 126-130 ≤125 
Potassium 
(mmol/l) 
3.5-5.0 3.2-3.4 
5.1-5.3 
2.9-3.1 
5.4-5.9 
≤2.8 
≥6.0 
ECG Normal  Atrial 
fibrillation 
Any other 
abnormal 
rhythm or ≥ 
ectopics / min Q 
waves or ST/T 
wave changes 
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Operative score 
  
 Score 
Risk Factor 1 2 4 8 
Operative 
severity 
Minor  Moderate Major Major + 
Multiple 
procedures 
1  2 >2 
Total blood 
loss (ml) 
≤100 101-500 501-999 ≥1000 
Peritoneal 
soiling 
None Minor (serous 
fluid) 
Local pus Free bowel 
content, pus or 
blood 
Presence of 
malignancy 
None Primary only Nodal 
metastases 
Distant 
metastases 
Mode of 
Surgery 
Elective  Emergency 
resuscitation of 
>2 h possible.  
Operation <24 h 
after admission 
Emergency 
(immediate 
surgery <2 h 
needed) 
 
P-POSSUM formula for mortality: 
 Ln[R/1-R] = -9.065 + (0.1692 * physiological score) + (0.1550 * operative severity 
score)  
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Fig 29.  Glasgow Aneurysm Score: 
 
Patient age Add patient age 
Presence of shock 
No shock 
Add 17 points 
Add 0 points 
Presence of myocardial disease 
No myocardial disease 
Add 17 points 
Add 0 points 
Presence of cerebro-vascular disease 
No cerebro-vascular disease 
Add 17 points 
Add 0 points 
Presence of renal disease (urea > 20) 
No renal disease (urea < 20) 
Add 17 points 
Add 0 points 
 
Glasgow aneurysm score mortality rates: 
 
Risk Score Predicted mortality rate 
< 73 15 
74 – 82 35 
83 – 89 48 
90 – 97 62 
>97 82 
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APPENDIX 2 Quality assessment tools 
Table 54   Checklist for quality assessment of case series studies on intervention 
(adapted from CRD’s Guidance for those Carrying out or Commissioning Reviews, 2001 and from 
Downs and Black, 1998) 
 
Criteria Yes No Unclear Comments 
Were participants a representative sample selected from a 
relevant patient population?  
    
Are the inclusion/exclusion criteria of patients in the study 
clearly described?) 
    
Were participants entering the study at a similar point in their 
disease progression? 
    
Was selection of patients consecutive?       
Were all important prognostic factors identified?     
Was data collection undertaken prospectively?     
Was the recruitment period clearly stated?     
Was the intervention that which is being considered in the 
review? (or was it a significant modification?) 
    
Was an attempt made to blind outcomes assessors?     
Was the operation undertaken by someone experienced in 
performing the procedure? 
    
Did the staff, place, and facilities where the patients were 
treated provide an appropriate environment for performing the 
procedure? (e.g.  was the intervention undertaken in a centre 
with the necessary back-up facilities?) 
    
Were objective (valid and reliable) outcome measures used?     
Were all the important outcomes considered?     
Was follow-up long enough to detect important effects on 
outcomes of interest? 
    
Was information provided on non-respondents, dropouts?     
Were participants lost to follow-up likely to introduce bias? 
(e.g.  high drop-out rate; no description of those lost) 
    
Were the main findings clearly described? (to allow 
replication)  
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Table 55   Checklist for quality assessment of non-randomised studies evaluating 
interventional procedures.  
 
Items specific for non-randomised comparative studies are in italic. 
 
  Criteria Yes No Unclear Not 
Relevant 
Comments 
Participants: sample definition and selection 
Were participants a representative sample selected 
from a relevant patient population? 
     
Were the inclusion/exclusion criteria of participants 
clearly described? 
     
Were participants entering the study at a similar point 
in their disease progression? 
     
Was selection of patients consecutive?      
Was data collection undertaken prospectively?      
Were the groups comparable on demographic 
characteristics and clinical features? 
     
Intervention: 
Was the intervention (and comparison) clearly 
defined? 
     
Was the intervention undertaken by someone 
experienced at performing the procedure? 
     
Were the staff, place, and facilities where the patients 
were treated appropriate for performing the 
procedure? (E.g. access to back-up facilities? 
     
Outcome measures: 
Were all the important outcomes considered?      
Were objective (valid and reliable) outcome 
measure/s used? 
     
Was the assessment of main outcomes blind?      
Follow-up: 
Was follow-up long enough to detect important 
effects on outcomes of interest? 
     
Was  information provided on non-respondents, 
dropouts? 
     
Were participants lost to follow-up likely to introduce 
bias? (e.g. high drop-out rate; differential drop-out; 
no description of those lost) 
     
Was length of follow-up similar between comparable 
groups 
     
Analysis: 
Were all the important prognostic factors identified?      
Were the analyses adjusted for confounding factors?      
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TABLE  56    Checklist of quality assessment of randomised control trials of an 
interventional procedure (adopted from Verhagen et al, 1998) 
 
Criteria Yes No Unclear Comments 
Was the assignment to the treatment groups really 
random?  
Adequate approaches to sequence generation   
computer-generated random tables  
random number tables 
Inadequate approaches to sequence generation 
use of alternation, case record numbers, birth dates or 
week days 
    
Was the treatment allocation concealed? 
Adequate approaches to concealment of randomisation 
centralised or pharmacy-controlled randomisation 
serially-numbered identical containers 
on-site computer based system with a randomisation 
sequence that is not readable until allocation 
other approaches with robust methods to prevent 
foreknowledge of the allocation sequence to clinicians 
and patients   
Inadequate approaches to concealment of 
randomisation 
use of alternation, case record numbers, birth dates or 
week days 
open random numbers lists 
serially numbered envelopes (even sealed opaque 
envelopes can be subject to manipulation) 
    
Were the groups similar at baseline in terms of 
prognostic factors? 
    
Were the eligibility criteria specified?     
Were the groups treated in the same way apart from the 
intervention received? 
    
Was the outcome assessor blinded to the treatment 
allocation? 
    
Was the care provider blinded?     
Were the patients blinded?     
Were the point estimates and measures of variability 
presented for the primary outcome measures? 
    
Was the withdrawal/drop-out rate likely to cause bias?     
Did the analyses include an intention-to-treat analysis?     
Was the operation undertaken by someone experienced 
in performing the procedure? 
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Table 57 Checklist for the quality assessment of comparative observational studies 
Criteria Yes No Unclear 
Were participants a representative sample selected from a 
relevant patient population? 
   
Were the inclusion/exclusion criteria of participants clearly 
described? 
   
Were participants entering the study at a similar point in their 
disease progression?a 
   
Was selection of patients consecutive?    
Was data collection undertaken prospectively?    
Were the groups comparable on demographic characteristics 
and clinical features?b 
   
Was the intervention (and comparison) clearly defined?    
Was the intervention undertaken by someone experienced at 
performing the procedure? 
   
Were the staff, place, and facilities where the patients were 
treated appropriate for performing the procedure? (E.g. access 
to back-up facilities? 
   
Were all the important outcomes considered?    
Were objective (valid and reliable) outcome measure/s used?    
Was the assessment of main outcomes blind?    
Was follow-up long enough to detect important effects on 
outcomes of interest? 
   
Was information provided on non-respondents, dropouts?    
Were participants lost to follow-up likely to introduce bias? 
(e.g. high drop-out rate; differential drop-out; no description 
of those lost) 
   
Was length of follow-up similar between comparable groups    
Were all the important prognostic factors identified?    
Were the analyses adjusted for confounding factors?    
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Appendix 4 Forest plots  
Figure 30 Cardiac event rate for EVAR versus open repair: Forest plot 
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Figure 31 Renal impairment rates for EVAR versus open repair: Forest plot 
 
 
 
Figure 32 Blood loss for EVAR versus open repair: Forest plot 
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 Figure  33  Overall long-term mortality rates following EVAR and open repair 
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Figure 34 ITU stay for EVAR versus open repair: Forest plot 
 
 
 
Figure 35 Hospital stay for EVAR versus open repair: Forest plot 
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APPENDIX  5   List of excluded papers 
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treatment on in-hospital mortality following non-ruptured AAA repair over a decade: 
A population based study of 16446 patients.  Eur J of Vasc Endovasc 
2004;28(1);41/46. 
Reasons for exclusion: Insufficient outcome data of interest. 
 
Arko 2002 
Arko FR, Lee AL, Hill BB, Olcott C, Dalman RL Harrus EJ er al.  Aneurysm-related 
death: Primary endpoint analysis for comparison of open and endovascular repair.  J 
Vasc Surg 2002; 36:297-304. 
Reasons for exclusion: Repeat publication from same data series. 
 
Aziz 2003 
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in patients undergoing endoluminal graft repair of abdominal aortic aneurysm: A 
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Reasons for exclusion: Uncertain follow-up period, insufficient outcome data of 
interest. 
 
Berg 2001 
Berg P, Kaufmann D, Marrewijk C, Buth J.  Spinal cord ischaemia after stent-graft 
treatment for infra-renal abdominal aortic aneurysms.  Analysis of the Eurostar 
database.  Eur J Vasc Endovasc Surg 2001;22:342-347. 
Reasons for exclusion: More recent registry publications exist. 
 
Bush 2006 
Bush RL, Johnson ML, Collins TC, Henderson WG et al.  Open versus endovascular 
abdominal aortic aneurysm repair in VA hospitals.  J Am Coll Surg 2006; 202:577-
587. 
Reasons for exclusion: Newer publications from same data series exist. 
 
Buth 2000 
Buth J, Laheij R.  Early complications and endoleaks after endovascular abdominal 
aortic aneurysm repair: Report of a multicentre study.  J Vasc Surg 2000;31:134-46. 
Reasons for exclusion: More recent registry publications exist. 
 
Buth 2002 
Buth J, Van Marrewijk CJ, Harris PL, Hop WCJ, Riambau V, Laheij RFJ.  Outcome 
of endovascular abdominal aortic aneurysm repair in patients with conditions 
considered unfit for and open procedure: A report on the EUROSTAR experience.  J 
Vasc Surg 2002; 35:211. 
Reasons for exclusion: Later publications from same data series exist. 
 
Carroccio 2002 
Carroccio A, Faries P, Morrissey N, Teodorescu V, Burks J, Gravereaux E et al.  
Predicting iliac limb occlusions after bifurcated aortic stent grafting: anatomic and 
device-related causes.  J Vasc Surg 2002;36:679-684. 
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Reasons for exclusion: No patient demographics, insufficient outcome data of interest. 
 
Cuypers 2000 
Cuypers P, Laheij R, Buth J.  Which factors increase the risk of conversion to open 
surgery following endovascular abdominal aortic aneurysm repair?  Eur J Vasc 
Endovasc Surg 2000;20;183-90. 
Reasons for exclusion: More recent registry publications exist. 
 
D’Ayala 2004 
D’Ayala M, Dietch JS, Wise L.  Complications of endovascular surgery for 
abdominal aortic aneurysms.  Current Surgery 2004; 61(2);163-165. 
Reasons for exclusion: No primary data (review article). 
 
Earnshaw 2005 
Earnshaw JJ, Murie JA.  Mid-term results of endovascular repair of abdominal aortic 
aneurysm.  British Journal of Surgery 2005; 92:925-927. 
Reasons for exclusion: No primary outcome data. 
 
Greenberg 2004 
Greenberg RK, Deaton D, Sullivan T, Walker E, Lyden SP, Srivastave SD et al.  
Variable sac behaviour after endovascular repair of abdominal aortic aneurysm: 
Analysis of core laboratory data.  J Vasc Surg 2004; 39:95-101. 
Reasons for exclusion: No significant outcome data of interest. 
 
Greenhalgh 2007 
The EVAR Trial Participants.  Secondary interventions and Mortality following 
endovascular aortic aneurysm repair: Device specific results from the UK EVAR 
trials.  Eur J Vasc Endovasc Surg 2007; 34, 281-290. 
Reasons for exclusion: No new data published compared to previous publications 
from same series. 
 
Harris 2000 
Harris PL, Vallabhaneni SR, Desgranges P, Becquemin J, Marrewijk C, Laheij RFJ.   
Incidence and risk factors of late rupture, conversion, and death after endovascular 
repair of infrarenal aortic aneurysms: The EUROSTAR experience.  J Vasc Surg 
2000; 32:39-49. 
Reasons for exclusion: Later publications from same series exist. 
 
Harris 2004 
Harris PL, Buth J. An update on the important findings from the EUROSTAR EVAR 
registry.  Vascular 2004;12(1);33-38. 
Reasons for exclusion: No significant outcome data of interest. 
 
Laheij 2000 
Leheij R, Buth J, Harris P, Moll F, Stelter W, Verhoeven E.  Need for secondary 
interventions after endovascular repair of abdominal aortic aneurysms.  Intermediate-
term follow-up results of a European collaborative registry (EUROSTAR).  Br J Surg 
2000;87(12):1666-1673. 
Reasons for exclusion: More recent publications exist . 
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Leurs 2004 
Leurs LJ, Hobo R, Buth J.  The multicentre experience with a third-generation 
endovascular device for abdominal aortic aneurysm repair.  J cardiovasc Surg 
2004;45:293-300. 
Reasons for exclusion: Large losses to follow up, little outcome data provided, large 
overlap with other EUROSTAR publications. 
 
Mohan 2001 
Mohan I, Laheij R, Harris P.  Risk factors for endoleak and the evidence for stent-
graft oversizing in patients undergoing endovascular aneurysm repair.  Eur J Vasc 
Endovasc Surg 2001;21:344-349. 
Reasons for exclusion: More recent publications exist.  
 
Ouriel 2003 
Ouriel K, Clair D, Greenberg R, Lyden S, O’Hara P, Sarac T et al.  Endovascular 
repair of abdominal aortic aneurysms:  Device-specific outcome.  J Vasc Surg 
2003;37:991-8. 
Reasons for exclusion: Publication from same data series. No new information 
included. 
 
Peppelenbosch 2004 
Peppelenbosch N, Buth J, Harris PL, Van-Marrewijk C, Fransen G, Ouriel K et al.  
Diameter of abdominal aortic aneurysm and outcome of endovascular aneurysm 
repair: Does size matter? A report from EUROSTAR.  Journal-of-Vascular-Surgery. 
2004; 39(2): 288-297. 
Reasons for exclusion: More relevant publications exist. 
 
Rhee 2002 
Rhee R, Muluk S, Tzeng E, Missig-Carroll N, Makaroun M.  Can the external iliac 
artery be safely covered during endovascular repair of abdominal and iliac artery 
aneurysms?  Ann Vasc Surg 2002;16:29-36. 
Reasons for exclusion: Small study, insufficient outcome data of interest. 
 
Riambau 2001 
Riambau V, Laheij R, Garcia-Madrid C, Sanchez-Espin G.  The association between 
co-morbidity and mortality after abdominal aortic aneurysm endografting in patient 
ineligible for elective open surgery.  Eur J Vasc Endovasc Surg 2001;22:265-270. 
Reasons for exclusion: More recent publications exist. 
 
Sampram 2003 
Sampram ESK, Karafa MT, Mascha EJ, Clair DG, Greenberg RK, Lyden SP et al.  
Nature, frequency and predictors of secondary procedures after endovascular repair of 
abdominal aortic aneurysm.  J Vasc Surg 2003; 37:930-7. 
Reasons for exclusion: Repeat publication from same data series. 
 
Sandridge LC 
Sandridge LC, Baglioni AJ, Kongable GL, Harthun NL.  Evaluation of the effect of 
endovascular options on infrarenal abdominal aortic aneurysm repair.  Am Surg 2006. 
Aug; 72(8):700-704. 
Reasons for exclusion: Insufficient outcome data of interest. 
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Schermerhorn 2002 
Schermerhorn M, Finlayson S, Fillinger M, Buth J, Marrewijk C, Cronenwett J.  Life 
expectancy after endovascular versus open abdominal aortic aneurysm repair: Results 
of a decision analysis model on the basis of data from EUROSTAR. J Vasc Surg 
2002;36:1112-20. 
Reasons for exclusion: No primary data. 
 
Steinmetz 2004 
Steinmetz E, Rubin BG, Sanchez LA, Choi ET, Geraghty PJ, Baty J et al.  Type II 
endoleak after endovascular abdominal aneurysm repair: A conservative approach 
with selective intervention is safe and cost-effective.  J Vasc Surg 2004; 39:306-13. 
Reasons for exclusion: Only patients with type II endoleak included (n=5). 
 
Sternbergh 2004 
Sternbergh W, Money S, Greenberg R, Chutter T.  Influence of endograft oversizing 
on device migration, endoleak, aneurysm shrinkage, and aortic neck dilatation: 
Results from the Zenith multicentre trial.  J Vasc Surg 2004;39:20-6. 
Reasons for exclusion: No patient demographics, unclear recruitment period, unclear 
follow-up, limited outcome data of interest. 
 
Thomas 2001 
Thomas S, Gaines P, Beard J.  Short-term (30-day) outcome of endovascular 
treatment of abdominal aortic aneurysm: results of the prospective registry of 
endovascular treatment of abdominal aortic aneurysms (RETA).  Eur J Vasc 
Endovasc Surg 2001;21:57-64. 
Reasons for exclusion: Only 1 month follow-up.  16% population were ruptured or 
symptomatic AAAs. Newer publications exist. 
 
Timaran 2007 
Timaran CH, Veith FJ, Rosero EB, Modrall JG, Arko FR et al.  Endovascular aortic 
aneurysm repair in patients with the highest risk and in hospital mortality in the 
United States.  Arch Surg 2007; 142:520-525. 
Reasons for exclusion: Repeat publication from same data series, no new data. 
 
Waasdorp 2005 
Waasdorp EJ, de Vries JP, Hobo R, Leurs LJ et al for EUROSTAR collaborators.  
Aneurysm diameter and proximal aortic neck diameter influence clinical outcome of 
endovascular abdominal aortic repair:  A 4-year EUROSTAR experience.  Annals of 
vascular surgery; 19:755-761 
Reasons for exclusion: Repeat publication from same data series, no new data. 
 
Wang 2009 
Wang GJ, Carpenter JP.  EVAR in small versus large aneurysms: does size influence 
outcome? Vasc Endovasc Surg 2009;443(3):244-51. 
Reasons for exclusion: Repeat publication from same data series, no new data. 
 
Zarins 2000 
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Zarins C, White R, Fogarty T.  Aneurysm rupture after endovascular repair using the 
AneuRx stent graft.  J Vasc Surg 2000;31:960-970. 
Reasons for exclusion: Later publications from same series exist. Insufficient outcome 
data of interest. 
 
Zarins 2000 
Zarins C, White R, Hodgson K, Schwarten D, Fogarty T.  Endoleak as a predictor of 
outcome after endovascular aneurysm repair: AneuRx multicenter clinical trial.  J 
Vasc Surg 2000;32:90-107. 
Reasons for exclusion: Later publications from same series exist with larger numbers 
and / or longer follow up. 
 
Zarins 2004 
Zarins CK, Bloch DA, Crabtree T, Matsumoto AH, White RA, Fogarty TJ.  
Aneurysm enlargement following endovascular aneurysm repair: AneuRx clinical 
trial.  Journal-of-Vascular-Surgery. 2004; 39(1): 109-117. 
Reasons for exclusion: More relevant publications from same series exist. 
Zarins 2006  
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aneurysm repair at 5 years: does aneurysm size predict outcome.  J Vasc Surg 
2006;44:920-30. 
Reasons for exclusion: More relevant publications from same series exist. 
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EVAR DATA FROM NON-CONTROLLED STUDIES 
Overview of the efficacy findings from non-controlled studies (Case series and 
comparative studies) 
Deployment success rate 
The results from the case series are displayed in the table below. The results were 
similar to the controlled studies with a success rate of 98%, (95% CI 97.9% to 
98.5%). 
Table:  Successful endograft deployment rate  
Author Number of patients (n) Deployment success 
rate %, (95% CI) Undergoing EVAR Successful deployment 
Cao 200634 649 640 99 
Carpenter 200437 227 224 99 
Criado 2001109 471 456 93 
Elkouri 200381 100 97 97 
Espinosa 200546 193 191 99 
Herwaarden 200790 212 209 99 
Howell 2001115 215 214 100 
    Howell 2000116 56a 56 100 
Lalka 2005128 136 136 100 
Lee 2002117 150 148 99 
Maldonado 200762 430 424 99 
May 200064 266 249 94 
Qu 200974 612 603 99 
     Qu 200775 378 372 98 
Ramaiah 2002119 230 230 100 
     Zarins 2000123 149 147 99 
Vallabhaneni 2001102 2862 2812 98 
Total 6753 6633 98% (97.9% - 98.5%) 
a n=56 patients who received an AneuRx stent 
 
Technical success rate 
• Primary technical success rate 
Correct stent placement and complete aneurysm exclusion at completion or discharge 
angiogram was the definition in the majority of the studies.   No definition was 
provided by 4 studies.   Four studies stated an alternative definition of technical 
success. Successful endograft deployment was used by Lee 2002.117,118  Successful 
endograft deployment without the need for surgical conversion or death; lack of a 
persistent (>48 hours) type I or type III endoleak; and a patent graft was used by Okhi 
2001.68  The definition used by Ramaiah 2002119 was that defined by the Society for 
Vascular Surgery / International Society for Cardiovascular reporting standards.  The 
success rate averaged 82%, (95% CI 81.3% to 83.0%). 
Table:  Primary technical success rate  
Author Number of patients (n) Technical success rate (%, 
95% CI) Undergoing EVAR Technical success 
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Blum 200123 298 269 90 
Boult 200625 961 890 93 
    Boult 200426 950 853 90 
Bos 200828 234 223 95 
Carpenter 200437 227 183 81 
Criado 2001109 471 383 81 
    Fairman 2004111 109 61 56 
Espinosa 200945 337 304 90 
Hinchliffe 200453 269 240 89 
Howell 2001115 215 132 61 
    Howell 2000116 89 57 64 
Lee 2002117 150 93 62 
    Lee 2000118 67 36 54 
    Zarins 2000123 149 94 63 
Nevla 200967 206 163 79 
Ohki 200168 239 212 89 
Ramaiah 2002119 260 220 85 
Sampaio 200980 241 155 64 
Thomas 200587 1000 721 72 
Vallabhaneni 2001102 2862 2322 81 
Wales 200892 286 272 95 
Total 8256 6782 82% (81.3% – 83.0%) 
 
• Thirty day technical success 
The results of the 8 included case series are displayed in the table below. The success 
rate was 91% (95% CI 90.1% to 92.1%). 
Table:  Thirty day technical success 
Author Number of patients (n) Technical success rate, 
% (95% CI) Undergoing EVAR Technical success 
Boult 200426 950 825 87 
Bos 200828 234 228 97 
Carpenter 200437 205 179 87 
Criado 2001109 355a 342 96 
Elkouri 200381 100 86 86 
Howell 2001115 215 200 93 
    Howell 2000116 56b 53 95 
Ramaiah 2002119 260 260 100 
    Zarins 2000123 147 121 82 
    Lee 2000117 67 52 78 
Thomas 200587 1000 904 90% 
Total 3319 3024 91% (90.1% - 92.1%) 
a n=355 patients who were available for evaluation 
b n=56 patients who received an AneuRx stent 
 
Aneurysm rupture following EVAR 
There were 25 case series that had reported the delayed AAA rupture rate following 
over a mean of 29.5 months follow up, (see table). Overall the mean rupture rate was 
1.4% (95% CI 1.2%, 1.5%).  
Table:  Delayed aneurysm rupture rates following EVAR  
Author Number of patients Rupture Rate, % 
(95% CI) 
Follow-up (months) 
Undergoing 
EVAR 
With rupture 
Mean Range 
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Abbruzzese 200814 565 6 1.1 30 Not reported 
Blum 200123 298 4 1.3 35 2-50 
Boult 200625 961 12 1.2 NR 5-60 
Brewster 200530 873 13 1.5 27  Not reported 
Cao 200933 349 2 0.6 25 12-60 
Conrad 200940 832 5 0.6 35 0-113 
Corriere 200441 220 0 0 NR Not reported 
Dias 200943 304 1 0.3 54 Not reported 
Elkouri 200381 100 1 1 7 1-60 
Herwaarden 200790 212 7 3.3 52 1-109 
Hinchliffe 200453 255 2 0.8 12 Not reported 
Hiramoto 200654 325 1 0.3 28 1-85 
Hobo 200895 7554 164 2.2 19 (0-108) 
    Marrewijk 200597 6787 50 0.8 21 0-108 
    Hobo 200699 2846 40 1.4 23 Not reported 
    Laheij 2002101 2863 16 0.6 NR Not reported 
Howell  2001115 215 0 0 14 Not reported 
    Howell 2000116 89 0 0 13 1-18 
Hugl 2007127 366 1 0.3  NR Not reported 
Lee 2002117 150 0 0 1 Not reported 
    Lee 2000118 67 0 0 18 Not reported 
Ohki 200168 239 2 0.8 16 <75 months 
Ouriel 200368 704 3 0.4 NR Not reported 
Parlani 200235 336 2 0.6 14 1-46 
Qu 200974 612 1 0.2 62 Not reported 
Ramaiah 2002119 230 0 0 NR Not reported 
Szmidt 200786 445 3 0.7 30 Not reported 
Thomas 200587 1000 11 1.1 37 Not reported 
Verhoeven 200429 306 1 0.3 36 Not reported 
Zarins 2004124 1193 15 1.3 NR <48 
    Zarins 2003125 383 3 0.8 36 Not reported 
    Zarins 2000123 149 1 0.7 12 1-39 
Total 18644 257 1.4 (1.2%-1.5%) 29.5 - 
NR – Not reported      
 
Nine studies reported the early AAA rupture rate with a mean of 0.1%, (95% CI 0.1%, 
0.2%). 
Table:  Early (<30 days) aneurysm rupture rates following EVAR 
Author Number of patients Rupture Rate, % 
(95%CI) Undergoing 
EVAR 
With rupture 
Abbruzzese 200814 565 2 0.4 
Blum 200123 298 1 0.3 
Carpenter 200437 227 2 0.9 
Hobo 200895 7554 5 0.07 
     Lange 2005198 4191 1 0.02 
Ouriel 200369 704 1 0.1 
Qu 200775 378 1 0.3 
Ricco 200376 1012 2 0.1 
Zannetti 200136 240 1 0.4 
Zarins 2003125 1193 3 0.3 
Total 12171 18 0.1 (0.1%-0.2%) 
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NR – Not reported    
 
Changes in aneurysm size 
From the 21 case series, 6.5% (95% CI 6.1% - 7.0%) of the EVAR population 
increased in size (Table 43). 
Table:  Changes in aneurysm size following EVAR 
Author Number of 
cases 
Changes in aneurysm size n (%) Follow-up 
(mean) Increase No change Decrease 
Arko 2003113 206 11 (5.3) 25 (12) 170 (82.5) 32 
Bos 200828 234 7 (3.0) NR NR 27 
Boult 200625 961 96 (10) 231 (24) 634 (66) NR 
Brewster 200630 873 46 (7.8) 375 (43) 452 (49) 27 
Carpenter 200437 48b 4 (8) a 28 (58) 16 (33) 11 
Elkouri 200381 97 2 (0.2) 32 (33) 63 (65) 7 
El Sayed 200944 438 NR NR 129 (29) 49 
Espinosa 200945 108 7 (6.5) NR NR 59 
Fairman 2004111 16 4 (25) NR NR  21 
Cao 200933 349 22 (6.3) 169 (48) 158 (45) 25 
    Parlani 200235 326c 21 (6.4) a 182 (56) 127 (39) 14 
Dias 200943 304 27 (8.9) NR NR 54 
Herwaarden 200790 204 15 (7.4) 109 (53) 80 (39) 52 
Hobo 200895 7554 910 (12.0) NR NR 19 
    Marrewijk 200597 6787 378 (6) 4756 (70) 2031 (30) 21 
Howell 2000115 84 2 (0.9) a 59 (27) 23 (11) 14 
Hugl 2007127 336 12 (3.6) NR NR NR 
Jones 200758 873 68 (7.8) NR NR 33 
Nevla 200967 206 16 (7.8) 64 (31.7) 109 (53.2) 29 
Ouriel 200369 700 70 (10) 419 (60) 211 (30) 12 
Qu 2009 612 25 (4.0) NR NR 62 
Zarins 2003122 383 46 (12) 138 (36) 199 (52) 36 
Lee 2000115 67 8 (12) NR NR 18 
Total 14653 777 (6.5) 6542 (55) 4200 (35.1) 23 
a No definition provided 
b n=48 patients who were available for evaluation at 12 months 
c n=326 patients with a successfully implanted stent-graft 
NR – Not reported 
 
Primary conversion rate 
This was reported by 30 studies, (Table 44). The largest single publication is a 
multicentre study from the EUROSTAR database100 that reported a primary 
conversion rate of 0.9%. Overall the mean conversion rate was 1.3% (95% CI 0.9%, 
1.2%). 
Table:  Primary conversion rates  
Author 
 
Total number of 
EVAR 
Primary conversion 
Number of patients Rate, % (95% CI) 
Blum 200126 298 5 0.8 
Boult 200628 961 10 1.0 
   Boult 200429 950 9 0.9 
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Brewster 200631 873 5 0.6 
Cao 200535 649 9 0.2 
     Parlani 200236 336 6 1.8 
    Zannetti 200137 266 6 2.3 
Carpenter 200438 227 3 1.3 
Dias 2009 304 1 0.3 
 Elkouri 200383 100 3 3 
Espinosa 200447 193 1 0.5 
Herwaarden 200757 212 2 0.9 
Hinchliffe 200458 269 0 0 
Hobo 2008 7554 68 0.9 
    Lange 200596    
      Age <80Y 4191 40 1.0 
      Age >80Y 697 11 1.6 
    Vallabhaneni 2001100 2862 47 1.6 
Howell 2001112 215 0 0 
    Howell 2000113 89 0 0 
Jiminez 2007 574 5 0.9 
Lalka 2005124 136 0 0 
Lee 2002114 150 2 1.3 
Maldonado 200765 430 6 1.4 
   Maldonado 200466 311 6 1.9 
May 200067 266 17 6.4 
Ouriel 200376 700 3 0.4 
Pitoulias 200973 625 8 1.3 
Qu 200974 612 9 1.5 
     Qu 200775 378 6 1.6 
Ramaiah 2002119 260 0 0 
Ricco 200376 1012 11 1.1 
Shames 2003a120 
     Males 
     Females 
245 
203 
42 
7 
1 
6 
2.9 
0.5 
14 
Thomas 200587 1000 14 1.4 
Tonnessen 2005121 205 3 1.5 
Traul 200888 245 1 0.4 
Verhoeven 200429 308 1 0.3 
Waasdorp 200889 291 1 0.3 
Wales 200892 286 0 0 
Zarins 2003125 1193 11 0.9 
    Zarins 2000123 149 2 1.3 
Total 20638 213 1.0 (0.9% - 1.2%) 
a Data extracted from Resch 200173 
 
Delayed conversion rate 
The results of the 37 case series are displayed in Table 45. The overall mean was 
3.7% (95% CI 3.4%, 3.9%). The single largest study from the EUROSTAR 
database100 reported a rate of 6.1%. The study with the longest follow-up,72 which 
stated a period of at least 60 months, reported a delayed conversion rate of 2.3%. 
Table:  Delayed conversion rates  
Author Total 
number of 
EVAR 
Secondary conversions Follow-up 
Number %, (95% CI) Mean Range 
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Abbruzzese 200814 565 4 0.77 30 Not reported 
Arko 2003113 206 3 1.5 32 3-55 
Becquemin 200418 250 11 4.4 28 Not reported 
Blum 200123 298 8 2.7 35 2-50 
Boult 200625 961 6 0.6 Not reported 5-60 
Brewster 200630 852 15 1.8 27 Not reported 
Cao 200634 649 29 4.5 38 Not reported 
     Cao 200933 349 8 2.3 25 12-60 
     Parlani 200235 336 4 1.2 14 1-46 
Carpenter 200437 227 2 0.9 11 0-41 
Conrad 200940 832 21 2.5 35 0-113 
Dias 200943 304 4 0.3 54 Not reported 
Elkouri 200381 100 1 1 7 1-60 
Fairman 2004111 237 6 2.5 21 Not reported 
Herwaarden 200790 212 11 5.2 52 1-109 
Hobo 200895 7554 462 6.1 19 0-108 
    Vallabhaneni 2001102 2862 41 1.4 12 0-72 
    Hobo 200699 2846 40 1.4 12 Not reported 
Howell 2001115 215 4 1.9 14 Not reported 
    Howell 2000116 89 2 2.2 13 1-18 
Hugl 2007127 366 5 0.3 Not reported Not reported 
Jiminez 200757 569 12 2.1 42 Not reported 
Jordan 200459 259 4 1.5 28 Not reported 
Lee 2000118 67 1 1.5 18 Not reported 
Moore 200366 573 2 0.3 Not reported 1-60 
Ohki 200168 239 5 2.1 16 <75 months 
Ouriel 200369 700 29 4.1 12 Not reported 
Pitoulias 2009 73 617 39 6.3 47 1-94 
Qu 200974 612 14 2.3 62 Not reported 
     Qu 200775 366 6 1.6 37 1-84 
Ricco 200376 1012 4 0.4 11 Not reported 
Thomas 200587 1000 23 2.3 37 Not reported  
Verhoeven 200429 308 9 2.9 36 Not reported  
Wales 200892 286 0 0 16 0-70 
Zarins 2004124 1193 42 3.5 Not reported Not reported 
    Zarins 2000123 149 1 0.7 12 1-39 
    Zarins 2003125 383 18 4.7 36 Not reported 
Total 21427 791 3.7 (3.4% - 3.9%) 28  
 
Secondary intervention rate 
Overall the mean secondary intervention rate from the 42 included case series was 
16.2%  (95% CI 15.6%, 16.7%). Again, the largest single publication was from the 
EUROSTAR registry (Hobo 2008), which reported a secondary intervention rate of 
16.9%. The study with the longest follow up (54 months) recorded a secondary 
reintervention rate of 25.6%. 
 
Table:  Secondary intervention rates  
Author Total number 
of EVAR 
Secondary interventions Follow-up 
Number % (95% CI) Mean Range 
Abbruzzese 200814 565  88 15.6 30 Not reported 
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Arko 2003113 206 19 9.2 32 3-55 
Becquemin 200418 250 112 44.8 28 Not reported 
Blum 200123 298 24 8.1 35 2-50 
Bos 200828 234 29 12.4 27 0-104 
     Verhoeven 200429 308 72 23.4 36 Not reported 
Boult 200625 961 136 14.2 Not reported 5-60 
    Boult 200426 950 23 2.4 Not reported Not reported 
Brewster 200630 848 102 12.0 27 Not reported 
Cao 200933 349 19 5.4 25 12-60 
      Parlani 200235 336 19 5.7 14 1-46 
Carpenter 200437 227 17 7.5 11 0-41 
Conrad 200940 832 131 15.7 35 0-113 
Dias 200943 304 78 26.6 54  Not reported 
Herwaarden 200790 212 96 45 52 1-109 
Hincliffe 200453 269 21 7.8 12 Not reported 
Hiramoto 200654 325 28 8.6 28 1-85 
Hobo 200895 7554 1273 16.9 19 0-108 
    Marrewijk 200597 6787 771 11.4 21 0-108 
    Hobo 200699 2846 247 8.7 12 Not reported 
    Laheij 2002101 2863 410 14.3 Not reported Not reported 
Howell 2001115 215 22 10.2 14 Not reported 
    Howell 2000116 89 11 12.4 13 1-18 
Hugl 2007127 366 63 17.2 Not reported Not reported 
Lalka 2005128 136 21 12.5 36 1-61 
Lee 2002117 150 7 4.7 Not reported Not reported 
    Lee 2000118 67 17 24.5 18 Not reported 
May 200064 266 43 16.2 6 > 6 months 
Nevla 200967 206 27 13.1 29 Not reported 
Ohki 200168 239 23 9.6 16 <75 months 
Ouriel 200369 700 173 24.7 12 Not reported 
Pitoulias 200973 617 139 22.5 47 1-94 
Qu 200775 366 41 11.2 27 1-84 
Ramaiah 2002119 230 41 17.8 Not reported Not reported 
Ricco 200376 1021 67 6.6 11 Not reported 
Sampaio 200480 241 66 27 10 1-71 
     Elkouri 200381 100 29 29.0 7 1-60 
Shames 2003120 245 36 14.7 11 1-26 
Thomas 200587 1000 380 38 37 Not reported 
Traul 200888 245 15 6.1 30  
Wolf 2002122 189 31 16.4 13 Not reported 
Zarins 2003125 383 67 17.5 36 Not reported 
    Zarins 2000123 149 21 14.1 12 1-39 
Total 20338 3446 16.2 (15.6% - 16.7%) 26  
 
 
Procedural blood loss 
Studies that reported blood loss following EVAR are displayed in Table 47. The 12 
studies were case series with a range of blood loss of 157 ml to 468 ml. 
Table:  Procedural blood loss  
Author Number of participants Mean Blood loss (ml) 
Bos 200828 234 157 
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Carpenter 200437 227 350 
 Fairman 2004111   
    Complicated neck 153 320 
    Uncomplicated neck 66 351 
Elkouri 200381 100 400 
Howell 2001115 215 352 
    Howell 2000116 56 b 428 
Hinchliffe 200453 269 400 
Ohki 200168 239 468 
 Parlani 200235   
      EVAR 277 293 
      AAA and IAAa 59 445 
Ramaiah 2002119   
     Early 30 400 
     Late 230 294 
Vasquez 200493   
    EVAR 129 255 
    Renal impairment 83 278 
Waasdorp 200889 291 330 
Total 2788 341 
a Combined abdominal and iliac artery aneurysms 
b results from late endovascular experience 
 
Length of ITU stay 
The results of the ITU length of stay are displayed in Table 48. EVAR was associated 
with a mean stay of 1 day. 
Table:  Length of ITU stay  
Author Number of participants ITU stay (days) 
Elkouri 200381 100 1.0 a 
 
Length of hospital stay 
Sixteen case series reported outcome data on length of hospital stay following EVAR, 
(Table 49). Overall from the 13 studies the average length of stay following EVAR 
was 3.8 days. 
Table:  Length of hospital stay  
Author Number of participants Mean length stay, days  
Ayerdi 2003114 96 a  
     Early EVAR 42 3b 
     Late EVAR 54 2b 
Bos 200828 234 4.6 
Carpenter 200437 227 4 
Herwaarden 200790 212 4.3 
Howell 2001115 215 2 
    Howell 2000116 89  
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         Early EVAR 33 4 
         Late EVAR 56 2 
Lange 200598   
  Age < 80Y 4191 5.5 
  Age > 80Y 697 7.3 
Ohki 200168 239 4 
Parlani 200235 336  
      EVAR 277 2 
      AAA + IAA 59 2 
    Zannetti 200136 266  
         EVAR 240 3 
         High risk EVAR 26 8 
Ramaiah 2002119 260  
     Early EVAR 30 4 
     Late EVAR 230 4 
Ricco 200376 1012 9 
Samapaio 200480   
   Male 212 3 
   Female 29 4 
     Elkouri 200381 100 3 
Shames 2003120 245  
     Male 203 3 
     Female 42 3 
Traul 200888 245 2.3 
Total 8450 3.8 
aTotal number of EVAR participants 
b Median  
 
Overview of the Safety findings from non-controlled studies (Case series) 
Common technical complications 
The incidence of the common technical complications is shown in Table 50. 
Table:  Incidence of common technical complications in EVAR  
Complication Author Number of 
participants 
Number of 
cases 
%  
Stent migration     
<30 days Hobo 200895 7554 99 1.3% 
  Vallabhaneni 2001102 2862 39 1.4% 
     
> 1 year Abbruzzese 200814 565 10 1.8% 
 Becquemin 200418 250 4 1.6% 
 Blum 200123 298 5 1.7% 
 Bos 200828 234 3 1.3% 
 Brewster 200630 852 25 2.9% 
 Cao 200933 349 17 4.9% 
 Herwaarden 200790 212 26 12% 
 Hinchliffe 200453 255 6 2.4% 
 Hobo 200895 7554 740 9.8% 
    Marrewicj 200597 6787 323 4.8 
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    Hobo 200699 2846 73 2.6% 
    Fransen 2003100 4613 156 3.4% 
 Hugl 2007127 366 6 1.6% 
 Nevla 200967 206 0 0% 
 Ouriel 200369 704 51 7.2% 
 Pitoulias 200973 617 60 9.7 
 Qu 200974 612 7 1.1% 
      Qu 200775 366 6 1.6% 
 Tonnessen 2005121 130 15 11.5% 
 Traul 200888 245 4 1.6% 
 Zarins 2000123 137 13 9.5% 
     Zarins 2003125 383 24 6.3% 
 Total 13694 994 7.3% 
     
Stent wire fracture Carpenter 2004.37 227 6 2.6% 
up to 1 year     
     
Graft limb thrombosis Abbruzzese 200814 565 2 0.4% 
<30 days Howell 2000115 215 5 2.3% 
 Lee 2002117 150 1 0.7% 
 Parlani 200235 336 4 1.2% 
 Wales 200892 286 6 2.1% 
 Total 1552 18 1.2% 
     
<1 year Blum 200123 298 4 1.3% 
 Carpenter 200437 227 0 0.0% 
 Elkouri 200381 100 4 4.0% 
 Shames 2003120 241 10 4.1% 
 Waasdorp 200889 291 3 1.0% 
 Zarins 2000123 149 1 0.7% 
 Total 1306 22 1.7% 
     
>1 year Abbruzzese 200814 565 6 1.1% 
 Becquemin 200418 250 15 6.0% 
 Bos 200828 234 4 0.4% 
    Verhoeven 200429 306 15 4.9% 
 Cao 200933 349 5 1.4% 
 Espinosa 200945 337 4 1.2% 
 Go 200851 376 3 0.1% 
 Herwaarden 200790 212 3 1.4% 
 Hiramoto 200654 325 2 0.6% 
 Hobo 200895 7554 352 4.7% 
    Marrewicj 200597 6787 267 5.4% 
    Hobo 200699 2846 68 2.4% 
    Fransen 2003100 4613 152 3.3% 
 Maldonado 200762 430 16 3.7% 
    Maldonado 200463 287 14 4.9% 
 Nevla 200967 206 5 2.4% 
 Ohki 200168 239 7 2.9% 
 Ouriel 200369 704 43 6.1% 
 Qu 200974 612 6 1.0% 
      Qu 200775 366 8 2.2% 
 Thomas 200587 1000 45 4.5% 
 Traul 200888 245 5 2.0% 
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 Total 13638 521 3.8% 
     
Graft stenosis Vallabhaneni 2001102 2862 10 0.3% 
 30 days     
     
<1 year Elkouri 200381 100 3 3.0% 
     
>1 year Becquemin 200418 250 8 3.2% 
 Carpenter 200437 188 3 1.6% 
 Fransen 2003100 4613 66 1.4% 
 Qu 200775 366 5 1.4% 
 Total 5417 82 1.5% 
     
Stent Kink Nevla 200967 206 5 2.4% 
 Pitoulias 200973 617 59 9.5% 
     
Type I endoleak Boult 200426 950 25 2.6% 
< 30 days Espinosa 200945 337 4 1.2% 
 Go 200851 376 5 1.3% 
 Hinchliffe 200453 255 2 0.8% 
 Hobo 200895 7554 334 4.4% 
     Lange 200598 4888 134 2.7% 
 Howell 2000115 215 2 0.9% 
     Howell 2000116 56 2 3.6% 
 Lee 2002117 150 5 3.3% 
 Nevla 200967 206 12 5.8% 
 Parlani 200235 336 3 1.2% 
 Qu 200775 378 0 0% 
 Waasdorp 200889 291 8 2.7% 
 Total 11048 400 3.6% 
     
up to 1 year Blum 200123 298 6 2.0% 
 Carpenter 200437 227 7 3.1% 
 Go 200851 130 1 0.8% 
 Hinchliffe 200453 255 2 0.8% 
 Howell 2000115 84 2 2.4% 
 Moore 200366 262 9 3.4% 
 Ouriel 200369 704 18 2.6% 
 Total 1960 45 2.3% 
     
>1 year Becquemin 200418 250 36 14.4% 
 Bos 200828 234 5 2.1% 
 Boult 200625 961 7 0.7% 
 Espinosa 200945 337 4 1.2% 
 Herwaarden 200790 212 22 10.4% 
 Howell 2000115 132 6 4.5% 
 Hobo 200895 7554 831 11.0% 
     Hobo 200699 2846 144 5.1% 
     Fransen 2003100 4613 375 8.1% 
 May 200065 266 21 7.9% 
 Nevla 200967 206 2 1.0% 
 Ohki 200168 239 7 2.9% 
 Ouriel 200369 700 25 3.6% 
 Qu 200974 612 11 1.8% 
 150 
      Qu 200775 366 10 2.7% 
 Sampaio 200480 212 9 4.2% 
 Wolf 2002122 189 13 6.9% 
 Zarins 2003125 383 10 2.6% 
 Total 12487 1009 8.1% 
     
Type II endoleak Boult 200426 950 44 4.6% 
<30 days Espinosa 200546 193 7 3.8% 
 Hinchliffe 200453 269 13 4.8% 
 Howell 2000115 215 3 1.4% 
 Jones 200758 873 164 18.8% 
 Lee 2002117 150 29 19.3% 
 Parlani 200235 336 22 6.5% 
 Waasdorp 200889 291 84 28.9% 
 Total 3277 366 11.1% 
     
up to 1 year Blum 200123 298 9 3.0% 
 Carpenter 200437 227 18 7.9% 
 Go 200851 130 3 2.3% 
 Hinchliffe 200453 269 17 6.3% 
 Howell 2000115 84 8 9.5% 
 Ouriel 200369 704 173 24.6% 
 Zarins 2003125 383 55 14.4% 
 Total 2095 283 13.5% 
     
>1 year Arko 2003113 206 40 19.4% 
 Becquemin 200418 250 33 13.2% 
 Bos 200828 234 43 18.4% 
     Verhoeven 200429 306 26 8.5% 
 Brewster 200630 873 161 18.9% 
 Espinosa 200945 337 5 1.5% 
 Herwaarden 200790 212 25 11.8% 
 Hiramoto 200654 325 74 22.8% 
 Hobo 200895 7554 1426 18.9% 
    Hobo 200699 2846 370 13% 
    Fransen 2003100 4613 485 10.5% 
 May 200064 383 4 1.0% 
 Nevla 200967 206 25 12.1% 
 Ohki 200168 239 13 5.4% 
 Qu 200974 612 26 4.2% 
      Qu 200775 366 9 2.5% 
 Zarins 2003125 573 61 10.6% 
 Total 12004 1936 16.1% 
     
Type III endoleak Go 200851 376 1 0.3% 
<30 days Waasdorp 200889 291 1 0.3% 
     
Type III endoleak Becquemin 200418 250 12 4.8% 
>1 year Blum 200123 298 5 1.7% 
 Bos 200828 234 2 0.9% 
 Boult 200625 961 2 0.2% 
 Espinosa 200945 337 3 0.9% 
 Hobo 200895 7554 525 6.9% 
     Hobo 200699 2846 101 3.5 
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     Fransen 2003100 4613 225 4.9% 
 Herwaarden 200790 212 7 3.3 
 Hiramoto 200654 325 3 0.9% 
 Nevla 200967 206 2 1.0% 
 Ohki 200168 239 1 0.4% 
 Ouriel 200369 704 23 3.3% 
 Pitoulias 200973 617 3 0.5% 
 Qu 200974 612 0 0% 
 Sampaio 200979 241 0 0% 
 Zarins 2003125 383 8 2.1% 
 Total   13173 596 4.5% 
     
Access artery injury Blum 200123 298 5 1.7% 
 Bos 200828 234 20 8.5% 
 Espinosa 200446 193 4 2.1% 
 Howell 2000115 215 4 1.9% 
   Howell 2000116 89 8 a 9.0% 
 Lange 200598 4888 314 6.4% 
 Lee 2002117 150 8 5.3% 
 Maldonado 200762 430 4 0.9% 
 Ricco 200376 1012 19 1.9% 
 Shames 2003120 241 11 4.6% 
 Total 7661 348 4.5% 
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Common non-technical complications 
The incidence of the common technical complications is shown in Table 51. 
Table:  Incidence of common non-technical complications (Case Series) 
Study ID Number of 
participants 
Number of events 
Number %  
Mortality rate (<30 days) 
Abbruzzese 200814 565 10 1.8% 
Ayerdi 2003114 96 0 0.0% 
Becquemin 200419 250 5 2.0% 
Blum 200123 270 1 0.4% 
Bos 200828 234 4 1.7% 
    Verhoeven 200429 308 2 0.6% 
Boult 200625 961 17 1.8% 
     Boult 200426 950 16 1.7% 
Brewster 200630 873 16 1.8% 
Cao 200933 557 10 1.8% 
    Parlani 200235 336 4 1.2% 
    Zannetti 200136 266 3 1.1% 
Carpenter 200437 227 3 1.3% 
Conrad 200940 832 13 1.5% 
Criado 2001109 152 5 3.3% 
Dias 200943 304 9 3.0% 
Espinosa 200945 337 13 3.9% 
Herwaarden 200790 212 5 2.4% 
Hinchliffe 200453 269 11 4.1% 
Hobo 200895 7554 181 2.4% 
   Marrewijk 200597 6787 168 2.5% 
   Lange 200598    
    <80Y age 4191 84 2.0% 
    >80Y age 697 35 5.0% 
    Laheij 2002101 2863 85 3.0% 
    Vallabhaneni 2001102 2862 85 3.0% 
Howell 2000115 215 0 0.0% 
   Howell 2000116 89 0 0.0% 
Lalka 2005128 136 0 0.0% 
Lee 2002117 150 2 1.3% 
    Lee 2000118 67 2 3.0% 
Nevla 200967 206 6 2.9% 
Ohki 200178 239 20 8.4% 
Ouriel 200370 704 11 1.6% 
Qu 200974 612 3 0.5% 
     Qu 200775 378 6 1.6% 
Ramaiah 2002119 260 2 0.8% 
Ricco 200376 891 27 3.0% 
Sampaio 200480 241 4 1.7% 
    Elkouri 200381 100 0 0.0% 
Shames 2003120 245 4 1.6% 
Thomas 200587 1000 58 5.8% 
Traul 200888 245 2 0.8% 
Vasquez 200493 213 7 3.3% 
Wales 200892 286 12 4.2% 
Wolf 2002122 189 2 1.1% 
Zarins 2003125 1193 22 1.8% 
    Zarins 2000123 149 2 1.3% 
Total 20718 485 2.5% 
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Mortality - AAA related (range 21-59 months) 
Abbruzzese 200814 565 14 2.5% 
Brewster 200630 857 11 1.3% 
Conrad 200940 832 21 2.5% 
Dias 200943 304 12 4.0% 
Espinosa 200945 337 3 0.9% 
Hiramoto 200654 325 3 0.9% 
Hobo 200895 7554 377 5.0% 
Hugl 2007127 366 9 2.5% 
Ouriel 200370 700 24 3.4% 
Pitoulias 200973 617 6 5.9% 
Traul 200888 245 2 0.8% 
Zarins 2003125 383 5 1.3% 
Total 13085 487 3.7% 
 
Mortality Non-AAA related (range 12-36 months) 
Ayerdi 2003114 96 1 1.0% 
Espinosa 200447 193 12 6.2% 
Howell 2001115 215 12 5.6% 
Ohki 200168 239 53 22.2% 
Zarins 2000123 149 15 10.1% 
Total 892 93 10.4% 
 
Mortality – Total (up to 1 year) 
Becquemin 200419 250 15 6.0% 
Carpenter 200437 227 15 6.6% 
Dias 200943 304 14 4.6% 
Elkouri 200381 100 3 3.0% 
Ouriel 200369 700 83 11.9% 
Shames 2003120 241 14 5.8% 
Tonnessen 2005121 205 17 8.3% 
Wolf 2002122 189 27 14.3% 
Zannetti 200136 266 10 3.8% 
Total 2482 198 8.0% 
    
Mortality – Total (>1 year) 
Abbruzzese 200814 565 220 39% 
Becquemin 200419 250 43 17.2% 
Brewster 200630 873 419 48% 
Cao 200933 349 38 10.8% 
Conrad 200940 832 247 29.7% 
Dias 200943 304 61 20.0% 
Espinosa 200945 337 75 25.3% 
Herwaarden 200790 212 146 69% 
Hiramoto 200654 325 92 28% 
Hobo 200895 7554 2141 28.3% 
   Marrewicj 200597 6787 647 9.5% 
   Vallabhaneni 2001102 2862 655 22.9% 
Hugl 2007127 366 48 13.1% 
Lee 2000117 67 15 22.4% 
Nevla 200967 206 73 35.5% 
Ouriel 200369 704 143 20.3% 
Qu 200974 612 124 20.2% 
Ricco 200376 891 47 4.6% 
Wales 200892 286 28 9.8% 
Zarins 2004124 1193 250 21.0% 
    Zarins 2003125 383 55 14.4% 
Total 15926 4210 24.4% 
    
Cardiac event rate (<30 days) 
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Bos 200828 234 5 2.1% 
Boult 200426 950 69 7.3% 
Elkouri 200381 100 12 12.0% 
Lange 200598 4888 167 3.4% 
Lee 2002117 150 11 7.3% 
Nevla 200967 206 10 4.9% 
Parlani 200235 336 4 1.2% 
Ramaiah 2002116 230 6 2.6% 
Ricco 200376 1012 8 0.8% 
Vasquez 200493 212 15 7.1% 
Wales 200892 286 8 2.8% 
Zarins 2000123 149 5 3.4% 
Total 8753 320 3.7% 
    
Renal impairment (<30 days) 
Carpenter 200437 192 2 1.0% 
 Elkouri 200381 100 3 3.0% 
Lange 200598 4888 101 2.1% 
Lee 2002117 150 2 1.3% 
Ramaiah 2002119 230 3 1.3% 
Ricco 200376 1012 11 1.1% 
Vasquez 200493 212 6 2.8% 
Wales 200892 286 7 2.4% 
Zarins 2000123 149 1 0.7% 
Total 7401 143 1.9% 
    
Graft infection (< 30 days) 
Parlani 200235 336 1 0.3% 
    
Graft infection (up to 1 year) 
Blum 200123 298 1 0.3% 
Criado 2003109 240 1 0.4% 
Total 538 2 0.38% 
    
Graft infection (>1 year) 
Hiramoto 200654 325 1 0.9% 
Hobo 200698 2846 3 0.1% 
Howell 2001115 215 1 0.5% 
Hugl 2007127 366 2 0.5% 
Total 3752 7 0.2% 
    
Colonic ischaemia (<30 days) 
Carpenter 200437 227 1 0.4% 
Hobo 200898 7554 24 0.3% 
Maldonado 200762 430 4 0.9% 
Ricco 200376 891 3 0.3% 
Vasquez 200493 212 3 1.4% 
Zarins 2000123 149 1 0.7% 
Total 9463 36 0.4% 
    
Lower limb ischaemia (<30 days) 
Blum 200123 298 6 2.0% 
Ricco 200376 891 16 1.6% 
Wales 200892 286 7 2.4% 
Vallabhaneni 2001102 2862 15 0.5% 
Total 4337 44 1.0% 
    
Pulmonary complications (<30 days) 
Bos 200828 234 1 0.4% 
Carpenter 200437 227 6 2.6% 
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Elkouri 200381 100 5 5.0% 
Lange 200598 4888 101 2.1% 
Lee 2002117 150 4 2.7% 
Ramaiah 2002119 230 3 1.3% 
Ricco 200376 891 6 0.7% 
Vasquez 200493 212 9 4.2% 
Wales 200892 286 9 3.1% 
Total 7218 144 2.0% 
    
Haemorrhage (<30 days) 
Nevla 200967 206 20 9.7% 
    
Local wound complications (<30 days) 
Ayerdi 2003114 96 1 1.0% 
Blum 200123 298 9 3.0% 
Carpenter 200437 227 27 11.9% 
Elkouri 200381 100 10 10.0% 
Espinosa 200445 193 6 3.1% 
Howell 2000115 215 6 2.8% 
    Howell 2000116 56 3 5.4% 
Ramaiah 2002119 230 12 5.2% 
Vasquez 200493 212 8 3.8% 
Wales 200892 286 3 1.0% 
Total 2277 124 5.4% 
    
 
Spinal Cord Ischaemia(<30 days) 
Maldonado 200762 430 2 0.5% 
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